{
  "hyalourinic acid": {
    "ingredient": "hyalourinic acid",
    "is_drug": true,
    "canonical_name": "hyaluronic acid",
    "fda_search_term": "hyaluronic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "AOAO Retinol Anti-aging Box Set",
      "ClearSoothingCream",
      "Roushun kojic Skin Lightening Nutural Skin Care treament serum 30ml"
    ],
    "generic_names": [
      "COLLAGEN,BUTYROSPERMUM PARKII (SHEA) BUTTER EXTRACT,HYALURONIC ACID,CAFFEINE,SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL,RETINOL.",
      "HYALURONIC ACID",
      "ROUSHUN KOJIC SKIN LIGHTENING NUTURAL SKIN CARE TREAMENT SERUM 30ML"
    ],
    "manufacturers": [
      "Guangdong Junhui Biotechnology Co., LTD",
      "Roushun Kojic Skin lightening natural skin care treatment serum",
      "Shengnan (Guangzhou) Cosmetics Co., LTD"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only",
      "Keep out ofreach of children.Avoid contact with eyes"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Take out a bottle of essence from the box 2",
      "Unscrew the top cap and squeeze the essence into the palm of your hand 3",
      "Apply evenly on the face and neck, gently massage until fully moisturized"
    ]
  },
  "hyalouronic acid": {
    "ingredient": "hyalouronic acid",
    "is_drug": true,
    "canonical_name": "hyaluronic acid",
    "fda_search_term": "hyaluronic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "AOAO Retinol Anti-aging Box Set",
      "ClearSoothingCream",
      "Roushun kojic Skin Lightening Nutural Skin Care treament serum 30ml"
    ],
    "generic_names": [
      "COLLAGEN,BUTYROSPERMUM PARKII (SHEA) BUTTER EXTRACT,HYALURONIC ACID,CAFFEINE,SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL,RETINOL.",
      "HYALURONIC ACID",
      "ROUSHUN KOJIC SKIN LIGHTENING NUTURAL SKIN CARE TREAMENT SERUM 30ML"
    ],
    "manufacturers": [
      "Guangdong Junhui Biotechnology Co., LTD",
      "Roushun Kojic Skin lightening natural skin care treatment serum",
      "Shengnan (Guangzhou) Cosmetics Co., LTD"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only",
      "Keep out ofreach of children.Avoid contact with eyes"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Take out a bottle of essence from the box 2",
      "Unscrew the top cap and squeeze the essence into the palm of your hand 3",
      "Apply evenly on the face and neck, gently massage until fully moisturized"
    ]
  },
  "hyaluronan": {
    "ingredient": "hyaluronan",
    "is_drug": true,
    "canonical_name": "hyaluronic acid",
    "fda_search_term": "hyaluronic acid",
    "groq_confidence": 0.98,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "AOAO Retinol Anti-aging Box Set",
      "ClearSoothingCream",
      "Roushun kojic Skin Lightening Nutural Skin Care treament serum 30ml"
    ],
    "generic_names": [
      "COLLAGEN,BUTYROSPERMUM PARKII (SHEA) BUTTER EXTRACT,HYALURONIC ACID,CAFFEINE,SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL,RETINOL.",
      "HYALURONIC ACID",
      "ROUSHUN KOJIC SKIN LIGHTENING NUTURAL SKIN CARE TREAMENT SERUM 30ML"
    ],
    "manufacturers": [
      "Guangdong Junhui Biotechnology Co., LTD",
      "Roushun Kojic Skin lightening natural skin care treatment serum",
      "Shengnan (Guangzhou) Cosmetics Co., LTD"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only",
      "Keep out ofreach of children.Avoid contact with eyes"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Take out a bottle of essence from the box 2",
      "Unscrew the top cap and squeeze the essence into the palm of your hand 3",
      "Apply evenly on the face and neck, gently massage until fully moisturized"
    ]
  },
  "hyaluronan sodium salt": {
    "ingredient": "hyaluronan sodium salt",
    "is_drug": true,
    "canonical_name": "hyaluronic acid",
    "fda_search_term": "hyaluronic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "AOAO Retinol Anti-aging Box Set",
      "ClearSoothingCream",
      "Roushun kojic Skin Lightening Nutural Skin Care treament serum 30ml"
    ],
    "generic_names": [
      "COLLAGEN,BUTYROSPERMUM PARKII (SHEA) BUTTER EXTRACT,HYALURONIC ACID,CAFFEINE,SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL,RETINOL.",
      "HYALURONIC ACID",
      "ROUSHUN KOJIC SKIN LIGHTENING NUTURAL SKIN CARE TREAMENT SERUM 30ML"
    ],
    "manufacturers": [
      "Guangdong Junhui Biotechnology Co., LTD",
      "Roushun Kojic Skin lightening natural skin care treatment serum",
      "Shengnan (Guangzhou) Cosmetics Co., LTD"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only",
      "Keep out ofreach of children.Avoid contact with eyes"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Take out a bottle of essence from the box 2",
      "Unscrew the top cap and squeeze the essence into the palm of your hand 3",
      "Apply evenly on the face and neck, gently massage until fully moisturized"
    ]
  },
  "hyaluronate sod": {
    "ingredient": "hyaluronate sod",
    "is_drug": true,
    "canonical_name": "sodium hyaluronate",
    "fda_search_term": "sodium hyaluronate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "BARUBT Luxuriose straffende lo-tion",
      "YOUBUY Acne Care and Moisturizing Gel-Night Use",
      "YOUBUY Snail Mucin 92% Moisturizer"
    ],
    "generic_names": [
      "ACNE CARE AND MOISTURIZING GEL-NIGHT USE",
      "LUXURIOSE STRAFFENDE LOTION",
      "SNAIL MUCIN 92% MOISTURIZER"
    ],
    "manufacturers": [
      "Guangdong Youbaijia Cosmetic Industry Co., Ltd"
    ],
    "dosage_forms": [],
    "warnings": [
      "For external use only"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "LONG-LASTING MOISTURIZING, EFFECTIVE SOOTHING,ENVIRONMENTALLY FRIENDLY"
    ]
  },
  "hyaluronic": {
    "ingredient": "hyaluronic",
    "is_drug": true,
    "canonical_name": "hyaluronic acid",
    "fda_search_term": "hyaluronic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "AOAO Retinol Anti-aging Box Set",
      "ClearSoothingCream",
      "Roushun kojic Skin Lightening Nutural Skin Care treament serum 30ml"
    ],
    "generic_names": [
      "COLLAGEN,BUTYROSPERMUM PARKII (SHEA) BUTTER EXTRACT,HYALURONIC ACID,CAFFEINE,SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL,RETINOL.",
      "HYALURONIC ACID",
      "ROUSHUN KOJIC SKIN LIGHTENING NUTURAL SKIN CARE TREAMENT SERUM 30ML"
    ],
    "manufacturers": [
      "Guangdong Junhui Biotechnology Co., LTD",
      "Roushun Kojic Skin lightening natural skin care treatment serum",
      "Shengnan (Guangzhou) Cosmetics Co., LTD"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only",
      "Keep out ofreach of children.Avoid contact with eyes"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Take out a bottle of essence from the box 2",
      "Unscrew the top cap and squeeze the essence into the palm of your hand 3",
      "Apply evenly on the face and neck, gently massage until fully moisturized"
    ]
  },
  "hyaluronic acid": {
    "ingredient": "hyaluronic acid",
    "is_drug": true,
    "canonical_name": "hyaluronic acid",
    "fda_search_term": "hyaluronic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "AOAO Retinol Anti-aging Box Set",
      "ClearSoothingCream",
      "Roushun kojic Skin Lightening Nutural Skin Care treament serum 30ml"
    ],
    "generic_names": [
      "COLLAGEN,BUTYROSPERMUM PARKII (SHEA) BUTTER EXTRACT,HYALURONIC ACID,CAFFEINE,SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL,RETINOL.",
      "HYALURONIC ACID",
      "ROUSHUN KOJIC SKIN LIGHTENING NUTURAL SKIN CARE TREAMENT SERUM 30ML"
    ],
    "manufacturers": [
      "Guangdong Junhui Biotechnology Co., LTD",
      "Roushun Kojic Skin lightening natural skin care treatment serum",
      "Shengnan (Guangzhou) Cosmetics Co., LTD"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only",
      "Keep out ofreach of children.Avoid contact with eyes"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Take out a bottle of essence from the box 2",
      "Unscrew the top cap and squeeze the essence into the palm of your hand 3",
      "Apply evenly on the face and neck, gently massage until fully moisturized"
    ]
  },
  "hyaluronic acid hydrolyzed": {
    "ingredient": "hyaluronic acid hydrolyzed",
    "is_drug": true,
    "canonical_name": "hyaluronic acid",
    "fda_search_term": "hyaluronic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "AOAO Retinol Anti-aging Box Set",
      "ClearSoothingCream",
      "Roushun kojic Skin Lightening Nutural Skin Care treament serum 30ml"
    ],
    "generic_names": [
      "COLLAGEN,BUTYROSPERMUM PARKII (SHEA) BUTTER EXTRACT,HYALURONIC ACID,CAFFEINE,SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL,RETINOL.",
      "HYALURONIC ACID",
      "ROUSHUN KOJIC SKIN LIGHTENING NUTURAL SKIN CARE TREAMENT SERUM 30ML"
    ],
    "manufacturers": [
      "Guangdong Junhui Biotechnology Co., LTD",
      "Roushun Kojic Skin lightening natural skin care treatment serum",
      "Shengnan (Guangzhou) Cosmetics Co., LTD"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only",
      "Keep out ofreach of children.Avoid contact with eyes"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Take out a bottle of essence from the box 2",
      "Unscrew the top cap and squeeze the essence into the palm of your hand 3",
      "Apply evenly on the face and neck, gently massage until fully moisturized"
    ]
  },
  "hyaluronic acid sodic salt": {
    "ingredient": "hyaluronic acid sodic salt",
    "is_drug": true,
    "canonical_name": "sodium hyaluronate",
    "fda_search_term": "sodium hyaluronate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "BARUBT Luxuriose straffende lo-tion",
      "YOUBUY Acne Care and Moisturizing Gel-Night Use",
      "YOUBUY Snail Mucin 92% Moisturizer"
    ],
    "generic_names": [
      "ACNE CARE AND MOISTURIZING GEL-NIGHT USE",
      "LUXURIOSE STRAFFENDE LOTION",
      "SNAIL MUCIN 92% MOISTURIZER"
    ],
    "manufacturers": [
      "Guangdong Youbaijia Cosmetic Industry Co., Ltd"
    ],
    "dosage_forms": [],
    "warnings": [
      "For external use only"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "LONG-LASTING MOISTURIZING, EFFECTIVE SOOTHING,ENVIRONMENTALLY FRIENDLY"
    ]
  },
  "hyaluronic acid sodium salt": {
    "ingredient": "hyaluronic acid sodium salt",
    "is_drug": true,
    "canonical_name": "sodium hyaluronate",
    "fda_search_term": "sodium hyaluronate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "BARUBT Luxuriose straffende lo-tion",
      "YOUBUY Acne Care and Moisturizing Gel-Night Use",
      "YOUBUY Snail Mucin 92% Moisturizer"
    ],
    "generic_names": [
      "ACNE CARE AND MOISTURIZING GEL-NIGHT USE",
      "LUXURIOSE STRAFFENDE LOTION",
      "SNAIL MUCIN 92% MOISTURIZER"
    ],
    "manufacturers": [
      "Guangdong Youbaijia Cosmetic Industry Co., Ltd"
    ],
    "dosage_forms": [],
    "warnings": [
      "For external use only"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "LONG-LASTING MOISTURIZING, EFFECTIVE SOOTHING,ENVIRONMENTALLY FRIENDLY"
    ]
  },
  "hyaluronic acide": {
    "ingredient": "hyaluronic acide",
    "is_drug": true,
    "canonical_name": "hyaluronic acid",
    "fda_search_term": "hyaluronic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "AOAO Retinol Anti-aging Box Set",
      "ClearSoothingCream",
      "Roushun kojic Skin Lightening Nutural Skin Care treament serum 30ml"
    ],
    "generic_names": [
      "COLLAGEN,BUTYROSPERMUM PARKII (SHEA) BUTTER EXTRACT,HYALURONIC ACID,CAFFEINE,SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL,RETINOL.",
      "HYALURONIC ACID",
      "ROUSHUN KOJIC SKIN LIGHTENING NUTURAL SKIN CARE TREAMENT SERUM 30ML"
    ],
    "manufacturers": [
      "Guangdong Junhui Biotechnology Co., LTD",
      "Roushun Kojic Skin lightening natural skin care treatment serum",
      "Shengnan (Guangzhou) Cosmetics Co., LTD"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only",
      "Keep out ofreach of children.Avoid contact with eyes"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Take out a bottle of essence from the box 2",
      "Unscrew the top cap and squeeze the essence into the palm of your hand 3",
      "Apply evenly on the face and neck, gently massage until fully moisturized"
    ]
  },
  "hyaluronidase": {
    "ingredient": "hyaluronidase",
    "is_drug": true,
    "canonical_name": "hyaluronidase",
    "fda_search_term": "hyaluronidase",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Allergen I",
      "Enviro I",
      "VITRASE"
    ],
    "generic_names": [
      "HYALURONIDASE, OVINE",
      "POTASSIUM GLUCONATE, GLANDULA SUPRARENALIS BOVINE, HEPAR BOVINE, ARSENICUM ALBUM, LYCOPODIUM CLAVATUM, NUX VOMICA, PHOSPHORUS, PEANUT, BLACK WALNUT, ENGLISH WALNUT, AMYGDALA AMARA, CASHEW, COCONUT, PECAN, BRAZIL NUT, TOMATO, SOLANUM TUBEROSUM, PIPER NIGRUM, EGGPLANT (SOLANUM MELONGENA), RAPE SEED OIL, LINUM USITATISSIMUM, SESAME SEED, CHEESE (STILTON), LAC VACCINUM, BEEF, LAMB, PORK, CHICKEN, EGG (WHOLE), PHASEOLUS, ALLIUM CEPA, APPLE, WHEAT, BANANA, STRAWBERRY, COD (GADUS MORHUA), TUNA (THUNNUS THYNNUS),",
      "POTASSIUM GLUCONATE, GLANDULA SUPRARENALIS SUIS, HEPAR SUIS, COFFEA TOSTA, THEA SINENSIS, CARBO VEGETABILIS, FERRUM IODATUM, FERRUM METALLICUM, GELSEMIUM SEMPERVIRENS, IODIUM, IRIDIUM METALLICUM, LYCOPODIUM CLAVATUM, PULSATILLA (PRATENSIS), SELENIUM METALLICUM, ZINCUM METALLICUM, PEANUT, BLACK WALNUT, ENGLISH WALNUT, AMYGDALA AMARA, CASHEW, COCONUT, PECAN, BRAZIL NUT, TOMATO, SOLANUM TUBEROSUM, PIPER NIGRUM, EGGPLANT, RAPE SEED OIL, LINUM USITATISSIMUM, SESAME, SEED, CHEESE (STILTON), LAC VACCINUM, BEEF,"
    ],
    "manufacturers": [
      "Bausch & Lomb Incorporated",
      "BioActive Nutritional",
      "Deseret Biologicals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: If pregnant or breast-feeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, contact a physician or Poison Control Center right away",
      "Tamper Evident: Sealed for your protection",
      "Do not use if seal is broken or missing"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS It is recommended that appropriate references be consulted regarding physical or chemical incompatibilities before adding VITRASE to a solution containing another drug",
      "Furosemide, benzodiazepines and phenytoin are incompatible with hyaluronidase",
      "( 7.1 ) Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs",
      "( 7.2 ) Local anesthetics: Hyaluronidase hastens onset and shortens duration of effect, increases incidence of systemic reactions",
      "( 7.3 ) Large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens or antihistamines: Concomitant use may require larger amounts of hyaluronidase for equivalent dispersing effect",
      "( 7.4 ) 7.1 Incompatibilities Furosemide, benzodiazepines and phenytoin have been found to be incompatible with hyaluronidase",
      "7.2 Drug-Specific Precautions Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs",
      "When considering the administration of any other drug with hyaluronidase, it is recommended that appropriate references first be consulted to determine the usual precautions for the use of the other drug",
      "7.3 Local Anesthetic Agent When hyaluronidase is added to a local anesthetic agent, it hastens the onset of analgesia and tends to reduce the swelling caused by local infiltration, but the wider spread of the local anesthetic solution increases its absorption; this shortens its duration of action an",
      "7.4 Salicylates, Cortisone, ACTH, Estrogens, Antihistamines Patients receiving large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens, or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect, since these drugs apparently render tis"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions have been identified during post-approval use of hyaluronidase products",
      "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure",
      "The most frequently reported adverse reactions have been local injection site reactions",
      "Hyaluronidase has been reported to enhance the adverse reactions associated with co-administered drug products",
      "Edema has been reported most frequently in association with hypodermoclysis",
      "Allergic reactions (e.g., urticaria, angioedema) have been reported in less than 0.1% of patients receiving hyaluronidase",
      "Anaphylactic-like reactions following retrobulbar block or intravenous injections have occurred, rarely",
      "Allergic and anaphylactic-like reactions have been reported, rarely",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "For the temporary relief of symptoms including:",
      "sensitivity to food",
      "swelling of lips",
      "occasional diarrhea",
      "skin rash These statements are based upon homeopathic principles"
    ]
  },
  "hydralazine": {
    "ingredient": "hydralazine",
    "is_drug": true,
    "canonical_name": "hydralazine",
    "fda_search_term": "hydralazine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Hydralazine Hydrochloride"
    ],
    "generic_names": [
      "HYDRALAZINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Chartwell RX, LLC",
      "Proficient Rx LP",
      "REMEDYREPACK INC."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS ​ In a few patients hydrALAZINE may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis",
      "In such patients hydrALAZINE should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug",
      "Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later",
      "Long-term treatment with steroids may be necessary",
      "(See PRECAUTIONS, Laboratory Tests .)"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS Adverse reactions with hydrALAZINE are usually reversible when dosage is reduced",
      "However, in some cases it may be necessary to discontinue the drug",
      "The following adverse reactions have been observed, but there has not been enough systematic collection of data to support an estimate of their frequency",
      "Common Headache, anorexia, nausea, vomiting, diarrhea, palpitations, tachycardia, angina pectoris",
      "Less Frequent: Digestive: constipation, paralytic ileus",
      "Cardiovascular: hypotension, paradoxical pressor response, edema",
      "Respiratory: dyspnea",
      "Neurologic: peripheral neuritis, evidenced by paresthesia, numbness, and tingling; dizziness; tremors; muscle cramps; psychotic reactions characterized by depression, disorientation, or anxiety",
      "Genitourinary: difficulty in urination",
      "Hematologic: blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia, agranulocytosis, purpura; lymphadenopathy; splenomegaly",
      "Hypersensitive Reactions: rash, urticaria, pruritus, fever, chills, arthralgia, eosinophilia, and rarely, hepatitis",
      "Other: nasal congestion, flushing, lacrimation, conjunctivitis"
    ],
    "indications": [
      "INDICATIONS AND USAGE Essential hypertension, alone or as an adjunct"
    ]
  },
  "hydrochlorothazide": {
    "ingredient": "hydrochlorothazide",
    "is_drug": true,
    "canonical_name": "hydrochlorothiazide",
    "fda_search_term": "hydrochlorothiazide",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Lisinopril and Hydrochlorothiazide",
      "olmesartan medoxomil-hydrochlorothiazide"
    ],
    "generic_names": [
      "LISINOPRIL AND HYDROCHLOROTHIAZIDE",
      "LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS",
      "OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE"
    ],
    "manufacturers": [
      "AvKARE",
      "PD-Rx Pharmaceuticals, Inc.",
      "ST. MARY'S MEDICAL PARK PHARMACY"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS General Lisinopril Anaphylactoid and Possibly Related Reactions: Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including lisinopril and hydrochlorothiazid",
      "Head and Neck Angioedema: Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported rarely in patients treated with angiotensin converting enzyme inhibitors, including lisinopril",
      "This may occur at any time during treatment",
      "ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients",
      "In such cases lisinopril and hydrochlorothiazide tablets should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred",
      "Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient",
      "Very rarely, fatalities have been reported due to angioedema associated with laryngeal edema or tongue edema",
      "Patients with involvement of the tongue, glottis or larynx are likely to experience airway obstruction, especially those with a history of airway surgery",
      "Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway should be promptly provided (See ADVERSE REACTIONS ",
      ") Patients with a history of angioedema unrelated to ACE-inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see also INDICATIONS AND USAGE and CONTRAINDICATIONS )"
    ],
    "drug_interactions": [
      "Drug Interactions Lisinopril Hypotension",
      "Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril",
      "The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril",
      "If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour",
      "(See WARNINGS , and DOSAGE AND ADMINISTRATION .) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed (See DOSAGE AND ADMINISTRATION .) Non-steroidal Anti-inflammatory Agents Including Selective Cyclooxygenase-2 (COX-2) ",
      "These effects are usually reversible",
      "Monitor renal function periodically in patients receiving lisinopril and NSAID therapy",
      "The antihypertensive effect of ACE inhibitors, including lisinopril, may be attenuated by NSAIDs",
      "Dual Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or direct renin inhibitors (such as aliskiren) is associated with increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute ren",
      "The VA NEPHRON trial enrolled 1448 patients with type 2 diabetes, elevated urinar"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Lisinopril and hydrochlorothiazide tablets have been evaluated for safety in 930 patients including 100 patients treated for 50 weeks or more",
      "In clinical trials with lisinopril and hydrochlorothiazide tablets no adverse experiences peculiar to this combination drug have been observed",
      "Adverse experiences that have occurred have been limited to those that have been previously reported with lisinopril or hydrochlorothiazide",
      "The most frequent clinical adverse experiences in controlled trials (including open label extensions) with any combination of lisinopril and hydrochlorothiazide tablets were: dizziness (7.5%), headache (5.2%), cough (3.9%), fatigue (3.7%) and orthostatic effects (3.2%) all of which were more common ",
      "Generally, adverse experiences were mild and transient in nature; but see WARNINGS regarding angioedema and excessive hypotension or syncope",
      "Discontinuation of therapy due to adverse effects was required in 4.4% of patients principally because of dizziness, cough, fatigue and muscle cramps",
      "Adverse experiences occurring in greater than one percent of patients treated with lisinopril plus hydrochlorothiazide in controlled clinical trials are shown below",
      "Percent of Patients in Controlled Studies Clinical adverse experiences occurring in 0.3% to 1.0% of patients in controlled trials included: Lisinopril-Hydrochlorothiazide (n=930) Incidence (discontinuation) Placebo (n=207) Incidence Dizziness 7.5 (0.8) 1.9 Headache 5.2 (0.3) 1.9 Cough 3.9 (0.6) 1.0 ",
      "Cardiovascular: Palpit"
    ],
    "indications": [
      "INDICATIONS AND USAGE Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure",
      "Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions",
      "These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide",
      "Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake",
      "Many patients will require more than 1 drug to achieve blood pressure goals"
    ]
  },
  "hydrochlorothiazide": {
    "ingredient": "hydrochlorothiazide",
    "is_drug": true,
    "canonical_name": "hydrochlorothiazide",
    "fda_search_term": "hydrochlorothiazide",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Lisinopril and Hydrochlorothiazide",
      "olmesartan medoxomil-hydrochlorothiazide"
    ],
    "generic_names": [
      "LISINOPRIL AND HYDROCHLOROTHIAZIDE",
      "LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS",
      "OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE"
    ],
    "manufacturers": [
      "AvKARE",
      "PD-Rx Pharmaceuticals, Inc.",
      "ST. MARY'S MEDICAL PARK PHARMACY"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS General Lisinopril Anaphylactoid and Possibly Related Reactions: Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including lisinopril and hydrochlorothiazid",
      "Head and Neck Angioedema: Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported rarely in patients treated with angiotensin converting enzyme inhibitors, including lisinopril",
      "This may occur at any time during treatment",
      "ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients",
      "In such cases lisinopril and hydrochlorothiazide tablets should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred",
      "Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient",
      "Very rarely, fatalities have been reported due to angioedema associated with laryngeal edema or tongue edema",
      "Patients with involvement of the tongue, glottis or larynx are likely to experience airway obstruction, especially those with a history of airway surgery",
      "Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway should be promptly provided (See ADVERSE REACTIONS ",
      ") Patients with a history of angioedema unrelated to ACE-inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see also INDICATIONS AND USAGE and CONTRAINDICATIONS )"
    ],
    "drug_interactions": [
      "Drug Interactions Lisinopril Hypotension",
      "Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril",
      "The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril",
      "If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour",
      "(See WARNINGS , and DOSAGE AND ADMINISTRATION .) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed (See DOSAGE AND ADMINISTRATION .) Non-steroidal Anti-inflammatory Agents Including Selective Cyclooxygenase-2 (COX-2) ",
      "These effects are usually reversible",
      "Monitor renal function periodically in patients receiving lisinopril and NSAID therapy",
      "The antihypertensive effect of ACE inhibitors, including lisinopril, may be attenuated by NSAIDs",
      "Dual Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or direct renin inhibitors (such as aliskiren) is associated with increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute ren",
      "The VA NEPHRON trial enrolled 1448 patients with type 2 diabetes, elevated urinar"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Lisinopril and hydrochlorothiazide tablets have been evaluated for safety in 930 patients including 100 patients treated for 50 weeks or more",
      "In clinical trials with lisinopril and hydrochlorothiazide tablets no adverse experiences peculiar to this combination drug have been observed",
      "Adverse experiences that have occurred have been limited to those that have been previously reported with lisinopril or hydrochlorothiazide",
      "The most frequent clinical adverse experiences in controlled trials (including open label extensions) with any combination of lisinopril and hydrochlorothiazide tablets were: dizziness (7.5%), headache (5.2%), cough (3.9%), fatigue (3.7%) and orthostatic effects (3.2%) all of which were more common ",
      "Generally, adverse experiences were mild and transient in nature; but see WARNINGS regarding angioedema and excessive hypotension or syncope",
      "Discontinuation of therapy due to adverse effects was required in 4.4% of patients principally because of dizziness, cough, fatigue and muscle cramps",
      "Adverse experiences occurring in greater than one percent of patients treated with lisinopril plus hydrochlorothiazide in controlled clinical trials are shown below",
      "Percent of Patients in Controlled Studies Clinical adverse experiences occurring in 0.3% to 1.0% of patients in controlled trials included: Lisinopril-Hydrochlorothiazide (n=930) Incidence (discontinuation) Placebo (n=207) Incidence Dizziness 7.5 (0.8) 1.9 Headache 5.2 (0.3) 1.9 Cough 3.9 (0.6) 1.0 ",
      "Cardiovascular: Palpit"
    ],
    "indications": [
      "INDICATIONS AND USAGE Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure",
      "Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions",
      "These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide",
      "Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake",
      "Many patients will require more than 1 drug to achieve blood pressure goals"
    ]
  },
  "hydrocortisone": {
    "ingredient": "hydrocortisone",
    "is_drug": true,
    "canonical_name": "hydrocortisone",
    "fda_search_term": "hydrocortisone",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Cortifoam",
      "PS-2896 Hydrocortisone Cream 1%, 0.9g",
      "anti itch"
    ],
    "generic_names": [
      "HYDROCORTISONE",
      "HYDROCORTISONE ACETATE",
      "PS-2896 HYDROCORTISONE CREAM 1%, 0.9G"
    ],
    "manufacturers": [
      "Meijer, Inc.",
      "ProStat First Aid LLC",
      "Viatris Specialty LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Do not use",
      "in the genital area if you have a vaginal discharge",
      "Consult a doctor",
      "for the treatment of diaper rash",
      "Consult a doctor",
      "When using this product",
      "avoid contact with the eyes",
      "do not use more than directed unless told to do so by a doctor",
      "do not put directly into the rectum by using fingers or any mechanical device or applicator Stop use and ask a doctor if",
      "condition worsens symptoms persist for more than 7 days or clear up and occur again within a few days, and do not begin use of any other hydrocortisone product unless you have asked a doctor"
    ],
    "drug_interactions": [
      "Drug Interactions Aminoglutethimide: Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression",
      "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia",
      "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure",
      "Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance",
      "Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis",
      "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy",
      "Anticoagulants, oral: Coadministration of corticosteroids and warfarin result in inhibition of response to warfarin",
      "Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect",
      "Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required",
      "Antitubercular drugs: Serum concentrations of isoniazid may be decreased"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS (listed alphabetically, under each subsection) To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc",
      "at 1-877-848-6608 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "Allergic reactions: Anaphylactoid reaction, anaphylaxis, angioedema",
      "Cardiovascular: Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction (see WARNINGS ), pulmonary ed",
      "Dermatologic: Acne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scaly skin, ecchymoses and petechiae, edema, erythema, hyperpigmentation, hypopigmentation, impaired wound healing, increased sweating, rash, sterile abscess, striae, suppressed reactions to skin tests, thin fragile ski",
      "Endocrine: Decreased carbohydrate and glucose tolerance, development of cushingoid state, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, menstrual irregularities, secondary adrenocortical ",
      "Fluid and electrolyte disturbances: Congestive heart failure in susceptible patients, fluid retention, hypokalemic alkalosis, potassium loss, sodium retention",
      "Where hypokalemia and other symptoms associated with fluid and electrolyte imbalance call for potassium supplementation and salt poor or salt-free diets, these may be instituted and are compatible with diet requirements for ulcerative proctitis",
      "Gastrointestinal: Abdominal distention, elevation in serum liver enzyme levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea,"
    ],
    "indications": [
      "temporarily relieves itching associated with minor skin irritations, inflammation, and rashes due to:",
      "poison ivy, oak, sumac",
      "seborrheic dermatitis",
      "temporarily relieves external anal and genital itching",
      "other uses of this product should only be under the advice and supervision of a doctor"
    ]
  },
  "hydrocortisone acetate": {
    "ingredient": "hydrocortisone acetate",
    "is_drug": true,
    "canonical_name": "hydrocortisone",
    "fda_search_term": "hydrocortisone",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Cortifoam",
      "PS-2896 Hydrocortisone Cream 1%, 0.9g",
      "anti itch"
    ],
    "generic_names": [
      "HYDROCORTISONE",
      "HYDROCORTISONE ACETATE",
      "PS-2896 HYDROCORTISONE CREAM 1%, 0.9G"
    ],
    "manufacturers": [
      "Meijer, Inc.",
      "ProStat First Aid LLC",
      "Viatris Specialty LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Do not use",
      "in the genital area if you have a vaginal discharge",
      "Consult a doctor",
      "for the treatment of diaper rash",
      "Consult a doctor",
      "When using this product",
      "avoid contact with the eyes",
      "do not use more than directed unless told to do so by a doctor",
      "do not put directly into the rectum by using fingers or any mechanical device or applicator Stop use and ask a doctor if",
      "condition worsens symptoms persist for more than 7 days or clear up and occur again within a few days, and do not begin use of any other hydrocortisone product unless you have asked a doctor"
    ],
    "drug_interactions": [
      "Drug Interactions Aminoglutethimide: Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression",
      "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia",
      "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure",
      "Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance",
      "Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis",
      "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy",
      "Anticoagulants, oral: Coadministration of corticosteroids and warfarin result in inhibition of response to warfarin",
      "Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect",
      "Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required",
      "Antitubercular drugs: Serum concentrations of isoniazid may be decreased"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS (listed alphabetically, under each subsection) To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc",
      "at 1-877-848-6608 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "Allergic reactions: Anaphylactoid reaction, anaphylaxis, angioedema",
      "Cardiovascular: Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction (see WARNINGS ), pulmonary ed",
      "Dermatologic: Acne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scaly skin, ecchymoses and petechiae, edema, erythema, hyperpigmentation, hypopigmentation, impaired wound healing, increased sweating, rash, sterile abscess, striae, suppressed reactions to skin tests, thin fragile ski",
      "Endocrine: Decreased carbohydrate and glucose tolerance, development of cushingoid state, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, menstrual irregularities, secondary adrenocortical ",
      "Fluid and electrolyte disturbances: Congestive heart failure in susceptible patients, fluid retention, hypokalemic alkalosis, potassium loss, sodium retention",
      "Where hypokalemia and other symptoms associated with fluid and electrolyte imbalance call for potassium supplementation and salt poor or salt-free diets, these may be instituted and are compatible with diet requirements for ulcerative proctitis",
      "Gastrointestinal: Abdominal distention, elevation in serum liver enzyme levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea,"
    ],
    "indications": [
      "temporarily relieves itching associated with minor skin irritations, inflammation, and rashes due to:",
      "poison ivy, oak, sumac",
      "seborrheic dermatitis",
      "temporarily relieves external anal and genital itching",
      "other uses of this product should only be under the advice and supervision of a doctor"
    ]
  },
  "hydrocortisone butyrate": {
    "ingredient": "hydrocortisone butyrate",
    "is_drug": true,
    "canonical_name": "hydrocortisone butyrate",
    "fda_search_term": "hydrocortisone butyrate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Hydrocortisone Butyrate"
    ],
    "generic_names": [
      "HYDROCORTISONE BUTYRATE"
    ],
    "manufacturers": [
      "Lupin Pharmaceuticals, Inc.",
      "Taro Pharmaceuticals U.S.A., Inc.",
      "The J. Molner Company LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling:",
      "HPA axis suppression [see Warnings and Precautions (5.1), Use in Specific Populations (8.4)]",
      "Ophthalmic Adverse Reactions [see Warnings and Precautions ( 5",
      "Skin infections [see Warnings and Precautions (5.3)]",
      "Allergic contact dermatitis [see Warnings and Precautions (5.4)] The most common adverse reactions (> 1%) are application site reactions",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact The J",
      "Molner Company LLC at 1-800-552-8750 and/or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "See 17 for PATIENT COUNSELING INFORMATION",
      "Revised: 11/2023 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of the drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed",
      "The safety data described below reflect Hydrocortisone Butyrate Lotion applied topically twice daily for up to 4 weeks in vehicle-controlled clinical trials of 284 pediatric subjects 3 months to 18 years of age and 301 adult subjects with mild to moderate atopic dermatitis [see Clinical Studies (14)",
      "The incidence of selected adverse reactions reported by ≥1% of subjects during the studies is presented in Table 1 and Table 2 ",
      "Frequency of adverse reactions in pediatric subjects with mild to moderate atopic dermatitis Hydrocortisone Butyrate Lotion (n=139) n (%) Vehicle (n=145) n (%) Application site reactions, including application site burning, pruritus, dermatitis, erythema, eczema, inflammation, or irritation 2 (1) 20",
      "Frequency of adverse reactions in adult subjects with mild to moderate atopic dermatitis Hydrocortisone Butyrate Lotion (n=151) n (%) Vehicle (n=150) n (%) Application site reactions, including app"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Hydrocortisone Butyrate Lotion is indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older",
      "Hydrocortisone Butyrate Lotion is a corticosteroid indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older"
    ]
  },
  "hydrocortisone sodium succinate": {
    "ingredient": "hydrocortisone sodium succinate",
    "is_drug": true,
    "canonical_name": "hydrocortisone",
    "fda_search_term": "hydrocortisone",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Cortifoam",
      "PS-2896 Hydrocortisone Cream 1%, 0.9g",
      "anti itch"
    ],
    "generic_names": [
      "HYDROCORTISONE",
      "HYDROCORTISONE ACETATE",
      "PS-2896 HYDROCORTISONE CREAM 1%, 0.9G"
    ],
    "manufacturers": [
      "Meijer, Inc.",
      "ProStat First Aid LLC",
      "Viatris Specialty LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Do not use",
      "in the genital area if you have a vaginal discharge",
      "Consult a doctor",
      "for the treatment of diaper rash",
      "Consult a doctor",
      "When using this product",
      "avoid contact with the eyes",
      "do not use more than directed unless told to do so by a doctor",
      "do not put directly into the rectum by using fingers or any mechanical device or applicator Stop use and ask a doctor if",
      "condition worsens symptoms persist for more than 7 days or clear up and occur again within a few days, and do not begin use of any other hydrocortisone product unless you have asked a doctor"
    ],
    "drug_interactions": [
      "Drug Interactions Aminoglutethimide: Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression",
      "Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia",
      "There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure",
      "Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance",
      "Anticholinesterases: Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis",
      "If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy",
      "Anticoagulants, oral: Coadministration of corticosteroids and warfarin result in inhibition of response to warfarin",
      "Therefore, coagulation indices should be monitored to maintain the desired anticoagulant effect",
      "Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required",
      "Antitubercular drugs: Serum concentrations of isoniazid may be decreased"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS (listed alphabetically, under each subsection) To report SUSPECTED ADVERSE REACTIONS, contact Meda Pharmaceuticals Inc",
      "at 1-877-848-6608 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "Allergic reactions: Anaphylactoid reaction, anaphylaxis, angioedema",
      "Cardiovascular: Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction (see WARNINGS ), pulmonary ed",
      "Dermatologic: Acne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scaly skin, ecchymoses and petechiae, edema, erythema, hyperpigmentation, hypopigmentation, impaired wound healing, increased sweating, rash, sterile abscess, striae, suppressed reactions to skin tests, thin fragile ski",
      "Endocrine: Decreased carbohydrate and glucose tolerance, development of cushingoid state, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, menstrual irregularities, secondary adrenocortical ",
      "Fluid and electrolyte disturbances: Congestive heart failure in susceptible patients, fluid retention, hypokalemic alkalosis, potassium loss, sodium retention",
      "Where hypokalemia and other symptoms associated with fluid and electrolyte imbalance call for potassium supplementation and salt poor or salt-free diets, these may be instituted and are compatible with diet requirements for ulcerative proctitis",
      "Gastrointestinal: Abdominal distention, elevation in serum liver enzyme levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea,"
    ],
    "indications": [
      "temporarily relieves itching associated with minor skin irritations, inflammation, and rashes due to:",
      "poison ivy, oak, sumac",
      "seborrheic dermatitis",
      "temporarily relieves external anal and genital itching",
      "other uses of this product should only be under the advice and supervision of a doctor"
    ]
  },
  "hydrogen peroxide": {
    "ingredient": "hydrogen peroxide",
    "is_drug": true,
    "canonical_name": "hydrogen peroxide",
    "fda_search_term": "hydrogen peroxide",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Hydrogen Peroxide",
      "Walgreens 3 Hydrogen Peroxide Wipes"
    ],
    "generic_names": [
      "HYDROGEN PEROXIDE"
    ],
    "manufacturers": [
      "HART Health",
      "Navajo Manufacturing Company Inc.",
      "Walgreen Company"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses first aid to help prevent the risk of infection in minor cuts, scrapes and burns aids in the removal of phlegm, mucous, or other secretions associated with occasional sore mouth"
    ]
  },
  "hydrogenated lecithin": {
    "ingredient": "hydrogenated lecithin",
    "is_drug": true,
    "canonical_name": "phosphatidylcholine",
    "fda_search_term": "phosphatidylcholine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "SAMe Liquescence 3036"
    ],
    "generic_names": [
      "SAME LIQUESCENCE"
    ],
    "manufacturers": [
      "Professional Complementary Health Formulas"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Consult a doctor if condition worsens or if symptoms persist",
      "Keep out of the reach of children",
      "In case of overdose, get medical help or contact a poison control center right away",
      "If pregnant or breastfeeding, ask a healthcare professional before use",
      "Keep out of the reach of children",
      "If pregnant or breastfeeding, ask a healthcare professional before use"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS For the temporary relief of sadness, anxiousness, mild muscle or joint pain, stiffness, or inflammation, occasional headache, or fatigue.*"
    ]
  },
  "hydrolite penthylene glycol": {
    "ingredient": "hydrolite penthylene glycol",
    "is_drug": true,
    "canonical_name": "polyethylene glycol",
    "fda_search_term": "polyethylene glycol",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Foster and Thrive Advanced Relief Eye Drops",
      "Foster and Thrive Dry Eye Relief",
      "Foster and Thrive Lubricating Tears Lubricant Eye Drops"
    ],
    "generic_names": [
      "POLYETHYLENE GLYCOL 400",
      "POLYETHYLENE GLYCOL 400, PROPYLENE GLYCOL",
      "POLYETHYLENE GLYCOL 400, TETRAHYDROZOLINE HCL"
    ],
    "manufacturers": [
      "Strategic Sourcing Services LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Do not use this product if solution changes color or becomes cloudy When using this product to avoid contamination, do not touch tip of container to any surface",
      "Replace cap after using",
      "remove contact lenses before using Stop use and ask a doctor if you experience eye pain changes in vision continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours If pregnant or breast-feeding, ask a health professional before use",
      "Keep out of reach of children",
      "If swallowed, get medical help or contact a Poison Control Center (1-800-222-1222) right away"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses for protection against further irritation for temporary relief of burning and irritation due to dryness of the eye"
    ]
  },
  "hydrolyzed glycosaminglycans": {
    "ingredient": "hydrolyzed glycosaminglycans",
    "is_drug": true,
    "canonical_name": "sodium hyaluronate",
    "fda_search_term": "sodium hyaluronate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "BARUBT Luxuriose straffende lo-tion",
      "YOUBUY Acne Care and Moisturizing Gel-Night Use",
      "YOUBUY Snail Mucin 92% Moisturizer"
    ],
    "generic_names": [
      "ACNE CARE AND MOISTURIZING GEL-NIGHT USE",
      "LUXURIOSE STRAFFENDE LOTION",
      "SNAIL MUCIN 92% MOISTURIZER"
    ],
    "manufacturers": [
      "Guangdong Youbaijia Cosmetic Industry Co., Ltd"
    ],
    "dosage_forms": [],
    "warnings": [
      "For external use only"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "LONG-LASTING MOISTURIZING, EFFECTIVE SOOTHING,ENVIRONMENTALLY FRIENDLY"
    ]
  },
  "hydromorphone hydrochloride": {
    "ingredient": "hydromorphone hydrochloride",
    "is_drug": true,
    "canonical_name": "hydromorphone",
    "fda_search_term": "hydromorphone",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "HYDROMORPHONE HYDROCHLORIDE",
      "Hydromorphone Hydrochloride"
    ],
    "generic_names": [
      "HYDROMORPHONE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "ASCLEMED USA INC.",
      "Bryant Ranch Prepack",
      "Padagis US LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with hydromorphone hydrochloride",
      "Table 1: Clinically Significant Drug Interactions with HYDROMORPHONE HYDROCHLORIDE Benzodiazepines and other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increas",
      "Intervention: Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate",
      "Limit dosages and durations to the minimum required",
      "Inform patients and caregivers of this potential interaction and educate them on the signs and symptoms of respiratory depression (including sedation)",
      "If concomitant use is warranted, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2) , Warnings and Precautions (5.2 , 5.3 , 5.4) ] ",
      "Examples: Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol",
      "Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome",
      "Intervention: If concomitant use is warranted, frequently evaluate the patient, particularly during treatment initiation and dose adjustment",
      "Discontinue hydromorphone hydrochloride oral solution or hydromorphone hydrochloride tablets if serotonin syndrome is suspected"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described, or described in greater detail, in other sections: Addiction, Abuse, and Misuse [see Warnings and Precautions (5.2) ] Life-Threatening Respiratory Depression [see Warnings and Precautions (5.3) ] Interactions with Benzodiazep",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Rhodes Pharmaceuticals at 1-888-827-0616 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials o",
      "Serious adverse reactions associated with hydromorphone hydrochloride include respiratory depression and apnea and, to a lesser degree, circulatory depression, respiratory arrest, shock, and cardiac arrest",
      "The most common adverse effects are lightheadedness, dizziness, sedation, nausea, vomiting, sweating, flushing, dysphoria, euphoria, dry mouth, and pruritus",
      "These effects seem to be more prominent in ambulatory patients and in those not experiencing severe pain",
      "Less Frequently Observed Adverse Reactions Cardiac disorders: tachycardia, bradycardia, palpitations Eye disorders:"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Hydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate",
      "Hydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets contain hydromorphone, an opioid agonist, and are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate",
      "( 1 ) Limitations of Use ( 1 ) Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration ( 5.2 ) , reserve hydromorphone hydrochloride oral solution or hydromorphone hydrochloride tablets for use in patients for whom alternative treatment options [e",
      "Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions (5.2) ] , reserve hydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets for use in patients for whom alternative t",
      "Hydromorphone hydrochloride oral solution and hydromorphone hydrochloride tablets should not be used for an extended period of time unless the pain remains severe enough to require"
    ]
  },
  "hydroquinone": {
    "ingredient": "hydroquinone",
    "is_drug": true,
    "canonical_name": "hydroquinone",
    "fda_search_term": "hydroquinone",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "OBAGI-C Rx system C-CLARIFYING SERUM NORMAL TO oily SKIN LIGHTENING SERUM WITH VITAMIN C",
      "Vivant True Tone",
      "Vivant True Tone Forte"
    ],
    "generic_names": [
      "HYDROQUINONE"
    ],
    "manufacturers": [
      "Obagi Cosmeceuticals LLC",
      "Vivant Pharmaceuticals, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Warnings ■Sun exposure should be avoided indefinitely by using a high SPF sunscreen agent, a sunblocking agent, or protective clothing to cover bleached skin in order to prevent darkening from reoccurring ■ Do not get into eyes ■Keep out of reach of children ■For external use only ■Not reco"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS No systemic adverse reactions have been reported",
      "Occasional hypersensitivity (localized contact dermatitis) may occur, in which case the product should be discontinued and physician notified immediately",
      "To report SUSPECTED ADVERSE REACTIONS, contact Obagi Medical Products, a division of Valeant Pharmaceuticals North America LLC, at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch"
    ],
    "indications": [
      "Uses Uses ■ For the gradual fading of age spots ■ Lightens dark pigment in the skin ■This product provides minimal SPF protection"
    ]
  },
  "hydroxocobalamin": {
    "ingredient": "hydroxocobalamin",
    "is_drug": true,
    "canonical_name": "hydroxocobalamin",
    "fda_search_term": "hydroxocobalamin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Cyanokit",
      "Hydroxocobalamin"
    ],
    "generic_names": [
      "HYDROXOCOBALAMIN"
    ],
    "manufacturers": [
      "Actavis Pharma, Inc.",
      "BTG INTERNATIONAL INC."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Avoid the intravenous route",
      "Folic acid is not a substitute for vitamin B 12 although it may improve vitamin B 12 deficient megaloblastic anemia",
      "Exclusive use of folic acid in treating vitamin B 12 deficient megaloblastic anemia could result in progressive and irreversible neurologic damage",
      "Blunted or impeded therapeutic response to vitamin B 12 may be due to such conditions as infection, uremia, drugs having bone marrow suppressant properties such as chloramphenicol, and concurrent iron or folic acid deficiency"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Formal drug interaction studies have not been conducted with CYANOKIT",
      "Interference with Laboratory Tests Because of its deep red color, hydroxocobalamin has been found to interfere with colorimetric determination of certain laboratory parameters (e.g., clinical chemistry, hematology, coagulation, and urine parameters)",
      "Be aware of this when reporting and interpreting laboratory results [see Warnings and Precautions ( 5.5 )]"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Mild transient diarrhea, itching, transitory exanthema, feeling of swelling of entire body, and anaphylaxis",
      "A few patients may experience pain after injection of hydroxocobalamin",
      "To report SUSPECTED ADVERSE EVENTS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or http://www.fda.gov/ for voluntary reporting of adverse reactions"
    ],
    "indications": [
      "INDICATIONS AND USAGE Pernicious anemia, both uncomplicated and accompanied by nervous system involvement",
      "Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants",
      "(Isolated vitamin B 12 deficiency is very rare)",
      "Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption",
      "These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy)"
    ]
  },
  "hydroxy ethylsalicylate": {
    "ingredient": "hydroxy ethylsalicylate",
    "is_drug": true,
    "canonical_name": "hydroxyethyl salicylate",
    "fda_search_term": "hydroxyethyl salicylate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Glimepiride",
      "Naproxen"
    ],
    "generic_names": [
      "GLIMEPIRIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "American Health Packaging"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity",
      "In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction",
      "Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects",
      "The use of thyroid hormones in the therapy of obesity, alone or combined with other drugs, is unjustified and has been shown to be ineffective",
      "Neither is their use justified for the treatment of male or female infertility unless this condition is accompanied by hypothyroidism"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Table 1 for clinically significant drug interactions with naproxen",
      "Table 1: Clinically Significant Drug Interactions with naproxen Drugs That Interfere with Hemostasis Clinical Impact:",
      "Naproxen and anticoagulants such as warfarin have a synergistic effect on bleeding",
      "The concomitant use of naproxen and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone",
      "Serotonin release by platelets plays an important role in hemostasis",
      "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone",
      "Intervention: Monitor patients with concomitant use of naproxen tablets or naproxen sodium tablets with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleedin",
      "Aspirin Clinical Impact: A pharmacodynamic (PD) study has demonstrated an interaction in which lower dose naproxen (220mg/day or 220mg twice daily) interfered with the antiplatelet effect of low-dose immediate-release aspirin, with the interaction most marked during the washout period of naproxen ( ",
      "There is reason to expect that the interaction would be present with prescription doses of naproxen or with enteric-coated low-dose aspirin; however, the peak interference with aspirin function may be later than observed in the PD study due to the longer washout period",
      "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling:",
      "Cardiovascular Thrombotic Events [ see Warnings and Precautions ( 5.1 ) ]",
      "GI Bleeding, Ulceration, and Perforation [ see Warnings and Precautions ( 5.2 ) ]",
      "Hepatotoxicity [ see Warnings and Precautions ( 5.3 ) ]",
      "Hypertension [ see Warnings and Precautions ( 5.4 ) ]",
      "Heart Failure and Edema [ see Warnings and Precautions ( 5.5 ) ]",
      "Renal Toxicity and Hyperkalemia [ see Warnings and Precautions ( 5.6 ) ]",
      "Anaphylactic Reactions [ see Warnings and Precautions ( 5.7 ) ]",
      "Serious Skin Reactions [ see Warnings and Precautions ( 5.9 ) ]",
      "Hematologic Toxicity [ see Warnings and Precautions ( 5.12 ) ] Most common adverse reactions to naproxen were dyspepsia, abdominal pain, nausea, headache, rash, ecchymosis, and edema",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adverse reactions reported in controlled clinical trials in 960 patients treated for rheumatoid arthritis or osteoarthritis are listed below",
      "In general, reactions in patients treated chronically were reported 2 to 10 times more frequently than they were in short-term studies in the 962 patients treated for mild to moderate pain or for dysmenorrhea",
      "The most frequent complaints reported related to the gastrointestinal tract"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Naproxen tablets and naproxen sodium tablets are indicated for: the relief of the signs and symptoms of:",
      "rheumatoid arthritis",
      "ankylosing spondylitis",
      "Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets and naproxen sodium tablets are also indicated for: the relief of signs and symptoms of:",
      "acute gout the management of:"
    ]
  },
  "hydroxybenzoa": {
    "ingredient": "hydroxybenzoa",
    "is_drug": true,
    "canonical_name": "benzoic acid",
    "fda_search_term": "benzoic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "CardCare",
      "RENELIX",
      "URIBEL TABS"
    ],
    "generic_names": [
      "BENZOIC ACID, NITRIC ACID, APIS MELLIFERA, BERBERIS VULGARIS ROOT BARK, COLCHICUM AUTUMNALE BULB, PROTORTONIA CACTI, SOLIDAGO VIRGAUREA FLOWERING TOP, AND CAPSELLA BURSA-PASTORIS TOP",
      "ECHINACEA, HYPERICUM, VALERIANA, ACONITUM NAP., ARSENICUM ALB., AUR. MET., BARYTA CARB., BENZOICUM AC., BERBER. VULG., BRYONIA, CALC. FLUOR., CANTHARIS, CEANOTHUS, CHELIDONIUM MAJ., CHIONANTHUS, CINCHONA, CONVALLARIA, CROTALUS HOR., DIGITALIS, GELSEMIUM, GLONOINUM, HYDROFLUORICUM AC. KALI IOD., LACHESIS, LYCOPUS, NAJA, NUX VOM., PHOS., PULSATILLA, RHUS TOX., VIPERA, ELAPS.",
      "METHENAMINE, BENZOIC ACID, PHENYL SALICYLATE, METHYLENE BLUE, AND HYOSCYAMINE SULFATE"
    ],
    "manufacturers": [
      "Mission Pharmacal Company",
      "Newton Laboratories, Inc.",
      "PEKANA Naturheilmittel GmbH"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS SECTION WARNINGS: Keep out of reach of children",
      "Do not use if tamper-evident seal is broken or missing",
      "If symptoms worsen or persist for more than a few days, consult a doctor",
      "If pregnant or breast-feeding , ask a doctor before use"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS & USAGE SECTION Formulated for symptoms such as fear, cold hands & feet, headache, weakness, sallow skin and palpitations"
    ]
  },
  "hydroxycarbamide": {
    "ingredient": "hydroxycarbamide",
    "is_drug": true,
    "canonical_name": "hydroxyurea",
    "fda_search_term": "hydroxyurea",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "DROXIA",
      "HYDROXYUREA"
    ],
    "generic_names": [
      "HYDROXYUREA"
    ],
    "manufacturers": [
      "Coupler LLC",
      "Golden State Medical Supply, Inc.",
      "Waylis Therapeutics LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Antiretroviral drugs (7.1) Laboratory Test Interference",
      "(7.2) 7.1 Increased Toxicity with Concomitant Use of Antiretroviral Drugs Pancreatitis In patients with HIV infection during therapy with hydroxyurea and didanosine, with or without stavudine, fatal and nonfatal pancreatitis have occurred",
      "Hydroxyurea is not indicated for the treatment of HIV infection; however, if patients with HIV infection are treated with hydroxyurea, and in particular, in combination with didanosine and/or stavudine, close monitoring for signs and symptoms of pancreatitis is recommended",
      "Permanently discontinue therapy with hydroxyurea in patients who develop signs and symptoms of pancreatitis",
      "Hepatotoxicity Hepatotoxicity and hepatic failure resulting in death have been reported during postmarketing surveillance in patients with HIV infection treated with hydroxyurea and other antiretroviral drugs",
      "Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine",
      "Avoid this combination",
      "Peripheral Neuropathy Peripheral neuropathy, which was severe in some cases, has been reported in patients with HIV infection receiving hydroxyurea in combination with antiretroviral drugs, including didanosine, with or without stavudine",
      "7.2 Laboratory Test Interference Interference with Uric Acid, Urea, or Lactic Acid Assays Studies have shown that there is an analytical interference of hydroxyurea with the enzymes (urease, uricase, and lactate dehydrogenase) used in the determination of urea, uric acid, and lactic acid, rendering ",
      "Interference with Continuous Glucose Monitoring Systems Hydroxyurea may falsely elevate sensor glucose results from certain continuous glucose monitoring (CGM) systems and may lead to hypoglycemia if sensor glucose results are relied upon to dose insulin"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS",
      "Myelosuppression [see Warnings and Precautions (5.1) ]",
      "Hemolytic anemia [see Warnings and Precautions (5.2) ]",
      "Malignancies [see Warnings and Precautions (5.3) ]",
      "Vasculitic toxicities [see Warnings and Precautions (5.5) ]",
      "Risks with concomitant use of antiretroviral drugs [see Warnings and Precautions (5.7) ]",
      "Radiation recall [see Warnings and Precautions (5.8) ]",
      "Macrocytosis [see Warnings and Precautions (5.9) ]",
      "Pulmonary Toxicity [see Warnings and Precautions (5.10) ] Most common adverse reactions (≥30%) are hematological, gastrointestinal symptoms, and anorexia",
      "(6) To report SUSPECTED ADVERSE REACTIONS, contact Leading Pharma, LLC at 1-844-740-7500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Postmarketing Experience The following adverse reactions have been identified during post-approval use of hydroxyurea capsules",
      "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency",
      "Reproductive System and Breast disorders: azoospermia, and oligospermia Gastrointestinal disorders: stomatitis, nausea, vomiting, diarrhea, and constipation Metabolism and Nutrition disorders: anorexia, tumor lysis syndrome Skin and subcutaneous tissue disorders: maculopapular rash, skin ulceration,"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Hydroxyurea capsules, USP is indicated for the treatment of: Resistant chronic myeloid leukemia",
      "Locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation",
      "Hydroxyurea capsules, USP is an antimetabolite indicated for the treatment of:",
      "Resistant chronic myeloid leukemia",
      "Locally advanced squamous cell carcinomas of the head and neck, (excluding lip) in combination with concurrent chemoradiation"
    ]
  },
  "hydroxychloroquine sulphate": {
    "ingredient": "hydroxychloroquine sulphate",
    "is_drug": true,
    "canonical_name": "hydroxychloroquine",
    "fda_search_term": "hydroxychloroquine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "HYDROXYCHLOROQUINE SULFATE",
      "Hydroxychloroquine Sulfate"
    ],
    "generic_names": [
      "HYDROXYCHLOROQUINE SULFATE"
    ],
    "manufacturers": [
      "Asclemed USA, Inc.",
      "Creekwood Pharmaceuticals LLC",
      "Laurus Labs Limited"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs",
      "( 7.1 ) See FPI for more important drug interactions",
      "( 7 ) 7.1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate tablets prolongs the QT interval",
      "There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate tablets are used concomitantly with other arrhythmogenic drugs",
      "Therefore, hydroxychloroquine sulfate tablets are not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic [see Warnings and Precautions (5.1) ]",
      "7.2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate tablets may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk",
      "Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary [see Warnings and Precautions (5.10) ]",
      "7.3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate tablets can lower the seizure threshold",
      "Co-administration of hydroxychloroquine sulfate tablets with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures",
      "7.4 Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with hydroxychloroquine sulfate tablets"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are described in greater detail in other sections: Cardiomyopathy and Ventricular Arrhythmias [see Warnings and Precautions (5.1) ] Retinal Toxicity [see Warnings and Precautions (5.2) ] Serious Skin Reactions [see Warnings and Precautions (5.3) ] ",
      "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Blood and lymphatic system disorders : Bone marrow depression, anemia, aplastic anemia, agranulocy"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Hydroxychloroquine sulfate tablets are an antimalarial and antirheumatic indicated for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients",
      "( 1.1 ) Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients",
      "( 1.1 ) Treatment of rheumatoid arthritis in adults",
      "( 1.2 ) Treatment of systemic lupus erythematosus in adults",
      "( 1.3 ) Treatment of chronic discoid lupus erythematosus in adults"
    ]
  },
  "hydroxycitric acid": {
    "ingredient": "hydroxycitric acid",
    "is_drug": true,
    "canonical_name": "hydroxycitric acid",
    "fda_search_term": "hydroxycitric acid",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Naproxen"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS NOT FOR INJECTION",
      "Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye",
      "There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin",
      "Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching",
      "A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin",
      "If an allergic reaction to ofloxacin occurs, discontinue the drug",
      "Serious acute hypersensitivity reactions may require immediate emergency treatment",
      "Oxygen and airway management, including intubation should be administered as clinically indicated"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:"
    ]
  },
  "hydroxyethyl": {
    "ingredient": "hydroxyethyl",
    "is_drug": true,
    "canonical_name": "hydroxyethyl",
    "fda_search_term": "hydroxyethyl",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Anubis Barcelona Regul Oil",
      "Naturally Inspired Irritated Eye Relief",
      "Nite"
    ],
    "generic_names": [
      "CETEARYL ETHYLHEXANOATE, PROPYLENE GLYCOL, GLYCERYL STEARATE SE",
      "HYDROXYETHYL CELLULOSE",
      "PERSONAL LUBRICANT LOTION"
    ],
    "manufacturers": [
      "ANUBIS COSMETICS SL",
      "Nite Storm LLC",
      "Similasan Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warning: If irritaiton or discomfort occurs, discontinue use immediately and consult a physician",
      "Keep out of eyes and ears",
      "Keep out of reach of Children and pets",
      "Very slippery, clean spills immediately",
      "This product is not a contraceptive or spermicide",
      "Bottle may leak if not stored upright",
      "Store at ambient weather"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Usage: Gently squeeze out an appropriate amount of lubricant, and evenly apply it on the desired area"
    ]
  },
  "hydroxyethyl cellulose": {
    "ingredient": "hydroxyethyl cellulose",
    "is_drug": true,
    "canonical_name": "hydroxyethyl cellulose",
    "fda_search_term": "hydroxyethyl cellulose",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Anubis Barcelona Regul Oil",
      "Naturally Inspired Irritated Eye Relief",
      "Nite"
    ],
    "generic_names": [
      "CETEARYL ETHYLHEXANOATE, PROPYLENE GLYCOL, GLYCERYL STEARATE SE",
      "HYDROXYETHYL CELLULOSE",
      "PERSONAL LUBRICANT LOTION"
    ],
    "manufacturers": [
      "ANUBIS COSMETICS SL",
      "Nite Storm LLC",
      "Similasan Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warning: If irritaiton or discomfort occurs, discontinue use immediately and consult a physician",
      "Keep out of eyes and ears",
      "Keep out of reach of Children and pets",
      "Very slippery, clean spills immediately",
      "This product is not a contraceptive or spermicide",
      "Bottle may leak if not stored upright",
      "Store at ambient weather"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Usage: Gently squeeze out an appropriate amount of lubricant, and evenly apply it on the desired area"
    ]
  },
  "hydroxyethyl ethylcellulose": {
    "ingredient": "hydroxyethyl ethylcellulose",
    "is_drug": true,
    "canonical_name": "hydroxyethyl cellulose",
    "fda_search_term": "hydroxyethyl cellulose",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Anubis Barcelona Regul Oil",
      "Naturally Inspired Irritated Eye Relief",
      "Nite"
    ],
    "generic_names": [
      "CETEARYL ETHYLHEXANOATE, PROPYLENE GLYCOL, GLYCERYL STEARATE SE",
      "HYDROXYETHYL CELLULOSE",
      "PERSONAL LUBRICANT LOTION"
    ],
    "manufacturers": [
      "ANUBIS COSMETICS SL",
      "Nite Storm LLC",
      "Similasan Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warning: If irritaiton or discomfort occurs, discontinue use immediately and consult a physician",
      "Keep out of eyes and ears",
      "Keep out of reach of Children and pets",
      "Very slippery, clean spills immediately",
      "This product is not a contraceptive or spermicide",
      "Bottle may leak if not stored upright",
      "Store at ambient weather"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Usage: Gently squeeze out an appropriate amount of lubricant, and evenly apply it on the desired area"
    ]
  },
  "hydroxyethyl salicylate": {
    "ingredient": "hydroxyethyl salicylate",
    "is_drug": true,
    "canonical_name": "hydroxyethyl salicylate",
    "fda_search_term": "hydroxyethyl salicylate",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Glimepiride",
      "Naproxen"
    ],
    "generic_names": [
      "GLIMEPIRIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "American Health Packaging"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity",
      "In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction",
      "Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects",
      "The use of thyroid hormones in the therapy of obesity, alone or combined with other drugs, is unjustified and has been shown to be ineffective",
      "Neither is their use justified for the treatment of male or female infertility unless this condition is accompanied by hypothyroidism"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Table 1 for clinically significant drug interactions with naproxen",
      "Table 1: Clinically Significant Drug Interactions with naproxen Drugs That Interfere with Hemostasis Clinical Impact:",
      "Naproxen and anticoagulants such as warfarin have a synergistic effect on bleeding",
      "The concomitant use of naproxen and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone",
      "Serotonin release by platelets plays an important role in hemostasis",
      "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone",
      "Intervention: Monitor patients with concomitant use of naproxen tablets or naproxen sodium tablets with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleedin",
      "Aspirin Clinical Impact: A pharmacodynamic (PD) study has demonstrated an interaction in which lower dose naproxen (220mg/day or 220mg twice daily) interfered with the antiplatelet effect of low-dose immediate-release aspirin, with the interaction most marked during the washout period of naproxen ( ",
      "There is reason to expect that the interaction would be present with prescription doses of naproxen or with enteric-coated low-dose aspirin; however, the peak interference with aspirin function may be later than observed in the PD study due to the longer washout period",
      "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling:",
      "Cardiovascular Thrombotic Events [ see Warnings and Precautions ( 5.1 ) ]",
      "GI Bleeding, Ulceration, and Perforation [ see Warnings and Precautions ( 5.2 ) ]",
      "Hepatotoxicity [ see Warnings and Precautions ( 5.3 ) ]",
      "Hypertension [ see Warnings and Precautions ( 5.4 ) ]",
      "Heart Failure and Edema [ see Warnings and Precautions ( 5.5 ) ]",
      "Renal Toxicity and Hyperkalemia [ see Warnings and Precautions ( 5.6 ) ]",
      "Anaphylactic Reactions [ see Warnings and Precautions ( 5.7 ) ]",
      "Serious Skin Reactions [ see Warnings and Precautions ( 5.9 ) ]",
      "Hematologic Toxicity [ see Warnings and Precautions ( 5.12 ) ] Most common adverse reactions to naproxen were dyspepsia, abdominal pain, nausea, headache, rash, ecchymosis, and edema",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adverse reactions reported in controlled clinical trials in 960 patients treated for rheumatoid arthritis or osteoarthritis are listed below",
      "In general, reactions in patients treated chronically were reported 2 to 10 times more frequently than they were in short-term studies in the 962 patients treated for mild to moderate pain or for dysmenorrhea",
      "The most frequent complaints reported related to the gastrointestinal tract"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Naproxen tablets and naproxen sodium tablets are indicated for: the relief of the signs and symptoms of:",
      "rheumatoid arthritis",
      "ankylosing spondylitis",
      "Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets and naproxen sodium tablets are also indicated for: the relief of signs and symptoms of:",
      "acute gout the management of:"
    ]
  },
  "hydroxyethyl starch": {
    "ingredient": "hydroxyethyl starch",
    "is_drug": true,
    "canonical_name": "hydroxyethyl starch",
    "fda_search_term": "hydroxyethyl starch",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Glimepiride",
      "Methocarbamol",
      "Pain Reliever Extra Strength"
    ],
    "generic_names": [
      "ACETAMINOPHEN",
      "GLIMEPIRIDE",
      "METHOCARBAMOL"
    ],
    "manufacturers": [
      "American Health Packaging",
      "Proficient Rx LP",
      "Valu Merchandisers Company"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Since methocarbamol may possess a general CNS depressant effect, patients receiving Methocarbamol tablets, USP should be cautioned about combined effects with alcohol and other CNS depressants",
      "Safe use of Methocarbamol tablets, USP has not been established with regard to possible adverse effects upon fetal development",
      "There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol",
      "Therefore, Methocarbamol tablets, USP should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards (see Precautions, Pregnancy )",
      "Use In Activities Requiring Mental Alertness Methocarbamol may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle",
      "Patients should be cautioned about operating machinery, including automobiles, until they are reasonably certain that methocarbamol therapy does not adversely affect their ability to engage in such activities"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Certain medications may affect glucose metabolism, requiring glimepiride tablets dose adjustment and close monitoring of blood glucose ( 7.1 )",
      "Miconazole: Severe hypoglycemia can occur when glimepiride and oral miconazole are used concomitantly",
      "Cytochrome P450 2C9 interactions: Inhibitors and inducers of cytochrome P450 2C9 may affect glycemic control by altering glimepiride plasma concentrations ( 7.3 )",
      "Colesevelam: Coadministration may reduce glimepiride absorption",
      "Glimepiride should be administered at least 4 hours prior to colesevelam ( 2.1 , 7.4 )",
      "7.1 Drugs Affecting Glucose Metabolism A number of medications affect glucose metabolism and may require glimepiride tablets dose adjustment and particularly close monitoring for hypoglycemia or worsening glycemic control",
      "The following are examples of medications that may increase the glucose-lowering effect of sulfonylureas including glimepiride, increasing the susceptibility to and/or intensity of hypoglycemia: oral anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibit",
      "When these medications are administered to a patient receiving glimepiride, monitor the patient closely for hypoglycemia",
      "When these medications are withdrawn from a patient receiving glimepiride, monitor the patient closely for worsening glycemic control",
      "The following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control:"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed in more detail below and elsewhere in the labeling: Hypoglycemia [see Warnings and Precautions (5.1) ] Hemolytic anemia [see Warnings and Precautions (5.3) ] In clinical trials, the most common adverse reactions with glimepiri",
      "Common adverse reactions in clinical trials (≥5% and more common than with placebo) include hypoglycemia, headache, nausea, and dizziness ( 6.1 )",
      "To report SUSPECTED ADVERSE REACTIONS, contact Dr",
      "Reddy’s Laboratories, Inc",
      "at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Approximately 2,800 patients with type 2 diabetes have been treated with glimepiride in the controlled clinical trials",
      "In these trials, approximately 1,700 patients were treated with glimepiride for at least 1 year",
      "Table 1 summarizes adverse events, other than hypoglycemia, that were reported in 11 pooled placebo-controlled trials, whether or not considered to be possibly or probably related to study medication",
      "Treatment duration ranged from 13 weeks to 12 months",
      "Terms that are reported represent those that occurred at an incidence of ≥5% among glimepiride-treated patients and more commonly than in patients who received placebo",
      "Eleven Pooled Placebo-Controlled Trials ranging from 13 weeks to 12 months: Adverse Events (excluding hypoglycemia) Occurring in ≥5% of glimepiride-treated Patients and at a Greater Incidence than with Placebo Glimepiride doses ranged from 1 to 16 mg administered daily Glimepiride N=745 % Placebo N="
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ]",
      "Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings",
      "Glimepiride tablets are a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ( 1 )",
      "Limitations of Use: Not for treating type 1 diabetes mellitus or diabetic ketoacidosis ( 1 )"
    ]
  },
  "hydroxyethylcellulose": {
    "ingredient": "hydroxyethylcellulose",
    "is_drug": true,
    "canonical_name": "hydroxyethylcellulose",
    "fda_search_term": "hydroxyethylcellulose",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "KENX WATER BASED PERSONAL LUBRICANT",
      "Naturally Inspired Complete Eye Relief"
    ],
    "generic_names": [
      "HYDROXYETHYL CELLULOSE",
      "WATER BASED PERSONAL LUBRICANT"
    ],
    "manufacturers": [
      "SB Innovations LLC",
      "Similasan Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "If iritation or discomfort occurs, discontinue use and consult a physician",
      "Very slippery on surfaces",
      "Clean spills immediately",
      "Keep out of reach of children and pets",
      "This product is not a contraceptive or spermicide"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Apply and massage desired areas for a bilssful massage experience",
      "Splash a bit on and enjoy!"
    ]
  },
  "hydroxyl ethyl cellulose": {
    "ingredient": "hydroxyl ethyl cellulose",
    "is_drug": true,
    "canonical_name": "hydroxyethyl cellulose",
    "fda_search_term": "hydroxyethyl cellulose",
    "groq_confidence": 0.98,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Anubis Barcelona Regul Oil",
      "Naturally Inspired Irritated Eye Relief",
      "Nite"
    ],
    "generic_names": [
      "CETEARYL ETHYLHEXANOATE, PROPYLENE GLYCOL, GLYCERYL STEARATE SE",
      "HYDROXYETHYL CELLULOSE",
      "PERSONAL LUBRICANT LOTION"
    ],
    "manufacturers": [
      "ANUBIS COSMETICS SL",
      "Nite Storm LLC",
      "Similasan Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warning: If irritaiton or discomfort occurs, discontinue use immediately and consult a physician",
      "Keep out of eyes and ears",
      "Keep out of reach of Children and pets",
      "Very slippery, clean spills immediately",
      "This product is not a contraceptive or spermicide",
      "Bottle may leak if not stored upright",
      "Store at ambient weather"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Usage: Gently squeeze out an appropriate amount of lubricant, and evenly apply it on the desired area"
    ]
  },
  "hydroxymethyl cellulose": {
    "ingredient": "hydroxymethyl cellulose",
    "is_drug": true,
    "canonical_name": "hydroxymethyl cellulose",
    "fda_search_term": "hydroxymethyl cellulose",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Mekinist",
      "Naproxen"
    ],
    "generic_names": [
      "NAPROXEN",
      "TRAMETINIB"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Novartis Pharmaceuticals Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Allergy alert This product may cause a severe allergic realction",
      "Symptoms may include: wheezing/difficulty breathing hives shock rash facial swelling If an allergic reaction occurs, stop use and seek medical help right away",
      "Do not use if you are allergic to chlorhexidine gluconate or any other ingredients in this product",
      "When using this product keep out of eyes, ears and mouth",
      "May cause serious and permanent eye injury if permitted to enter or allowed to remain",
      "if contact occurs, rinse with cold water right away do not use routinely if you have wounds which involve more than the superficial layers of the skin Stop use and ask a doctor if irritation, sensitization, or allergic reaction occurs",
      "These may be signs of a serious condition",
      "Keep out of reach of children",
      "If swallowed, get medical help or contact a Poison Control Center right away"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Table 1 for clinically significant drug interactions with naproxen",
      "Table 1: Clinically Significant Drug Interactions with naproxen Drugs That Interfere with Hemostasis Clinical Impact:",
      "Naproxen and anticoagulants such as warfarin have a synergistic effect on bleeding",
      "The concomitant use of naproxen and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone",
      "Serotonin release by platelets plays an important role in hemostasis",
      "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone",
      "Intervention: Monitor patients with concomitant use of naproxen tablets or naproxen sodium tablets with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleedin",
      "Aspirin Clinical Impact: A pharmacodynamic (PD) study has demonstrated an interaction in which lower dose naproxen (220mg/day or 220mg twice daily) interfered with the antiplatelet effect of low-dose immediate-release aspirin, with the interaction most marked during the washout period of naproxen ( ",
      "There is reason to expect that the interaction would be present with prescription doses of naproxen or with enteric-coated low-dose aspirin; however, the peak interference with aspirin function may be later than observed in the PD study due to the longer washout period",
      "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling:",
      "Cardiovascular Thrombotic Events [ see Warnings and Precautions ( 5.1 ) ]",
      "GI Bleeding, Ulceration, and Perforation [ see Warnings and Precautions ( 5.2 ) ]",
      "Hepatotoxicity [ see Warnings and Precautions ( 5.3 ) ]",
      "Hypertension [ see Warnings and Precautions ( 5.4 ) ]",
      "Heart Failure and Edema [ see Warnings and Precautions ( 5.5 ) ]",
      "Renal Toxicity and Hyperkalemia [ see Warnings and Precautions ( 5.6 ) ]",
      "Anaphylactic Reactions [ see Warnings and Precautions ( 5.7 ) ]",
      "Serious Skin Reactions [ see Warnings and Precautions ( 5.9 ) ]",
      "Hematologic Toxicity [ see Warnings and Precautions ( 5.12 ) ] Most common adverse reactions to naproxen were dyspepsia, abdominal pain, nausea, headache, rash, ecchymosis, and edema",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adverse reactions reported in controlled clinical trials in 960 patients treated for rheumatoid arthritis or osteoarthritis are listed below",
      "In general, reactions in patients treated chronically were reported 2 to 10 times more frequently than they were in short-term studies in the 962 patients treated for mild to moderate pain or for dysmenorrhea",
      "The most frequent complaints reported related to the gastrointestinal tract"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Naproxen tablets and naproxen sodium tablets are indicated for: the relief of the signs and symptoms of:",
      "rheumatoid arthritis",
      "ankylosing spondylitis",
      "Polyarticular Juvenile Idiopathic Arthritis Naproxen tablets and naproxen sodium tablets are also indicated for: the relief of signs and symptoms of:",
      "acute gout the management of:"
    ]
  },
  "hydroxyprogesterone caproate": {
    "ingredient": "hydroxyprogesterone caproate",
    "is_drug": true,
    "canonical_name": "hydroxyprogesterone caproate",
    "fda_search_term": "hydroxyprogesterone caproate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Hydroxyprogesterone Caproate"
    ],
    "generic_names": [
      "HYDROXYPROGESTERONE CAPROATE"
    ],
    "manufacturers": [
      "AuroMedics Pharma LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Thrombotic and Thromboembolic Events Discontinue the medication pending examination if there is a sudden partial or complete loss of vision or if there is a sudden onset of proptosis, diplopia, or migraine",
      "Medication should be stopped if examination reveals papilledema or retinal vascular lesions",
      "Allergic reactions Hypersensitivity reaction to progestins have been reported",
      "Hydroxyprogesterone caproate is contraindicated in women with a history of hypersensitivity to a progestin",
      "Glucose tolerance Progestins may decrease glucose tolerance and the blood glucose concentration should be monitored in diabetic users"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS A",
      "Serious arterial thrombotic and venous thromboembolic events, including cases of pulmonary emboli (some fatal), deep vein thrombosis, myocardial infarction, and strokes, have been reported in women using progestins",
      "neuroocular lesions (e.g., retinal thrombosis and optic neuritis); nausea; vomiting; gastrointestinal symptoms (such as abdominal cramps or bloating); edema; breakthrough bleeding, spotting, or withdrawal bleeding; breast tenderness; changes in body weight (increase or decrease); headache; increase ",
      "chloasma or melasma, cholestatic jaundice, rise in blood pressure, mental depression, and amenorrhea during or after treatment",
      "posttreatment anovulation, cystitis, hirsutism, loss of scalp hair, changes in libido, changes in appetite, dizziness, fatigue, backache, itching, or amenorrhea",
      "The following laboratory tests may be affected by progestins: hepatic function (increased sulfobromophthalein retention and other tests); coagulation tests (increased in prothrombin and Factors VII, VIII, IX, and X); thyroid function tests (increase in PBI and butanol extractable protein-bound iodin",
      "A few instances of coughing, dyspnea, constriction of the chest, and/or allergic-like reactions have occurred following hydroxyprogesterone caproate therapy; the likelihood of these occurring may be increased at higher dosage levels"
    ],
    "indications": [
      "INDICATIONS AND USAGE Hydroxyprogesterone Caproate Injection, USP is indicated in non-pregnant women: for the treatment of advanced adenocarcinoma of the uterine corpus (Stage III or IV); in the management of amenorrhea (primary and secondary) and abnormal uterine bleeding due to hormonal imbalance "
    ]
  },
  "hydroxypropyl cel": {
    "ingredient": "hydroxypropyl cel",
    "is_drug": true,
    "canonical_name": "hydroxypropyl cellulose",
    "fda_search_term": "hydroxypropyl cellulose",
    "groq_confidence": 0.98,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Lacrisert"
    ],
    "generic_names": [
      "HYDROXYPROPYL CELLULOSE"
    ],
    "manufacturers": [
      "Bausch & Lomb Incorporated"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Instructions for inserting and removing LACRISERT should be carefully followed"
    ],
    "drug_interactions": [
      "Drug Interactions Application of hydroxypropyl cellulose ophthalmic inserts to the eyes of unanesthetized rabbits immediately prior to or two hours before instilling pilocarpine, proparacaine HCl (0.5%), or phenylephrine (5%) did not markedly alter the magnitude and/or duration of the miotic, local ",
      "Under various treatment schedules, the anti-inflammatory effect of ocularly instilled dexamethasone (0.1%) in unanesthetized rabbits with primary uveitis was not affected by the presence of hydroxypropyl cellulose inserts"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The following adverse reactions have been reported in patients treated with LACRISERT, but were in most instances mild and transient: Transient blurring of vision (see PRECAUTIONS ) Ocular discomfort or irritation Matting or stickiness of eyelashes Photophobia Hypersensitivity Edem"
    ],
    "indications": [
      "INDICATIONS AND USAGE LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca",
      "LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions",
      "LACRISERT is also indicated for patients with: Exposure keratitis Decreased corneal sensitivity Recurrent corneal erosions"
    ]
  },
  "hydroxypropyl cellulose": {
    "ingredient": "hydroxypropyl cellulose",
    "is_drug": true,
    "canonical_name": "hydroxypropyl cellulose",
    "fda_search_term": "hydroxypropyl cellulose",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Lacrisert"
    ],
    "generic_names": [
      "HYDROXYPROPYL CELLULOSE"
    ],
    "manufacturers": [
      "Bausch & Lomb Incorporated"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Instructions for inserting and removing LACRISERT should be carefully followed"
    ],
    "drug_interactions": [
      "Drug Interactions Application of hydroxypropyl cellulose ophthalmic inserts to the eyes of unanesthetized rabbits immediately prior to or two hours before instilling pilocarpine, proparacaine HCl (0.5%), or phenylephrine (5%) did not markedly alter the magnitude and/or duration of the miotic, local ",
      "Under various treatment schedules, the anti-inflammatory effect of ocularly instilled dexamethasone (0.1%) in unanesthetized rabbits with primary uveitis was not affected by the presence of hydroxypropyl cellulose inserts"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The following adverse reactions have been reported in patients treated with LACRISERT, but were in most instances mild and transient: Transient blurring of vision (see PRECAUTIONS ) Ocular discomfort or irritation Matting or stickiness of eyelashes Photophobia Hypersensitivity Edem"
    ],
    "indications": [
      "INDICATIONS AND USAGE LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca",
      "LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions",
      "LACRISERT is also indicated for patients with: Exposure keratitis Decreased corneal sensitivity Recurrent corneal erosions"
    ]
  },
  "hydroxypropyl methylcellulose": {
    "ingredient": "hydroxypropyl methylcellulose",
    "is_drug": true,
    "canonical_name": "hydroxypropyl methylcellulose",
    "fda_search_term": "hydroxypropyl methylcellulose",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Etodolac"
    ],
    "generic_names": [
      "ETODOLAC"
    ],
    "manufacturers": [
      "A-S Medication Solutions"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Cardiovascular Effects Cardiovascular Thrombotic Events Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can ",
      "Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs",
      "The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease",
      "However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate",
      "Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment",
      "The increase in CV thrombotic risk has been observed most consistently at higher doses",
      "To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible",
      "Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms",
      "Patients should be informed about the symptoms of serious CV events and the steps to take if they occur",
      "There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use"
    ],
    "drug_interactions": [
      "Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors",
      "This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors (see PRECAUTIONS , General , Renal Effects )",
      "Antacids The concomitant administration of antacids has no apparent effect on the extent of absorption of etodolac",
      "However, antacids can decrease the peak concentration reached by 15% to 20% but have no detectable effect on the time-to-peak",
      "Aspirin When etodolac is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered",
      "The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of etodolac and aspirin is not generally recommended because of the potential of increased adverse effects",
      "Cyclosporine, Digoxin, Methotrexate Etodolac, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity",
      "Nephrotoxicity associated with cyclosporine may also be enhanced",
      "Patients receiving these drugs who are given etodolac, or any other NSAID, and particularly those patients with altered renal function, should be observed for the development of the specific toxicities of these drugs",
      "NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS In patients taking etodolac or other NSAIDs, the most frequently reported adverse experiences occurring in approximately 1 to 10% of patients are: Gastrointestinal experiences including : abdominal pain, constipation, diarrhea, dyspepsia, flatulence, gross bleeding/perforation, hea",
      "Other events including : abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritis, rashes, tinnitus",
      "Adverse-reaction information for etodolac was derived from 2,629 arthritic patients treated with etodolac in double-blind and open-label clinical trials of 4 to 320 weeks in duration and worldwide postmarketing surveillance studies",
      "In clinical trials, most adverse reactions were mild and transient",
      "The discontinuation rate in controlled clinical trials, because of adverse events, was up to 10% for patients treated with etodolac",
      "New patient complaints (with an incidence greater than or equal to 1%) are listed below by body system",
      "The incidences were determined from clinical trials involving 465 patients with osteoarthritis treated with 300 to 500 mg of etodolac b.i.d",
      "(i.e., 600 to 1,000 mg/day)",
      "Incidence Greater Than Or Equal To 1%",
      "Probably Causally Related Body as a whole",
      "Chills and fever",
      "Digestive system",
      "Dyspepsia (10%), abdominal pain*, diarrhea*, flatulence*, nausea*, constipation, gastritis, melena, vomiting",
      "Asthenia/malaise*, dizziness*, depression, nervousness",
      "Skin and appendages"
    ],
    "indications": [
      "INDICATIONS AND USAGE Carefully consider the potential benefits and risks of etodolac and other treatment options before deciding to use etodolac",
      "Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS )",
      "Etodolac tablets, USP are indicated: For acute and long-term use in the management of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis For the management of acute pain"
    ]
  },
  "hydroxystearic acid": {
    "ingredient": "hydroxystearic acid",
    "is_drug": true,
    "canonical_name": "hydroxystearic acid",
    "fda_search_term": "hydroxystearic acid",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Naproxen"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS NOT FOR INJECTION",
      "Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye",
      "There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin",
      "Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching",
      "A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin",
      "If an allergic reaction to ofloxacin occurs, discontinue the drug",
      "Serious acute hypersensitivity reactions may require immediate emergency treatment",
      "Oxygen and airway management, including intubation should be administered as clinically indicated"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:"
    ]
  },
  "hydroxyurea": {
    "ingredient": "hydroxyurea",
    "is_drug": true,
    "canonical_name": "hydroxyurea",
    "fda_search_term": "hydroxyurea",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "DROXIA",
      "HYDROXYUREA"
    ],
    "generic_names": [
      "HYDROXYUREA"
    ],
    "manufacturers": [
      "Coupler LLC",
      "Golden State Medical Supply, Inc.",
      "Waylis Therapeutics LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Antiretroviral drugs (7.1) Laboratory Test Interference",
      "(7.2) 7.1 Increased Toxicity with Concomitant Use of Antiretroviral Drugs Pancreatitis In patients with HIV infection during therapy with hydroxyurea and didanosine, with or without stavudine, fatal and nonfatal pancreatitis have occurred",
      "Hydroxyurea is not indicated for the treatment of HIV infection; however, if patients with HIV infection are treated with hydroxyurea, and in particular, in combination with didanosine and/or stavudine, close monitoring for signs and symptoms of pancreatitis is recommended",
      "Permanently discontinue therapy with hydroxyurea in patients who develop signs and symptoms of pancreatitis",
      "Hepatotoxicity Hepatotoxicity and hepatic failure resulting in death have been reported during postmarketing surveillance in patients with HIV infection treated with hydroxyurea and other antiretroviral drugs",
      "Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine",
      "Avoid this combination",
      "Peripheral Neuropathy Peripheral neuropathy, which was severe in some cases, has been reported in patients with HIV infection receiving hydroxyurea in combination with antiretroviral drugs, including didanosine, with or without stavudine",
      "7.2 Laboratory Test Interference Interference with Uric Acid, Urea, or Lactic Acid Assays Studies have shown that there is an analytical interference of hydroxyurea with the enzymes (urease, uricase, and lactate dehydrogenase) used in the determination of urea, uric acid, and lactic acid, rendering ",
      "Interference with Continuous Glucose Monitoring Systems Hydroxyurea may falsely elevate sensor glucose results from certain continuous glucose monitoring (CGM) systems and may lead to hypoglycemia if sensor glucose results are relied upon to dose insulin"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS",
      "Myelosuppression [see Warnings and Precautions (5.1) ]",
      "Hemolytic anemia [see Warnings and Precautions (5.2) ]",
      "Malignancies [see Warnings and Precautions (5.3) ]",
      "Vasculitic toxicities [see Warnings and Precautions (5.5) ]",
      "Risks with concomitant use of antiretroviral drugs [see Warnings and Precautions (5.7) ]",
      "Radiation recall [see Warnings and Precautions (5.8) ]",
      "Macrocytosis [see Warnings and Precautions (5.9) ]",
      "Pulmonary Toxicity [see Warnings and Precautions (5.10) ] Most common adverse reactions (≥30%) are hematological, gastrointestinal symptoms, and anorexia",
      "(6) To report SUSPECTED ADVERSE REACTIONS, contact Leading Pharma, LLC at 1-844-740-7500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Postmarketing Experience The following adverse reactions have been identified during post-approval use of hydroxyurea capsules",
      "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency",
      "Reproductive System and Breast disorders: azoospermia, and oligospermia Gastrointestinal disorders: stomatitis, nausea, vomiting, diarrhea, and constipation Metabolism and Nutrition disorders: anorexia, tumor lysis syndrome Skin and subcutaneous tissue disorders: maculopapular rash, skin ulceration,"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Hydroxyurea capsules, USP is indicated for the treatment of: Resistant chronic myeloid leukemia",
      "Locally advanced squamous cell carcinomas of the head and neck (excluding the lip) in combination with chemoradiation",
      "Hydroxyurea capsules, USP is an antimetabolite indicated for the treatment of:",
      "Resistant chronic myeloid leukemia",
      "Locally advanced squamous cell carcinomas of the head and neck, (excluding lip) in combination with concurrent chemoradiation"
    ]
  },
  "hydroxyzine": {
    "ingredient": "hydroxyzine",
    "is_drug": true,
    "canonical_name": "hydroxyzine",
    "fda_search_term": "hydroxyzine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Hydroxyzine Pamoate",
      "hydroxyzine pamoate"
    ],
    "generic_names": [
      "HYDROXYZINE PAMOATE"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "Proficient Rx LP",
      "Teva Pharmaceuticals USA, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Nursing Mothers It is not known whether this drug is excreted in human milk",
      "Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS Side effects reported with the administration of hydroxyzine pamoate are usually mild and transitory in nature",
      "Skin and Appendages Oral hydroxyzine hydrochloride is associated with Acute Generalized Exanthematous Pustulosis (AGEP) and fixed drug eruptions in post-marketing reports",
      "Anticholinergic Dry mouth",
      "Central Nervous System Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of the dose",
      "Involuntary motor activity, including rare instances of tremor and convulsions, has been reported, usually with doses considerably higher than those recommended",
      "Clinically significant respiratory depression has not been reported at recommended doses",
      "Cardiac System QT prolongation, Torsade de Pointes",
      "In post-marketing experience, the following additional undesirable effects have been reported: Body as a Whole Allergic reaction Nervous System Headache Psychiatric Hallucination Skin and Appendages Pruritus, rash, urticaria"
    ],
    "indications": [
      "INDICATIONS For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested",
      "Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus",
      "As a sedative when used as premedication and following general anesthesia, hydroxyzine may potentiate meperidine (Demerol ® ) and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis",
      "Atropine and other belladonna alkaloids are not affected by the drug",
      "Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent"
    ]
  },
  "hydroxyzine hydrochloride": {
    "ingredient": "hydroxyzine hydrochloride",
    "is_drug": true,
    "canonical_name": "hydroxyzine",
    "fda_search_term": "hydroxyzine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Hydroxyzine Pamoate",
      "hydroxyzine pamoate"
    ],
    "generic_names": [
      "HYDROXYZINE PAMOATE"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "Proficient Rx LP",
      "Teva Pharmaceuticals USA, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Nursing Mothers It is not known whether this drug is excreted in human milk",
      "Since many drugs are so excreted, hydroxyzine should not be given to nursing mothers"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS Side effects reported with the administration of hydroxyzine pamoate are usually mild and transitory in nature",
      "Skin and Appendages Oral hydroxyzine hydrochloride is associated with Acute Generalized Exanthematous Pustulosis (AGEP) and fixed drug eruptions in post-marketing reports",
      "Anticholinergic Dry mouth",
      "Central Nervous System Drowsiness is usually transitory and may disappear in a few days of continued therapy or upon reduction of the dose",
      "Involuntary motor activity, including rare instances of tremor and convulsions, has been reported, usually with doses considerably higher than those recommended",
      "Clinically significant respiratory depression has not been reported at recommended doses",
      "Cardiac System QT prolongation, Torsade de Pointes",
      "In post-marketing experience, the following additional undesirable effects have been reported: Body as a Whole Allergic reaction Nervous System Headache Psychiatric Hallucination Skin and Appendages Pruritus, rash, urticaria"
    ],
    "indications": [
      "INDICATIONS For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested",
      "Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus",
      "As a sedative when used as premedication and following general anesthesia, hydroxyzine may potentiate meperidine (Demerol ® ) and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis",
      "Atropine and other belladonna alkaloids are not affected by the drug",
      "Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent"
    ]
  },
  "hylaronic acid": {
    "ingredient": "hylaronic acid",
    "is_drug": true,
    "canonical_name": "hylaronic acid",
    "fda_search_term": "hylaronic acid",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Naproxen"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS NOT FOR INJECTION",
      "Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye",
      "There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin",
      "Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching",
      "A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin",
      "If an allergic reaction to ofloxacin occurs, discontinue the drug",
      "Serious acute hypersensitivity reactions may require immediate emergency treatment",
      "Oxygen and airway management, including intubation should be administered as clinically indicated"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:"
    ]
  },
  "hylauronic": {
    "ingredient": "hylauronic",
    "is_drug": true,
    "canonical_name": "hyaluronic acid",
    "fda_search_term": "hyaluronic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "AOAO Retinol Anti-aging Box Set",
      "ClearSoothingCream",
      "Roushun kojic Skin Lightening Nutural Skin Care treament serum 30ml"
    ],
    "generic_names": [
      "COLLAGEN,BUTYROSPERMUM PARKII (SHEA) BUTTER EXTRACT,HYALURONIC ACID,CAFFEINE,SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL,RETINOL.",
      "HYALURONIC ACID",
      "ROUSHUN KOJIC SKIN LIGHTENING NUTURAL SKIN CARE TREAMENT SERUM 30ML"
    ],
    "manufacturers": [
      "Guangdong Junhui Biotechnology Co., LTD",
      "Roushun Kojic Skin lightening natural skin care treatment serum",
      "Shengnan (Guangzhou) Cosmetics Co., LTD"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only",
      "Keep out ofreach of children.Avoid contact with eyes"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Take out a bottle of essence from the box 2",
      "Unscrew the top cap and squeeze the essence into the palm of your hand 3",
      "Apply evenly on the face and neck, gently massage until fully moisturized"
    ]
  },
  "hylornic acid": {
    "ingredient": "hylornic acid",
    "is_drug": true,
    "canonical_name": "hylornic acid",
    "fda_search_term": "hylornic acid",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Naproxen"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS NOT FOR INJECTION",
      "Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye",
      "There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin",
      "Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching",
      "A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin",
      "If an allergic reaction to ofloxacin occurs, discontinue the drug",
      "Serious acute hypersensitivity reactions may require immediate emergency treatment",
      "Oxygen and airway management, including intubation should be administered as clinically indicated"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:"
    ]
  },
  "hylouronic acid": {
    "ingredient": "hylouronic acid",
    "is_drug": true,
    "canonical_name": "hyaluronic acid",
    "fda_search_term": "hyaluronic acid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "AOAO Retinol Anti-aging Box Set",
      "ClearSoothingCream",
      "Roushun kojic Skin Lightening Nutural Skin Care treament serum 30ml"
    ],
    "generic_names": [
      "COLLAGEN,BUTYROSPERMUM PARKII (SHEA) BUTTER EXTRACT,HYALURONIC ACID,CAFFEINE,SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL,RETINOL.",
      "HYALURONIC ACID",
      "ROUSHUN KOJIC SKIN LIGHTENING NUTURAL SKIN CARE TREAMENT SERUM 30ML"
    ],
    "manufacturers": [
      "Guangdong Junhui Biotechnology Co., LTD",
      "Roushun Kojic Skin lightening natural skin care treatment serum",
      "Shengnan (Guangzhou) Cosmetics Co., LTD"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only",
      "Keep out ofreach of children.Avoid contact with eyes"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Take out a bottle of essence from the box 2",
      "Unscrew the top cap and squeeze the essence into the palm of your hand 3",
      "Apply evenly on the face and neck, gently massage until fully moisturized"
    ]
  },
  "hyoscyamine": {
    "ingredient": "hyoscyamine",
    "is_drug": true,
    "canonical_name": "hyoscyamine",
    "fda_search_term": "hyoscyamine",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Hyoscyamine ER",
      "Hyosyne",
      "URIBEL TABS"
    ],
    "generic_names": [
      "HYOSCYAMINE SULFATE",
      "METHENAMINE, BENZOIC ACID, PHENYL SALICYLATE, METHYLENE BLUE, AND HYOSCYAMINE SULFATE"
    ],
    "manufacturers": [
      "ATLANTIC BIOLOGICALS CORP.",
      "Mission Pharmacal Company",
      "Pharma Packaging Solutions, LLC dba Tjopack LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS In the presence of high environmental temperature, heat prostration can occur with drug use (fever and heat stroke due to decreased sweating)",
      "Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy",
      "In this instance, treatment with this drug would be inappropriate and possibly harmful",
      "Like other anticholinergic agents, hyoscyamine sulfate may produce drowsiness, dizziness, or blurred vision",
      "In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery or to perform hazardous work while taking this drug",
      "Psychosis has been reported in sensitive individuals given anticholinergic drugs including hyoscyamine sulfate",
      "CNS signs and symptoms include confusion, disorientation, short-term memory loss, hallucinations, dysarthria, ataxia, euphoria, anxiety, fatigue, insomnia, agitation and mannerisms, and inappropriate affect",
      "These CNS signs and symptoms usually resolve within 12 to 48 hours after discontinuation of the drug"
    ],
    "drug_interactions": [
      "Drug Interactions Additive adverse effects resulting from cholinergic blockade may occur when hyoscyamine sulfate is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines",
      "Antacids may interfere with the absorption of hyoscyamine sulfate"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS All of the following adverse reactions have been reported with hyoscyamine sulfate",
      "Adverse reactions may include dryness of the mouth; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; mydriasis; increased ocular tension; loss of taste; headache; nervousness; drowsiness; weakness; fatigue; dizziness; insomnia; nausea; vomiting; impotence; constipation; bl"
    ],
    "indications": [
      "INDICATIONS AND USAGE Hyoscyamine sulfate extended-release tablets are effective as adjunctive therapy in the treatment of peptic ulcer",
      "They can also be used to control gastric secretion, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm, and associated abdominal cramps",
      "May be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis, and acute enterocolitis",
      "For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders",
      "Also used as adjunctive therapy in the treatment of neurogenic bladder andmneurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon)"
    ]
  },
  "hyoscyamine sulfate": {
    "ingredient": "hyoscyamine sulfate",
    "is_drug": true,
    "canonical_name": "hyoscyamine",
    "fda_search_term": "hyoscyamine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Hyoscyamine ER",
      "Hyosyne",
      "URIBEL TABS"
    ],
    "generic_names": [
      "HYOSCYAMINE SULFATE",
      "METHENAMINE, BENZOIC ACID, PHENYL SALICYLATE, METHYLENE BLUE, AND HYOSCYAMINE SULFATE"
    ],
    "manufacturers": [
      "ATLANTIC BIOLOGICALS CORP.",
      "Mission Pharmacal Company",
      "Pharma Packaging Solutions, LLC dba Tjopack LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS In the presence of high environmental temperature, heat prostration can occur with drug use (fever and heat stroke due to decreased sweating)",
      "Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy",
      "In this instance, treatment with this drug would be inappropriate and possibly harmful",
      "Like other anticholinergic agents, hyoscyamine sulfate may produce drowsiness, dizziness, or blurred vision",
      "In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery or to perform hazardous work while taking this drug",
      "Psychosis has been reported in sensitive individuals given anticholinergic drugs including hyoscyamine sulfate",
      "CNS signs and symptoms include confusion, disorientation, short-term memory loss, hallucinations, dysarthria, ataxia, euphoria, anxiety, fatigue, insomnia, agitation and mannerisms, and inappropriate affect",
      "These CNS signs and symptoms usually resolve within 12 to 48 hours after discontinuation of the drug"
    ],
    "drug_interactions": [
      "Drug Interactions Additive adverse effects resulting from cholinergic blockade may occur when hyoscyamine sulfate is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines",
      "Antacids may interfere with the absorption of hyoscyamine sulfate"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS All of the following adverse reactions have been reported with hyoscyamine sulfate",
      "Adverse reactions may include dryness of the mouth; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; mydriasis; increased ocular tension; loss of taste; headache; nervousness; drowsiness; weakness; fatigue; dizziness; insomnia; nausea; vomiting; impotence; constipation; bl"
    ],
    "indications": [
      "INDICATIONS AND USAGE Hyoscyamine sulfate extended-release tablets are effective as adjunctive therapy in the treatment of peptic ulcer",
      "They can also be used to control gastric secretion, visceral spasm and hypermotility in spastic colitis, spastic bladder, cystitis, pylorospasm, and associated abdominal cramps",
      "May be used in functional intestinal disorders to reduce symptoms such as those seen in mild dysenteries, diverticulitis, and acute enterocolitis",
      "For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and functional gastrointestinal disorders",
      "Also used as adjunctive therapy in the treatment of neurogenic bladder andmneurogenic bowel disturbances (including the splenic flexure syndrome and neurogenic colon)"
    ]
  },
  "hypericum": {
    "ingredient": "hypericum",
    "is_drug": true,
    "canonical_name": "hypericum",
    "fda_search_term": "hypericum",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "EMF Protect and Balance",
      "Sports For Trauma Gel",
      "T-Relief Extra Strength"
    ],
    "generic_names": [
      "ALFALFA, CADMIUM SULPHURATUM, CALCAREA CARBONICA, CUPRUM METALLICUM, FERRUM METALLICUM, FUCUS VESICULOSUS, HYPERICUM PERFORATUM, KALI PHOSPHORICUM, MAGNESIA PHOSPHORICA, MANGANUM METALLICUM, MERCURIUS VIVUS, PLUMBUM METALLICUM, SILICEA, SYMPHYTUM OFFICINALE, TARENTULA HISPANA, X-RAY, YTTERBIUM OXIDE",
      "BELLIS PERENNIS, HYPERICUM PERFOMATUM,TOXICODENDRON PUBSCENS LEAF, RUTA GRAVEOLENS FLOWERING TOP",
      "CALENDULA OFFICINALIS FLOWERING TOP, MATRICARIA RECUTITA, HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK, ACHILLEA MILLEFOLIUM, RUTA GRAVEOLENS FLOWERING TOP, COMFREY ROOT, ACONITUM NAPELLUS, ECHINACEA, UNSPECIFIED, BAPTISIA TINCTORIA ROOT, ATROPA BELLADONNA, ARNICA MONTANA, BELLIS PERENNIS AND HYPERICUM PERFORATUM"
    ],
    "manufacturers": [
      "Deseret Biologicals, Inc.",
      "MediNatura Inc",
      "Schwabe Mexico, S.A. de C.V."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only",
      "Avoid contact with eyes and broken skin"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Indications & Usage Temporarily relieves deep muscle and back pain, stiffness, and swelling associated with overexertion, sprains, falls, blows, and minor sports injuries",
      "Relieves joint and tendon pain and inflammation"
    ]
  },
  "hypericum perforatum": {
    "ingredient": "hypericum perforatum",
    "is_drug": true,
    "canonical_name": "hypericum perforatum",
    "fda_search_term": "hypericum perforatum",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "EMF Protect and Balance",
      "Sports For Trauma Gel",
      "T-Relief Extra Strength"
    ],
    "generic_names": [
      "ALFALFA, CADMIUM SULPHURATUM, CALCAREA CARBONICA, CUPRUM METALLICUM, FERRUM METALLICUM, FUCUS VESICULOSUS, HYPERICUM PERFORATUM, KALI PHOSPHORICUM, MAGNESIA PHOSPHORICA, MANGANUM METALLICUM, MERCURIUS VIVUS, PLUMBUM METALLICUM, SILICEA, SYMPHYTUM OFFICINALE, TARENTULA HISPANA, X-RAY, YTTERBIUM OXIDE",
      "BELLIS PERENNIS, HYPERICUM PERFOMATUM,TOXICODENDRON PUBSCENS LEAF, RUTA GRAVEOLENS FLOWERING TOP",
      "CALENDULA OFFICINALIS FLOWERING TOP, MATRICARIA RECUTITA, HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK, ACHILLEA MILLEFOLIUM, RUTA GRAVEOLENS FLOWERING TOP, COMFREY ROOT, ACONITUM NAPELLUS, ECHINACEA, UNSPECIFIED, BAPTISIA TINCTORIA ROOT, ATROPA BELLADONNA, ARNICA MONTANA, BELLIS PERENNIS AND HYPERICUM PERFORATUM"
    ],
    "manufacturers": [
      "Deseret Biologicals, Inc.",
      "MediNatura Inc",
      "Schwabe Mexico, S.A. de C.V."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only",
      "Avoid contact with eyes and broken skin"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Indications & Usage Temporarily relieves deep muscle and back pain, stiffness, and swelling associated with overexertion, sprains, falls, blows, and minor sports injuries",
      "Relieves joint and tendon pain and inflammation"
    ]
  },
  "hypertonic seawater 2": {
    "ingredient": "hypertonic seawater 2",
    "is_drug": true,
    "canonical_name": "hypertonic seawater 2",
    "fda_search_term": "hypertonic seawater 2",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Betadine",
      "SILICEA"
    ],
    "generic_names": [
      "POVIDONE-IODINE",
      "SILICEA"
    ],
    "manufacturers": [
      "Atlantis Consumer Healthcare, Inc.",
      "Rxhomeo Private Limited d.b.a. Rxhomeo, Inc"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS This product is to be used for self-limiting conditions If symptoms do not improve in 4 days, or worsen, discontinue use and seek assistance of health professional",
      "As with any drug, if you are pregnant, or nursing a baby, seek professional advice before taking this product",
      "Keep this and all medication out of reach of children Do not use if capseal is broken or missing",
      "Close the cap tightly after use"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS Condition listed above or as directed by the physician"
    ]
  },
  "hypochlorus acid": {
    "ingredient": "hypochlorus acid",
    "is_drug": true,
    "canonical_name": "hypochlorus acid",
    "fda_search_term": "hypochlorus acid",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Naproxen"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS NOT FOR INJECTION",
      "Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye",
      "There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin",
      "Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching",
      "A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin",
      "If an allergic reaction to ofloxacin occurs, discontinue the drug",
      "Serious acute hypersensitivity reactions may require immediate emergency treatment",
      "Oxygen and airway management, including intubation should be administered as clinically indicated"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:"
    ]
  },
  "hypromellose": {
    "ingredient": "hypromellose",
    "is_drug": true,
    "canonical_name": "hypromellose",
    "fda_search_term": "hypromellose",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Rohto Dual Light Relief",
      "Vista Gonio Eye Lubricant"
    ],
    "generic_names": [
      "HYPROMELLOSE OPHTHALMIC SOLUTION",
      "HYPROMELLOSE, POVIDONE"
    ],
    "manufacturers": [
      "Red Wedding LLC",
      "Rohto Pharmaceutical Co., Ltd.",
      "The Mentholatum Company"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnngs For external use only Do not use ■ if this product changes color or becomes cloudy ■ if seal is broken or punctured When using this product ■ do not touch tip of container to any surface to avoid contamination ■ replace cap after each use Stop use and consult a physician if you experience an",
      "Do not use if this product changes color or becomes cloudy if you are sensitive to any ingredient in this product When using this product do not touch the tip of container to any surface to avoid contamination replace cap after each use Stop use and consult a physician if you experience any of the f"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses for use as a lubricant to prevent further irritation to relieve dryness of the eye"
    ]
  },
  "ibandronic acid": {
    "ingredient": "ibandronic acid",
    "is_drug": true,
    "canonical_name": "ibandronic acid",
    "fda_search_term": "ibandronic acid",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Naproxen"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS NOT FOR INJECTION",
      "Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye",
      "There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin",
      "Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching",
      "A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin",
      "If an allergic reaction to ofloxacin occurs, discontinue the drug",
      "Serious acute hypersensitivity reactions may require immediate emergency treatment",
      "Oxygen and airway management, including intubation should be administered as clinically indicated"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:"
    ]
  },
  "ibrutinib": {
    "ingredient": "ibrutinib",
    "is_drug": true,
    "canonical_name": "ibrutinib",
    "fda_search_term": "ibrutinib",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Imbruvica"
    ],
    "generic_names": [
      "IBRUTINIB"
    ],
    "manufacturers": [
      "Pharmacyclics LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS CYP3A Inhibitors: Modify IMBRUVICA dose as described ( 2.3 , 7.1 )",
      "CYP3A Inducers: Avoid coadministration with strong CYP3A inducers ( 7.2 )",
      "7.1 Effect of CYP3A Inhibitors on Ibrutinib The coadministration of IMBRUVICA with a strong or moderate CYP3A inhibitor may increase ibrutinib plasma concentrations [see Clinical Pharmacology ( 12.3 )] ",
      "Increased ibrutinib concentrations may increase the risk of drug-related toxicity",
      "Dose modifications of IMBRUVICA are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors [see Dosage and Administration ( 2.3 )]",
      "Avoid concomitant use of other strong CYP3A inhibitors",
      "Interrupt IMBRUVICA if these inhibitors will be used short-term (such as anti-infectives for seven days or less) [see Dosage and Administration ( 2.3 ) ] ",
      "Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain strong or moderate inhibitors of CYP3A",
      "7.2 Effect of CYP3A Inducers on Ibrutinib The coadministration of IMBRUVICA with strong CYP3A inducers may decrease ibrutinib concentrations",
      "Avoid coadministration with strong CYP3A inducers [see Clinical Pharmacology ( 12.3 ) ] "
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Hemorrhage [see Warnings and Precautions ( 5.1 )] Infections [see Warnings and Precautions ( 5.2 )] Cardiac Arrhythmias, Cardiac Failure, and Sudden Death [see Warnings and Precautions",
      "The most common (≥20%) adverse reactions in adult or pediatric patients with cGVHD are fatigue, anemia, bruising, diarrhea, thrombocytopenia, musculoskeletal pain, pyrexia, muscle spasms, stomatitis, hemorrhage, nausea, abdominal pain, pneumonia, and headache ( 6 )",
      "To report SUSPECTED ADVERSE REACTIONS, contact AbbVie at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely variable conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice",
      "Unless otherwise specified, the pooled safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to IMBRUVICA in 6 trials",
      "IMBRUVICA was administered as a single agent at 420 mg orally once daily (475 patients), as a single agent at 560 mg orally once daily [1.3 times the recommended adult dosage (174 patients)], and in combination with other drugs at 420 mg orally once daily (827 patients) in patients with B-cell malig",
      "In this pooled safety population of 1,476 patients, 87% were ex"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE IMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) ( 1.1 )",
      "Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion ( 1.2 )",
      "Adult patients with Waldenström’s macroglobulinemia (WM) ( 1.3 )",
      "Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy ( 1.4 )",
      "1.1 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)"
    ]
  },
  "ibuprofen": {
    "ingredient": "ibuprofen",
    "is_drug": true,
    "canonical_name": "ibuprofen",
    "fda_search_term": "ibuprofen",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Ibuprofen",
      "Ibuprofen Dye Free",
      "care one ibuprofen"
    ],
    "generic_names": [
      "IBUPROFEN"
    ],
    "manufacturers": [
      "American Sales Company",
      "Aurobindo Pharma Limited",
      "CVS Pharmacy"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Allergy alert: Ibuprofen may cause a severe allergic reaction, especially in people allergic to aspirin",
      "Symptoms may include: rash facial swelling asthma (wheezing) hives skin reddening shock blisters If an allergic reaction occurs, stop use and seek medical help right away",
      "Stomach bleeding warning: This product contains an NSAID, which may cause severe stomach bleeding",
      "The chance is higher if you: take more or for a longer time than directed take a blood thinning (anticoagulant) or steroid drug have had stomach ulcers or bleeding problems have 3 or more alcoholic drinks every day while using this product are age 60 or older take other drugs containing prescription",
      "These can be fatal",
      "The risk is higher if you use more than directed or for longer than directed",
      "Do not use if you have ever had an allergic reaction to any other pain reliever/fever reducer right before or after heart surgery Ask a doctor before use if stomach bleeding warning applies to you you have a history of stomach problems, such as heartburn you have high blood pressure, heart disease, "
    ],
    "drug_interactions": [
      "Preexisting asthma Patients with asthma may have aspirin-sensitive asthma",
      "The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe bronchospasm, which can be fatal",
      "Since cross reactivity, including bronchospasm, between aspirin and NSAIDs has been reported in such aspirin-sensitive patients, ibuprofen tablets should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The most frequent type of adverse reaction occurring with ibuprofen tablets is gastrointestinal",
      "In controlled clinical trials the percentage of patients reporting one or more gastrointestinal complaints ranged from 4% to 16%",
      "In controlled studies when ibuprofen tablets were compared to aspirin and indomethacin in equally effective doses, the overall incidence of gastrointestinal complaints was about half that seen in either the aspirin",
      "or indomethacin-treated patients",
      "Adverse reactions observed during controlled clinical trials at an incidence greater than 1% are listed in the table",
      "Those reactions listed in Column one encompass observations in approximately 3,000 patients",
      "More than 500 of these patients were treated for periods of at least 54 weeks",
      "Still other reactions occurring less frequently than 1 in 100 were reported in controlled clinical trials and from marketing experience",
      "These reactions have been divided into two categories: Column two of the table lists reactions with therapy with ibuprofen tablets where the probability of a causal relationship exists: for the reactions in Column three, a causal relationship with ibuprofen tablets has not been established",
      "Reported side effects were higher at doses of 3200 mg/day than at doses of 2400 mg or less per day in clinical trials of patients with rheumatoid arthritis",
      "The increases in incidence were slight and still within the ranges reported in the table",
      "Incidence Greater than 1% (but less than 3%) Probable Causal Relationship Precise Incidence Unknown (but less than 1%) Probable Causal Relationship* Precise Incidence Unknown (but less than 1%) Causal Relationship Unknown* *Reactions are classified under \"Probable Causal Relationship (PCR)\" if there",
      "Reactions are classified under \"Causal Relationship Unknown\" if seven or more events have been reported but the criteria for PCR have not b"
    ],
    "indications": [
      "Uses temporarily relieves minor aches and pains due to: headache toothache backache menstrual cramps the common cold muscular aches minor pain of arthritis temporarily reduces fever"
    ]
  },
  "ichthammol": {
    "ingredient": "ichthammol",
    "is_drug": true,
    "canonical_name": "ichthammol",
    "fda_search_term": "ichthammol",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "D-104",
      "Ichthammol 20%",
      "Prid"
    ],
    "generic_names": [
      "APIUM GRAVEOLENS WHOLE, ASCLEPIAS INCARNATA ROOT, CALCIUM ARSENATE, CAMPHOR (NATURAL), ECHINACEA ANGUSTIFOLIA, EUPATORIUM PERFOLIATUM FLOWERING TOP, EUPHRASIA STRICTA, FERROUS IODIDE, ICHTHAMMOL, SCABIES LESION LYSATE (HUMAN), THUJA OCCIDENTALIS LEAFY TWIG, AND TRIFOLIUM REPENS FLOWER",
      "ICHTHAMMOL",
      "ICHTHAMMOL, CALCIUM SULFIDE, CALENDULA OFFICINALIS FLOWERING TOP, ARNICA MONTANA, ECHINACEA ANGUSTIFOLIA, SILICON DIOXIDE, SULFUR"
    ],
    "manufacturers": [
      "Chain Drug Marketing Association, Inc.",
      "DNA Labs, Inc.",
      "Hyland's Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Use only if cap seal is unbroken",
      "If pregnant or breastfeeding, ask a healthcare professional before use",
      "Keep this and all medication out of the reach of children"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS For viral infections"
    ]
  },
  "icosapent ethyl": {
    "ingredient": "icosapent ethyl",
    "is_drug": true,
    "canonical_name": "icosapent ethyl",
    "fda_search_term": "icosapent ethyl",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ICOSAPENT ETHYL",
      "Icosapent Ethyl"
    ],
    "generic_names": [
      "ICOSAPENT ETHYL"
    ],
    "manufacturers": [
      "AvKARE",
      "Bryant Ranch Prepack",
      "XLCare Pharmaceuticals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time",
      "Monitor patients receiving icosapent ethyl and concomitant anticoagulants and/or antiplatelet agents for bleeding",
      "(7) 7.1 Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents Some published studies with omega-3 fatty acids have demonstrated prolongation of bleeding time",
      "The prolongation of bleeding time reported in those studies has not exceeded normal limits and did not produce clinically significant bleeding episodes",
      "Monitor patients receiving icosapent ethyl and concomitant anticoagulants and/or antiplatelet agents for bleeding"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following important adverse reactions are described below and elsewhere in the labeling: Atrial Fibrillation or Atrial Flutter [see Warnings and Precautions (5.1)] Potential for Allergic Reactions in Patients with Fish Allergy [see Warnings and Precautions (5.2)] Bleeding [se",
      "(6.1) Common adverse reactions in the hypertriglyceridemia trials (incidence ≥1% more frequent than placebo): arthralgia and oropharyngeal pain",
      "(6.1) To report SUSPECTED ADVERSE REACTIONS, contact XLCare Pharmaceuticals, Inc",
      "at 1-866-495-1995 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Common adverse reactions (incidence ≥3% on icosapent ethyl and ≥1% more frequent than placebo) included musculoskeletal pain, peripheral edema, constipation, gout, and atrial fibrillation",
      "Hypertriglyceridemia Trials In two randomized, double-blind, placebo-controlled trials in patients with triglyceride levels between 200 and 2000 mg/dL treated for 12 weeks, adverse reactions reported with icosapent ethyl at an incidence ≥1% more frequent than placebo based on pooled data included ar",
      "6.2 Postmarketing Experience Additional adverse reactions have been identified during post-approval use of icosapent ethyl capsules",
      "Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure",
      "Diarrhea Blood triglycerides increased Abd"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Icosapent ethyl capsules are indicated: as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia",
      "Limitations of Use: The effect of icosapent ethyl capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined",
      "Icosapent ethyl capsules are an ethyl ester of eicosapentaenoic acid (EPA) indicated: as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia",
      "(1) Limitations of Use: The effect of icosapent ethyl capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined"
    ]
  },
  "ictamol acid oint": {
    "ingredient": "ictamol acid oint",
    "is_drug": true,
    "canonical_name": "ictamol acid oint",
    "fda_search_term": "ictamol acid oint",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Naproxen"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "NAPROXEN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS NOT FOR INJECTION",
      "Ofloxacin ophthalmic solution should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye",
      "There are rare reports of anaphylactic reaction/shock and fatal hypersensitivity reactions in patients receiving systemic quinolones, some following the first dose, including ofloxacin",
      "Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial edema), airway obstruction, dyspnea, urticaria, and itching",
      "A rare occurrence of Stevens-Johnson syndrome, which progressed to toxic epidermal necrolysis, has been reported in a patient who was receiving topical ophthalmic ofloxacin",
      "If an allergic reaction to ofloxacin occurs, discontinue the drug",
      "Serious acute hypersensitivity reactions may require immediate emergency treatment",
      "Oxygen and airway management, including intubation should be administered as clinically indicated"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:"
    ]
  },
  "idarubicin": {
    "ingredient": "idarubicin",
    "is_drug": true,
    "canonical_name": "idarubicin",
    "fda_search_term": "idarubicin",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Idamycin PFS",
      "Idarubicin Hydrochloride"
    ],
    "generic_names": [
      "IDARUBICIN HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Hikma Pharmaceuticals USA Inc.",
      "Pfizer Laboratories Div Pfizer Inc"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Idarubicin is intended for administration under the supervision of a physician who is experienced in leukemia chemotherapy",
      "Idarubicin is a potent bone marrow suppressant",
      "Idarubicin should not be given to patients with pre-existing bone marrow suppression induced by previous drug therapy or radiotherapy unless the benefit warrants the risk",
      "Severe myelosuppression will occur in all patients given a therapeutic dose of this agent for induction, consolidation or maintenance",
      "Careful hematologic monitoring is required",
      "Deaths due to infection and/or bleeding have been reported during the period of severe myelosuppression",
      "Facilities with laboratory and supportive resources adequate to monitor drug tolerability and protect and maintain a patient compromised by drug toxicity should be available",
      "It must be possible to treat rapidly and completely a severe hemorrhagic condition and/or a severe infection",
      "Pre-existing heart disease and previous therapy with anthracyclines at high cumulative doses or other potentially cardiotoxic agents are co-factors for increased risk of idarubicin-induced cardiac toxicity and the benefit to risk ratio of idarubicin therapy in such patients should be weighed before ",
      "Myocardial toxicity as manifested by potentially fatal congestive heart failure, acute life-threatening arrhythmias or other cardiomyopathies may occur following therapy with idarubicin"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling:",
      "Cardiomyopathy [see Warnings and Precautions (5.1) ]",
      "Secondary Malignancies [see Warnings and Precautions (5.2) ]",
      "Severe Local Tissue Necrosis with Extravasation [see Warnings and Precautions (5.3) ]",
      "Severe Myelosuppression [see Warnings and Precautions (5.4) ]",
      "Tumor Lysis Syndrome [see Warnings and Precautions (5.5) ]",
      "Hypersensitivity [see Warnings and Precautions (5.6) ] Most common adverse reactions (≥30%) are infection, nausea/vomiting, alopecia, abdominal pain/diarrhea, hemorrhage, mucositis, dermatologic, mental status changes, and pulmonary disorders",
      "(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials and Postmarketing Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed ",
      "The safety of IDAMYCIN PFS in combination with cytarabine has been evaluated in four controlled clinical studies with 823 patients with AML randomized to receive idarubicin hydrochloride (n=401) or daunorubicin (n=422) [see Clinical Studies (14) ] ",
      "Southeastern Cancer Study Group (SEG) Table 3 below lists the adverse reactions that occurred in patients with AML who received idarubicin hydrochloride in the Southeastern Cancer Study Group (SEG) study",
      "Table 3: Adverse Reactions (≥5%) in Patients with AML Who Received Idarubicin Hydrochloride as Induction Therapy in the SEG Trial Adverse Reactions Idarubicin with Cytarabine (N=110) Daunorubicin with Cytarabine (N=118) All Grades % All Grades % Infection 95 97 Nausea/Vomiting 82 80 Alopecia 77 72 A"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE IDAMYCIN PFS is indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen",
      "IDAMYCIN PFS is an anthracycline topoisomerase inhibitor indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen"
    ]
  },
  "ifosfamide": {
    "ingredient": "ifosfamide",
    "is_drug": true,
    "canonical_name": "ifosfamide",
    "fda_search_term": "ifosfamide",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "IFEX",
      "IFOSFAMIDE",
      "Ifosfamide"
    ],
    "generic_names": [
      "IFOSFAMIDE"
    ],
    "manufacturers": [
      "Baxter Healthcare Corporation",
      "Fresenius Kabi USA, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers",
      "CYP3A4 Inhibitors: Use in combination with CYP3A4 inhibitors could decrease the effectiveness of ifosfamide",
      "( 7.2 ) 7.1 Inducers of CYP3A4 CYP3A4 inducers may increase the metabolism of ifosfamide to its active alkylating metabolites",
      "CYP3A4 inducers may increase the formation of the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde",
      "Closely monitor patients taking ifosfamide with CYP3A4 inducers for toxicities and consider dose adjustment",
      "7.2 Inhibitors of CYP3A4 CYP3A4 inhibitors may decrease the metabolism of ifosfamide to its active alkylating metabolites, perhaps decreasing the effectiveness of ifosfamide treatment"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common (≥ 10%) adverse reactions were alopecia, nausea/vomiting, hematuria, leukopenia, anemia, CNS toxicity, infection",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare at phone: 1 866 888 2472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted from widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practic",
      "The adverse reactions in Table 2 below are based on 30 publications describing clinical experience with fractionated administration of ifosfamide as a single agent with a total dose of 4 to 12 g/m 2 per course",
      "Table 2: Adverse Reactions in Patients Treated with Single Agent Ifosfamide for Injection Adverse Reaction Single Agent Ifosfamide for Injection % (number of patients) Skin and Subcutaneous Tissue Disorders Alopecia 90% (540/603) Dermatitis 0.08% (1/1317) Papular rash 0.08% (1/1317) Gastrointestinal",
      "without mesna 44% (282/640)",
      "with mesna 21% (33/155) Macrohematuria",
      "without mesna 11% (66/594)",
      "with mesna 5% (5/97) Renal dysfunction Includes acute renal failure, irreversible renal failure (fatal outcomes) serum creatinine increased, BUN increased, creatinine clearance decreased, metabolic acidosis, anuria, oliguria, glycosuria, hyponatremia, uremia, creatinine clearance increased ",
      "Renal structural damage Includes acute tubular necrosis, renal parenchymal damage, enzymuria, cylindruria, proteinuria ",
      "Blood and Lymphatic System Disorders Leukopenia Includes neutropenia, granulocytopenia, lymphopenia, and pancytopenia (any) ",
      "Leukopenia <1 x 10 3 /µL 44% (267/614) Anemia Includes anemia"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Ifosfamide for Injection is indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer",
      "Ifosfamide for Injection is an alkylating drug indicated for use in adults in combination with certain other approved antineoplastic agents for third-line chemotherapy of germ cell testicular cancer"
    ]
  },
  "imatinib": {
    "ingredient": "imatinib",
    "is_drug": true,
    "canonical_name": "imatinib",
    "fda_search_term": "imatinib",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Imatinib Mesylate",
      "imatinib mesylate"
    ],
    "generic_names": [
      "IMATINIB",
      "IMATINIB MESYLATE"
    ],
    "manufacturers": [
      "Apotex Corp",
      "Mylan Institutional Inc",
      "Sun Pharmaceutical Industries, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS CYP3A4 inducers may decrease imatinib mesylate C max and area under curve (AUC)",
      "( 2.12 , 7.1 , 12.3 ) CYP3A4 inhibitors may increase imatinib mesylate C max and AUC",
      "( 7.2 , 12.3 ) Imatinib mesylate is an inhibitor of CYP3A4 and CYP2D6 which may increase the C max and AUC of other drugs",
      "( 7.3 , 7.4 , 12.3 ) Patients who require anticoagulation should receive low-molecular weight or standard heparin and not warfarin",
      "( 7.3 ) Imatinib mesylate tablets delay the clearance of methotrexate when methotrexate is used at high doses (> 500 mg/m 2 )",
      "( 7.5 ) 7.1 Agents Inducing CYP3A Metabolism Concomitant administration of imatinib mesylate tablets and strong CYP3A4 inducers may reduce total exposure of imatinib; consider alternative agents [see Clinical Pharmacology ( 12.3 )] ",
      "7.2 Agents Inhibiting CYP3A Metabolism Concomitant administration of imatinib mesylate tablets and strong CYP3A4 inhibitors may result in a significant imatinib exposure increase",
      "Grapefruit juice may also increase plasma concentrations of imatinib; avoid grapefruit juice [see Clinical Pharmacology ( 12.3 )] ",
      "7.3 Interactions With Drugs Metabolized by CYP3A4 Imatinib mesylate will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.)",
      "Use caution when administering imatinib mesylate tablets with CYP3A4 substrates that have a narrow therapeutic window"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: Fluid Retention and Edema [see Warnings and Precautions ( 5.1 )] Hematologic Toxicity [see Warnings and Precautions ( 5.2 )] Congestive Heart Failure and Left Ventricular Dysfunction [see Warnings an",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp",
      "at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Chronic Myeloid Leukemia The majority of imatinib mesylate-treated patients experienced adverse reactions at some time",
      "Imatinib was discontinued due to drug-related adverse reactions in 2.4% of patients receiving imatinib mesylate in the randomized trial of newly diagnosed patients with Ph+ CML in chronic phase comparing imatinib mesylate versus IFN+Ara-C, and in 12.5% of patients receiving imati"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of:",
      "Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 )",
      "Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 )",
      "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 )",
      "Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy ( 1.4 )"
    ]
  },
  "imatinib mesylate": {
    "ingredient": "imatinib mesylate",
    "is_drug": true,
    "canonical_name": "imatinib",
    "fda_search_term": "imatinib",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Imatinib Mesylate",
      "imatinib mesylate"
    ],
    "generic_names": [
      "IMATINIB",
      "IMATINIB MESYLATE"
    ],
    "manufacturers": [
      "Apotex Corp",
      "Mylan Institutional Inc",
      "Sun Pharmaceutical Industries, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS CYP3A4 inducers may decrease imatinib mesylate C max and area under curve (AUC)",
      "( 2.12 , 7.1 , 12.3 ) CYP3A4 inhibitors may increase imatinib mesylate C max and AUC",
      "( 7.2 , 12.3 ) Imatinib mesylate is an inhibitor of CYP3A4 and CYP2D6 which may increase the C max and AUC of other drugs",
      "( 7.3 , 7.4 , 12.3 ) Patients who require anticoagulation should receive low-molecular weight or standard heparin and not warfarin",
      "( 7.3 ) Imatinib mesylate tablets delay the clearance of methotrexate when methotrexate is used at high doses (> 500 mg/m 2 )",
      "( 7.5 ) 7.1 Agents Inducing CYP3A Metabolism Concomitant administration of imatinib mesylate tablets and strong CYP3A4 inducers may reduce total exposure of imatinib; consider alternative agents [see Clinical Pharmacology ( 12.3 )] ",
      "7.2 Agents Inhibiting CYP3A Metabolism Concomitant administration of imatinib mesylate tablets and strong CYP3A4 inhibitors may result in a significant imatinib exposure increase",
      "Grapefruit juice may also increase plasma concentrations of imatinib; avoid grapefruit juice [see Clinical Pharmacology ( 12.3 )] ",
      "7.3 Interactions With Drugs Metabolized by CYP3A4 Imatinib mesylate will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.)",
      "Use caution when administering imatinib mesylate tablets with CYP3A4 substrates that have a narrow therapeutic window"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: Fluid Retention and Edema [see Warnings and Precautions ( 5.1 )] Hematologic Toxicity [see Warnings and Precautions ( 5.2 )] Congestive Heart Failure and Left Ventricular Dysfunction [see Warnings an",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp",
      "at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Chronic Myeloid Leukemia The majority of imatinib mesylate-treated patients experienced adverse reactions at some time",
      "Imatinib was discontinued due to drug-related adverse reactions in 2.4% of patients receiving imatinib mesylate in the randomized trial of newly diagnosed patients with Ph+ CML in chronic phase comparing imatinib mesylate versus IFN+Ara-C, and in 12.5% of patients receiving imati"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Imatinib mesylate is a kinase inhibitor indicated for the treatment of:",
      "Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 )",
      "Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 )",
      "Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 )",
      "Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy ( 1.4 )"
    ]
  },
  "imiglucerase": {
    "ingredient": "imiglucerase",
    "is_drug": true,
    "canonical_name": "imiglucerase",
    "fda_search_term": "imiglucerase",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Cerezyme"
    ],
    "generic_names": [
      "IMIGLUCERASE"
    ],
    "manufacturers": [
      "Genzyme Corporation"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions Including Anaphylaxis [see Warnings and Precautions (5.1) ] Infusion-Associated Reactions [see Warnings and Precautions (5.2) ] Adverse reactions reported in",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Genzyme at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials and Postmarketing Experience The following adverse reactions associated with the use of imiglucerase were identified in clinical studies or postmarketing reports",
      "Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure",
      "See Table 2 for adverse reactions occurring in adults and pediatric patients treated with CEREZYME in clinical trials and the postmarketing setting",
      "Table 2: Adverse Reactions in Adults and Pediatric Patients Treated with CEREZYME Adverse Reactions Nervous system disorders dizziness, headache Cardiac disorders tachycardia Vascular disorders cyanosis, Signs and symptoms suggestive of hypersensitivity reactions including anaphylaxis [see Warnings ",
      "flushing, hypotension, hypertension Respiratory, thoracic and mediastinal disorders cough, dyspnea, pneumonia, pulmonary hypertension Gastrointestinal disorders abdominal pain, diarrhea, nausea, vomiting Immune system disorders anaphylaxis, hypersensitivity Skin and subcutaneous tissue disorders ang"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE CEREZYME is indicated for the treatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patients",
      "CEREZYME is a hydrolytic lysosomal glucocerebrosidase-specific enzyme indicated for the treatment of non-central nervous system (CNS) manifestations of Type 1 or Type 3 Gaucher disease in adults and pediatric patients"
    ]
  },
  "imipramine": {
    "ingredient": "imipramine",
    "is_drug": true,
    "canonical_name": "imipramine",
    "fda_search_term": "imipramine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Imipramine Hydrochloride"
    ],
    "generic_names": [
      "IMIPRAMINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "NuCare Pharmaceuticals, Inc.",
      "REMEDYREPACK INC."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Clinical Worsening and Suicide Risk Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antid",
      "Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide",
      "There has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment",
      "Pooled analyses of short-term placebo-controlled trials of antidepressant drugs",
      "(SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with major depressive disorder (MDD) and other psychiatric disorders",
      "Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older",
      "The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4400 patients",
      "The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients",
      "There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied",
      "There were differences in absolute risk of suicidality across the different indic"
    ],
    "drug_interactions": [
      "Drug Interactions Drugs Metabolized by P450 2D6 : The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so-called \"poor metabolizers\"); reliable estimates of the pr",
      "Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses",
      "Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA)",
      "In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers",
      "An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy",
      "The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide)",
      "While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition",
      "The extent to which SSRI-TCA interaction may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved",
      "Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other",
      "Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary)"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Note",
      "Although the listing which follows includes a few adverse reactions which have not been reported with this specific drug, the pharmacological similarities among the tricyclic antidepressant drugs require that each of the reactions be considered when imipramine hydrochloride is administered",
      "Cardiovascular : Orthostatic hypotension, hypertension, tachycardia, palpitation, myocardial infarction, arrhythmias, heart block, ECG changes, precipitation of congestive heart failure, stroke",
      "Psychiatric : Confusional states (especially in the elderly) with hallucinations, disorientation, delusions; anxiety, restlessness, agitation; insomnia and nightmares; hypomania; exacerbation of psychosis",
      "Neurological : Numbness, tingling, paresthesias of extremities; incoordination, ataxia, tremors; peripheral neuropathy; extrapyramidal symptoms; seizures, alterations in EEG patterns; tinnitus",
      "Anticholinergic : Dry mouth, and, rarely, associated sublingual adenitis; blurred vision, disturbances of accommodation, mydriasis; constipation, paralytic ileus; urinary retention, delayed micturition, dilation of the urinary tract",
      "Allergic : Skin rash, petechiae, urticaria, itching, photosensitization; edema (general or of face and tongue); drug fever; cross-sensitivity with desipramine",
      "Hematologic : Bone marrow depression including agranulocytosis; eosinophilia; purpura; thrombocytopenia",
      "Gastrointestinal : Nausea and vomiting, anorexia, epigastric distress, diarrhea; peculiar taste, stomatitis, abdominal cramps, black tongue",
      "Endocrine : Gynecomastia in the male; breast enlargement and galactorrhea in the female; increased or decreased libido, impotence; testicular swelling; elevation or depression of blood sugar levels; inappropriate antidiuretic hormone (ADH) secretion syndrome",
      "Other : Jaundice (simulating obstructive); altered liver function; weight gain or loss; perspiration; flushing; urinary frequency; drowsiness, dizziness, weakness and fatigue; headache; par"
    ],
    "indications": [
      "INDICATIONS AND USAGE Depression -For the relief of symptoms of depression",
      "Endogenous depression is more likely to be alleviated than other depressive states",
      "One to three weeks of treatment may be needed before optimal therapeutic effects are evident",
      "Childhood Enuresis -May be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excluded by appropriate tests",
      "In patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary"
    ]
  },
  "imiquimod": {
    "ingredient": "imiquimod",
    "is_drug": true,
    "canonical_name": "imiquimod",
    "fda_search_term": "imiquimod",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Imiquimod",
      "Zyclara"
    ],
    "generic_names": [
      "IMIQUIMOD"
    ],
    "manufacturers": [
      "Bausch Health US, LLC",
      "Bryant Ranch Prepack",
      "Padagis Israel Pharmaceuticals Ltd"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling:",
      "Local Skin Reactions [see Warnings and Precautions ( 5.1 )]",
      "Local Hypopigmentation Reactions [see Warnings and Precautions ( 5.2 )]",
      "Systemic Reactions [see Warnings and Precautions ( 5.3 )] Most common application site or local skin adverse reactions (incidence >28%) are erythema, flaking/scaling/dryness, scabbing/crusting, edema, erosion/ulceration, induration, itching, burning, excoriation, vesicles",
      "Other reported systemic adverse reactions (≥1%): fatigue, fever, and headache",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Padagis ® at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Actinic Keratosis The data described below reflect exposure to Imiquimod Cream or vehicle in 436 subjects with AK enrolled in two double-blind, vehicle-controlled trials (Studies AK1 and AK2) [see Clinical Studies (14.1)] ",
      "Subjects applied Imiquimod Cream, 5% or vehicle topically, to a 25 cm 2 contiguous treatment area on the face or scalp once daily 2 times per week for 16 weeks",
      "The incidence of selected adverse reactions reported by ≥1% of subjects during the trials is presented in Table 2",
      "Table 2: Selected Adverse Reactions Occurring in ≥1% of Imiquimod-Treated Subjects with AK and at a Greater Frequency than Vehicle in Studies AK1 and AK2 Imiquimod Cream (n= 215) Vehicle (n= 221) Application Site Reaction 71 (33%) 32 (14%) Upper Respiratory Tract Infection 33 (15%) 27 (12%) Sinusiti"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Imiquimod Cream is indicated for the topical treatment of:",
      "Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults",
      "Biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults with a maximum tumor diameter of 2.0 cm on trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up c",
      "External genital and perianal warts (EGW) in immunocompetent patients 12 years of age and older",
      "( 1.3 ) 1.1 Actinic Keratosis Imiquimod Cream is indicated for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults"
    ]
  },
  "immunoglobin": {
    "ingredient": "immunoglobin",
    "is_drug": true,
    "canonical_name": "immunoglobulin",
    "fda_search_term": "immunoglobulin",
    "groq_confidence": 0.98,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "GUNA-FLAM",
      "GUNA-HEMORRHOIDS",
      "QIVIGY kthm"
    ],
    "generic_names": [
      "ACONITUM NAPELLUS - APIS MELLIFERA - ATROPA BELLADONNA - BASIC CUPRIC CARBONATE - BRYONIA ALBA ROOT - CALCIUM SULFIDE - CITRIC ACID MONOHYDRATE - FERRIC PHOSPHATE - INTERLEUKIN-10 - MELATONIN - METENKEFALIN - PHYTOLACCA AMERICANA ROOT - RANCID BEEF - SODIUM PYRUVATE - SUS SCROFA CONJUNCTIVA - SUS SCROFA PINEAL GLAND - SUS SCROFA PITUITARY GLAND - TRANSFORMING GROWTH FACTOR BETA-1 - ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT -",
      "ACTIVATED CHARCOAL - ARNICA MONTANA - ATROPA BELLADONNA - CANAKINUMAB - HYDROCOTYLE ASIATICA EXTRACT - AESCULUS HIPPOCASTANUM FLOWER - MELISSA OFFICINALIS - PAEONIA OFFICINALIS ROOT - PODOPHYLLUM PELTATUM ROOT - PORK LIVER - STRYCHNOS NUX-VOMICA SEED - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA VEIN - HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK - ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT -",
      "HUMAN IMMUNOGLOBULIN G"
    ],
    "manufacturers": [
      "Guna spa",
      "Kedrion S.p.A."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Stop use and ask doctor if symptoms persist more than 5 days",
      "If pregnant or breast-feeding ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away",
      "Contains ethyl alcohol 30%"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTION The passive transfer of antibodies may: Interfere with the response to live virus vaccines, such as measles, rubella, mumps and varicella",
      "( 7 ) Result in misleading positive results in serological testing",
      "( 5.9 , 7 ) 7.1 Effect of QIVIGY on Live attenuated virus vaccines Immune globulin administration may transiently impair the efficacy of live attenuated virus vaccines such as measles, mumps, rubella, s and varicella because the continued presence of high levels of passively acquired antibody may in",
      "Inform the immunizing physician of recent therapy with QIVIGY so that appropriate measures may be taken",
      "7.2 Effect of QIVIGY on Serological Testing Passive transmission of antibodies through immune globulin administration may interfere with some serological testing [see Warnings and Precautions (5.10) ]",
      "7.3 Effect of Loop diuretics on QIVIGY The use of loop diuretics should be avoided",
      "Concomitant use of loop diuretics with IGIV may contribute to an increased blood viscosity and subsequently increase the risk of thromboembolic events"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common adverse reactions observed in ≥ 5% of patients were headache, fatigue, nausea, infusion-related reaction, Coombs direct test positive, sinusitis, dizziness and diarrhea",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc",
      "at 1-855-3KDRION (1-855-353-7466) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of one drug cannot be directly compared to rates in oth",
      "The safety data described in this section reflects exposure to QIVIGY in one clinical study",
      "A total of 47 patients with PI received intravenous infusion of QIVIGY at a dose range of 266 to 826 mg/kg every 3 or 4 weeks for up to 12 months [see Clinical Studies (14) ] ",
      "A total of 643 infusions of QIVIGY were administered, 136 in the every 3-week schedule and 507 in the 4-week schedule",
      "During the study, 4 out of 47 (9%) patients received premedication",
      "The most common product-related adverse events observed in ≥ 5% of clinical study patients with PI were headache, infusion-related reaction, Coombs direct test positive, fatigue, and nausea",
      "Table 2 lists the most common adverse reactions reported in ≥5% of patients",
      "Table 2: Adverse Reactions Adverse reactions were defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period",
      "Occurring in ≥ 5% of Patients Adverse Reaction By Patients n (%) [n = 47] By Infusions n (%) [n = 643] Headache 14 (30) 26 (4) Fatigue 7 (15) 10 (2) Nausea 6 (13) 6 (<1) Infusion-related Reaction 5 (11) 7 (1) Coombs Direct Test Positive 5 (11) 8 (1) Sinusitis 3 (6) 3 (<1) Dizziness 3 (6) 3 (<1) Diar"
    ],
    "indications": [
      "Take 15 minutes before meals"
    ]
  },
  "immunoglobulin": {
    "ingredient": "immunoglobulin",
    "is_drug": true,
    "canonical_name": "immunoglobulin",
    "fda_search_term": "immunoglobulin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "GUNA-FLAM",
      "GUNA-HEMORRHOIDS",
      "QIVIGY kthm"
    ],
    "generic_names": [
      "ACONITUM NAPELLUS - APIS MELLIFERA - ATROPA BELLADONNA - BASIC CUPRIC CARBONATE - BRYONIA ALBA ROOT - CALCIUM SULFIDE - CITRIC ACID MONOHYDRATE - FERRIC PHOSPHATE - INTERLEUKIN-10 - MELATONIN - METENKEFALIN - PHYTOLACCA AMERICANA ROOT - RANCID BEEF - SODIUM PYRUVATE - SUS SCROFA CONJUNCTIVA - SUS SCROFA PINEAL GLAND - SUS SCROFA PITUITARY GLAND - TRANSFORMING GROWTH FACTOR BETA-1 - ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT -",
      "ACTIVATED CHARCOAL - ARNICA MONTANA - ATROPA BELLADONNA - CANAKINUMAB - HYDROCOTYLE ASIATICA EXTRACT - AESCULUS HIPPOCASTANUM FLOWER - MELISSA OFFICINALIS - PAEONIA OFFICINALIS ROOT - PODOPHYLLUM PELTATUM ROOT - PORK LIVER - STRYCHNOS NUX-VOMICA SEED - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA VEIN - HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK - ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT -",
      "HUMAN IMMUNOGLOBULIN G"
    ],
    "manufacturers": [
      "Guna spa",
      "Kedrion S.p.A."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Stop use and ask doctor if symptoms persist more than 5 days",
      "If pregnant or breast-feeding ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away",
      "Contains ethyl alcohol 30%"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTION The passive transfer of antibodies may: Interfere with the response to live virus vaccines, such as measles, rubella, mumps and varicella",
      "( 7 ) Result in misleading positive results in serological testing",
      "( 5.9 , 7 ) 7.1 Effect of QIVIGY on Live attenuated virus vaccines Immune globulin administration may transiently impair the efficacy of live attenuated virus vaccines such as measles, mumps, rubella, s and varicella because the continued presence of high levels of passively acquired antibody may in",
      "Inform the immunizing physician of recent therapy with QIVIGY so that appropriate measures may be taken",
      "7.2 Effect of QIVIGY on Serological Testing Passive transmission of antibodies through immune globulin administration may interfere with some serological testing [see Warnings and Precautions (5.10) ]",
      "7.3 Effect of Loop diuretics on QIVIGY The use of loop diuretics should be avoided",
      "Concomitant use of loop diuretics with IGIV may contribute to an increased blood viscosity and subsequently increase the risk of thromboembolic events"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common adverse reactions observed in ≥ 5% of patients were headache, fatigue, nausea, infusion-related reaction, Coombs direct test positive, sinusitis, dizziness and diarrhea",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc",
      "at 1-855-3KDRION (1-855-353-7466) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of one drug cannot be directly compared to rates in oth",
      "The safety data described in this section reflects exposure to QIVIGY in one clinical study",
      "A total of 47 patients with PI received intravenous infusion of QIVIGY at a dose range of 266 to 826 mg/kg every 3 or 4 weeks for up to 12 months [see Clinical Studies (14) ] ",
      "A total of 643 infusions of QIVIGY were administered, 136 in the every 3-week schedule and 507 in the 4-week schedule",
      "During the study, 4 out of 47 (9%) patients received premedication",
      "The most common product-related adverse events observed in ≥ 5% of clinical study patients with PI were headache, infusion-related reaction, Coombs direct test positive, fatigue, and nausea",
      "Table 2 lists the most common adverse reactions reported in ≥5% of patients",
      "Table 2: Adverse Reactions Adverse reactions were defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period",
      "Occurring in ≥ 5% of Patients Adverse Reaction By Patients n (%) [n = 47] By Infusions n (%) [n = 643] Headache 14 (30) 26 (4) Fatigue 7 (15) 10 (2) Nausea 6 (13) 6 (<1) Infusion-related Reaction 5 (11) 7 (1) Coombs Direct Test Positive 5 (11) 8 (1) Sinusitis 3 (6) 3 (<1) Dizziness 3 (6) 3 (<1) Diar"
    ],
    "indications": [
      "Take 15 minutes before meals"
    ]
  },
  "immunoglobulin g": {
    "ingredient": "immunoglobulin g",
    "is_drug": true,
    "canonical_name": "immunoglobulin g",
    "fda_search_term": "immunoglobulin g",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "GUNA-FLAM",
      "GUNA-HEMORRHOIDS",
      "QIVIGY kthm"
    ],
    "generic_names": [
      "ACONITUM NAPELLUS - APIS MELLIFERA - ATROPA BELLADONNA - BASIC CUPRIC CARBONATE - BRYONIA ALBA ROOT - CALCIUM SULFIDE - CITRIC ACID MONOHYDRATE - FERRIC PHOSPHATE - INTERLEUKIN-10 - MELATONIN - METENKEFALIN - PHYTOLACCA AMERICANA ROOT - RANCID BEEF - SODIUM PYRUVATE - SUS SCROFA CONJUNCTIVA - SUS SCROFA PINEAL GLAND - SUS SCROFA PITUITARY GLAND - TRANSFORMING GROWTH FACTOR BETA-1 - ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT -",
      "ACTIVATED CHARCOAL - ARNICA MONTANA - ATROPA BELLADONNA - CANAKINUMAB - HYDROCOTYLE ASIATICA EXTRACT - AESCULUS HIPPOCASTANUM FLOWER - MELISSA OFFICINALIS - PAEONIA OFFICINALIS ROOT - PODOPHYLLUM PELTATUM ROOT - PORK LIVER - STRYCHNOS NUX-VOMICA SEED - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA VEIN - HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK - ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT -",
      "HUMAN IMMUNOGLOBULIN G"
    ],
    "manufacturers": [
      "Guna spa",
      "Kedrion S.p.A."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Stop use and ask doctor if symptoms persist more than 5 days",
      "If pregnant or breast-feeding ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away",
      "Contains ethyl alcohol 30%"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTION The passive transfer of antibodies may: Interfere with the response to live virus vaccines, such as measles, rubella, mumps and varicella",
      "( 7 ) Result in misleading positive results in serological testing",
      "( 5.9 , 7 ) 7.1 Effect of QIVIGY on Live attenuated virus vaccines Immune globulin administration may transiently impair the efficacy of live attenuated virus vaccines such as measles, mumps, rubella, s and varicella because the continued presence of high levels of passively acquired antibody may in",
      "Inform the immunizing physician of recent therapy with QIVIGY so that appropriate measures may be taken",
      "7.2 Effect of QIVIGY on Serological Testing Passive transmission of antibodies through immune globulin administration may interfere with some serological testing [see Warnings and Precautions (5.10) ]",
      "7.3 Effect of Loop diuretics on QIVIGY The use of loop diuretics should be avoided",
      "Concomitant use of loop diuretics with IGIV may contribute to an increased blood viscosity and subsequently increase the risk of thromboembolic events"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common adverse reactions observed in ≥ 5% of patients were headache, fatigue, nausea, infusion-related reaction, Coombs direct test positive, sinusitis, dizziness and diarrhea",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc",
      "at 1-855-3KDRION (1-855-353-7466) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of one drug cannot be directly compared to rates in oth",
      "The safety data described in this section reflects exposure to QIVIGY in one clinical study",
      "A total of 47 patients with PI received intravenous infusion of QIVIGY at a dose range of 266 to 826 mg/kg every 3 or 4 weeks for up to 12 months [see Clinical Studies (14) ] ",
      "A total of 643 infusions of QIVIGY were administered, 136 in the every 3-week schedule and 507 in the 4-week schedule",
      "During the study, 4 out of 47 (9%) patients received premedication",
      "The most common product-related adverse events observed in ≥ 5% of clinical study patients with PI were headache, infusion-related reaction, Coombs direct test positive, fatigue, and nausea",
      "Table 2 lists the most common adverse reactions reported in ≥5% of patients",
      "Table 2: Adverse Reactions Adverse reactions were defined as adverse events occurring during or within 72 hours of infusion or any causally related event occurring within the study period",
      "Occurring in ≥ 5% of Patients Adverse Reaction By Patients n (%) [n = 47] By Infusions n (%) [n = 643] Headache 14 (30) 26 (4) Fatigue 7 (15) 10 (2) Nausea 6 (13) 6 (<1) Infusion-related Reaction 5 (11) 7 (1) Coombs Direct Test Positive 5 (11) 8 (1) Sinusitis 3 (6) 3 (<1) Dizziness 3 (6) 3 (<1) Diar"
    ],
    "indications": [
      "Take 15 minutes before meals"
    ]
  },
  "inactivated": {
    "ingredient": "inactivated",
    "is_drug": true,
    "canonical_name": "inactivated",
    "fda_search_term": "inactivated",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Flu-Tone",
      "INFLUENZINUM",
      "Lycopodium Combination 9231"
    ],
    "generic_names": [
      "ANAS BARBARIAE, HEPATIS ET CORDIS EXTRACTUM, AZADIRACHTA INDICA, BAPTISIA TINCTORIA, BRYONIA (ALBA), CROTALUS HORRIDUS, ECHINACEA (ANGUSTIFOLIA), EUPATORIUM PERFOLIATUM, FERRUM PHOSPHORICUM, GELSEMIUM SEMPERVIRENS, GINKGO BILOBA, INFLUENZINUM, MUCOSA NASALIS SUIS, PHYTOLACCA DECANDRA, PINUS SYLVESTRIS, PYROGENIUM, SELENIUM METALLICUM, STILLINGIA SYLVATICA",
      "INFLUENZA A VIRUS A/VICTORIA/4897/2022 IVR-238 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/DARWIN/9/2021 IVR-228 (H3N2) HEMAGGLUTININ ANTIGEN (UV, FORMALDEHYDE INACTIVATED),INFLUENZA B VIRUS B/MICHIGAN/01/2021 HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA B VIRUS B/PHUKET/3073/2013 HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)",
      "LYCOPODIUM COMBINATION"
    ],
    "manufacturers": [
      "Boiron",
      "Energetix Corporation",
      "Professional Complementary Health Formulas"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS If symptoms do not improve or are accompanied by a fever, consult a doctor",
      "Keep out of the reach of children",
      "In case of overdose, get medical help or contact a poison control center right away",
      "If pregnant or breastfeeding, ask a healthcare professional before use",
      "Keep out of the reach of children",
      "If pregnant or breastfeeding, ask a healthcare professional before use"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS For the temporary relief of loss of appetite, minor abdominal pain, nausea, or vomiting.*"
    ]
  },
  "inclisiran": {
    "ingredient": "inclisiran",
    "is_drug": true,
    "canonical_name": "inclisiran",
    "fda_search_term": "inclisiran",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "LEQVIO"
    ],
    "generic_names": [
      "INCLISIRAN"
    ],
    "manufacturers": [
      "Novartis Pharmaceuticals Corporation"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are also discussed in other sections of the label: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Common adverse reactions in clinical trials (≥ 3%): injection site reaction, arthralgia, and bronchitis",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adverse Reactions in Adults with Hypercholesterolemia The data in Table 1 are derived from 3 placebo-controlled trials that included 1,833 adults with hypercholesterolemia treated with LEQVIO, including 1,682 exposed for 18 months (median treatment duration of 77 weeks) [see Clinical Studies (14)] ",
      "The mean age of the population was 64 years, 32% of the population were female, 92% were White, 6% were Black or African American, 1% were Asian, and < 1% were other races; 6% identified as Hispanic or Latino ethnicity",
      "At baseline, 12% of patients had a diagnosis of HeFH and 85% had clinical atherosclerotic cardiovascular disease (ASCVD)",
      "Adverse reactions reported in at least 3% of LEQVIO-treated patients, and more frequently than in placebo-treated patients, are shown in Table 1",
      "Table 1: Adverse Reactions Occurring in Greater Than or Equal to 3% of LEQVIO-treated Adults with Hypercholesterolemia and More Frequently than with Placebo (Trials 1, 2, and 3) Adverse Reactions Placebo (N = 1,822) % LEQVIO (N = 1,833) % †includes related terms such as: injection site pain, erythem"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE LEQVIO ® is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia",
      "adults and pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH)",
      "pediatric patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH)",
      "LEQVIO is a small interfering RNA (siRNA) directed to proprotein convertase subtilisin kexin type 9 (PCSK9) mRNA indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia",
      "( 1 ) adults and pediatric patients aged 12 years and older with heterozygous familial hypercholesterolemia (HeFH)"
    ]
  },
  "indapamide": {
    "ingredient": "indapamide",
    "is_drug": true,
    "canonical_name": "indapamide",
    "fda_search_term": "indapamide",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Indapamide"
    ],
    "generic_names": [
      "INDAPAMIDE"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "Direct_Rx",
      "Rising Pharma Holdings, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Severe cases of hyponatremia, accompanied by hypokalemia have been reported with recommended doses of indapamide",
      "This occurred primarily in elderly females",
      "(See PRECAUTIONS , Geriatric Use .) This appears to be dose related",
      "Also, a large case-controlled pharmacoepidemiology study indicates that there is an increased risk of hyponatremia with indapamide 2.5 mg and 5 mg doses",
      "Hyponatremia considered possibly clinically significant (< 125 mEq/L) has not been observed in clinical trials with the 1.25 mg dosage (see PRECAUTIONS )",
      "Thus, patients should be started at the 1.25 mg dose and maintained at the lowest possible dose",
      "(See DOSAGE AND ADMINISTRATION .) Hypokalemia occurs commonly with diuretics (see ADVERSE REACTIONS, hypokalemia ), and electrolyte monitoring is essential, particularly in patients who would be at increased risk from hypokalemia, such as those with cardiac arrhythmias or who are receiving concomita",
      "In general, diuretics should not be given concomitantly with lithium because they reduce its renal clearance and add a high risk of lithium toxicity",
      "Read prescribing information for lithium preparations before use of such concomitant therapy"
    ],
    "drug_interactions": [
      "Drug Interactions Other Antihypertensives : Indapamide may add to or potentiate the action of other antihypertensive drugs",
      "In limited controlled trials that compared the effect of indapamide combined with other antihypertensive drugs with the effect of the other drugs administered alone, there was no notable change in the nature or frequency of adverse reactions associated with the combined therapy",
      "Lithium : See WARNINGS ",
      "Post-Sympathectomy Patient : The antihypertensive effect of the drug may be enhanced in the post-sympathectomized patient",
      "Norepinephrine : Indapamide, like the thiazides, may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Most adverse effects have been mild and transient",
      "The clinical adverse reactions listed in Table 1 represent data from Phase II/III placebo-controlled studies (306 patients given indapamide 1.25 mg)",
      "The clinical adverse reactions listed in Table 2 represent data from Phase II placebo-controlled studies and long-term controlled clinical trials (426patients given indapamide 2.5 mg or 5.0 mg)",
      "The reactions are arranged into two groups: 1) a cumulative incidence equal to or greater than 5%; 2)a cumulative incidence less than 5%",
      "Reactions are counted regardless of relation to drug",
      "TABLE 1: Adverse Reaction from Studies of 1.25mg Incidence ≥ 5% Incidence < 5%* BODY AS A WHOLE Headache Asthenia Infection Flu Syndrome Pain Abdominal Pain Back Pain Chest Pain GASTROINTESTINAL SYSTEM Constipation Diarrhea Dyspepsia Nausea METABOLIC SYSTEM Peripheral Edema CENTRAL NERVOUS SYSTEM Ne",
      "Approximately 4% of patients given indapamide 1.25 mg compared to 5% of the patients given placebo discontinued treatment in the trials of up to eight weeks because of adverse reactions",
      "In controlled clinical trials of six to eight weeks in duration, 20% of patients receiving indapamide 1.25 mg, 61% of patients receiving indapamide 5.0 mg, and 80% of patients receiving indapamide 10.0 mg had at least one potassium value below 3.4 mEq/L",
      "In the indapamide 1.25 mg group, about 40% of those patients who reported hypokalemia as a laboratory adverse event returned to normal serum potassium values without intervention",
      "Hypokalemia with concomitant clinical signs or symptoms occurred in 2% of patients receiving indapamide 1.25 mg",
      "TABLE 2: Adverse Reactions from Studies of 2.5 mg and 5.0 mg Incidence ≥ 5% Incidence < 5% CENTRAL NERVOUS SYSTEM/ NEUROMUSCULAR Headache Lightheadedness Dizziness D"
    ],
    "indications": [
      "INDICATIONS Indapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs",
      "Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure",
      "Usage in Pregnancy : The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard (see PRECAUTIONS below)",
      "Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia",
      "Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy"
    ]
  },
  "indian penny wort": {
    "ingredient": "indian penny wort",
    "is_drug": true,
    "canonical_name": "indian penny wort",
    "fda_search_term": "indian penny wort",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Sertraline Hydrochloride"
    ],
    "generic_names": [
      "SERTRALINE HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Proficient Rx LP"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Kidney, Liver, and Heart Transplant Cyclosporine, when used in high doses, can cause hepatotoxicity and nephrotoxicity ( see BOXED WARNING )",
      "Nephrotoxicity It is not unusual for serum creatinine and BUN levels to be elevated during cyclosporine therapy",
      "These elevations in renal transplant patients do not necessarily indicate rejection, and each patient must be fully evaluated before dosage adjustment is initiated",
      "Nephrotoxicity has been noted in 25% of cases of renal transplantation, 38% of cases of cardiac transplantation, and 37% of cases of liver transplantation",
      "Mild nephrotoxicity was generally noted 2 to 3 months after transplant and consisted of an arrest in the fall of the preoperative elevations of BUN and creatinine at a range of 35 to 45 mg/dl and 2.0 to 2.5 mg/dl, respectively",
      "These elevations were often responsive to dosage reduction",
      "More overt nephrotoxicity was seen early after transplantation and was characterized by a rapidly rising BUN and creatinine",
      "Since these events are similar to rejection episodes, care must be taken to differentiate between them",
      "This form of nephrotoxicity is usually responsive to cyclosporine dosage reduction",
      "Although specific diagnostic criteria which reliably differentiate renal graft rejection from drug toxicity have not been found, a number of parameters have been significantly associated to one or the other"
    ],
    "drug_interactions": [
      "Drug Interactions A",
      "Effect of Drugs and Other Agents on Cyclosporine Pharmacokinetics and/or Safety All of the individual drugs cited below are well substantiated to interact with cyclosporine",
      "In addition, concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with cyclosporine, particularly in the setting of dehydration, may potentiate renal dysfunction",
      "Caution should be exercised when using other drugs which are known to impair renal function (see WARNINGS , Nephrotoxicity ) ",
      "Drugs That May Potentiate Renal Dysfunction Antibiotics Antineoplastics Antifungals Anti-Inflammatory Drugs Gastrointestinal Agents Immunosuppressives Other Drugs ciprofloxacin melphalan amphotericin B azapropazon cimetidine tacrolimus fibric acid derivatives (e.g., bezafibrate, fenofibrate) gentami",
      "If a significant impairment of renal function occurs, reduction in the dosage of cyclosporine and/or coadministered drug or an alternative treatment should be considered",
      "Cyclosporine is extensively metabolized by CYP 3A isoenzymes, in particular CYP3A4, and is a substrate of the multidrug efflux transporter P-glycoprotein",
      "Various agents are known to either increase or decrease plasma or whole blood concentrations of cyclosporine usually by inhibition or induction of CYP3A4 or P-glycoprotein transporter or both",
      "Compounds that decrease cyclosporine absorption, such as orlistat, should be avoided",
      "Appropriate cyclosporine dosage adjustment to achieve the desired cyclosporine concentrations is essential when drugs that significantly alter cyclosporine concentrations are used concomitantly (see DOSAGE AND ADMINISTRATION , Blood Concentration"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The principal adverse reactions of cyclosporine therapy are renal dysfunction, tremor, hirsutism, hypertension, and gum hyperplasia",
      "Hypertension Hypertension, which is usually mild to moderate, may occur in approximately 50% of patients following renal transplantation and in most cardiac transplant patients",
      "Glomerular Capillary Thrombosis Glomerular capillary thrombosis has been found in patients treated with cyclosporine and may progress to graft failure",
      "The pathologic changes resemble those seen in the hemolytic-uremic syndrome and include thrombosis of the renal microvasculature, with platelet-fibrin thrombi occluding glomerular capillaries and afferent arterioles, microangiopathic hemolytic anemia, thrombocytopenia, and decreased renal function",
      "Similar findings have been observed when other immunosuppressives have been employed post transplantation",
      "Hypomagnesemia Hypomagnesemia has been reported in some, but not all, patients exhibiting convulsions while on cyclosporine therapy",
      "Although magnesium-depletion studies in normal subjects suggest that hypomagnesemia is associated with neurologic disorders, multiple factors, including hypertension, high-dose methylprednisolone, hypocholesterolemia, and nephrotoxicity associated with high plasma concentrations of cyclosporine appe",
      "Clinical Studies The following reactions occurred in 3% or greater of 892 patients involved in clinical trials of kidney, heart, and liver transplants: Randomized Kidney Patients All Cyclosporine Patients Cyclosporine Azathioprine Kidney Heart Liver Body System/ (N = 227) (N = 228) (N = 705) (N = 11"
    ],
    "indications": [
      "INDICATIONS AND USAGE Cyclosporine is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants",
      "It is always to be used with adrenal corticosteroids",
      "The drug may also be used in the treatment of chronic rejection in patients previously treated with other immunosuppressive agents",
      "Because of the risk of anaphylaxis, cyclosporine injection should be reserved for patients who are unable to take the soft gelatin capsules or oral solution"
    ]
  },
  "indomethacin": {
    "ingredient": "indomethacin",
    "is_drug": true,
    "canonical_name": "indomethacin",
    "fda_search_term": "indomethacin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Indomethacin"
    ],
    "generic_names": [
      "INDOMETHACIN"
    ],
    "manufacturers": [
      "Camber Pharmaceuticals, Inc.",
      "PD-Rx Pharmaceuticals, Inc.",
      "Sportpharm LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Table 2 for clinically significant drug interactions with indomethacin",
      "Table 2 Clinically Significant Drug Interactions with Indomethacin Drugs That Interfere with Hemostasis Clinical Impact: Indomethacin and anticoagulants such as warfarin have a synergistic effect on bleeding",
      "The concomitant use of indomethacin and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone",
      "Serotonin release by platelets plays an important role in hemostasis",
      "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone",
      "Intervention: Monitor patients with concomitant use of indomethacin capsules with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [ see Warnings and P",
      "Aspirin Clinical Impact: Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone",
      "In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [ see Warnings and Precautions ( 5.2 ) ]",
      "Intervention: Concomitant use of indomethacin capsules and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [ see Warnings and Precautions ( 5.12 )] ",
      "Indomethacin capsules are not substitute for low dose aspirin for cardiovascular protection"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: Cardiovascular Thrombotic Events [see Warnings and Precautions ( 5.1 )] GI Bleeding, Ulceration and Perforation [see Warnings and Precautions ( 5.2 )] Hepatotoxicity [see Warnings a",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practi",
      "In a gastroscopic study in 45 healthy subjects, the number of gastric mucosal abnormalities was significantly higher in the group receiving indomethacin capsules than in the group taking indomethacin suppositories or placebo",
      "In a double-blind comparative clinical study involving 175 patients with rheumatoid arthritis, however, the incidence of upper gastrointestinal adverse effects with indomethacin capsules or suppositories was comparable",
      "The incidence of lower gastrointestinal adverse effects was greater in the suppository group",
      "The adverse reactions for indomethacin capsules listed in the following table have been arranged into two groups: (1) incidence greater than 1%; and (2) incidence less than 1%",
      "The incidence for group (1) wa"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Indomethacin capsules are indicated for: Moderate to severe rheumatoid arthritis including acute flares of chronic disease Moderate to severe ankylosing spondylitis Moderate to severe osteoarthritis Acute painful shoulder (bursitis and/or tendinitis) Acute gouty arthritis Ind"
    ]
  },
  "infliximab": {
    "ingredient": "infliximab",
    "is_drug": true,
    "canonical_name": "infliximab",
    "fda_search_term": "infliximab",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "INFLECTRA",
      "REMICADE",
      "ZYMFENTRA"
    ],
    "generic_names": [
      "INFLIXIMAB",
      "INFLIXIMAB-DYYB"
    ],
    "manufacturers": [
      "CELLTRION USA Inc.",
      "Janssen Biotech, Inc.",
      "Pfizer Laboratories Div Pfizer Inc"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Other Biological Products – increased risk of serious infections ( 7.1 ) 7.1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended [see Warnings and Precautions (5.10) ]",
      "An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit",
      "Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers",
      "Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended [see Warnings and Precautions (5.10) ] ",
      "The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection",
      "7.2 Methotrexate and Other Concomitant Medications Specific drug interaction studies, including interactions with methotrexate (MTX), have not been conducted",
      "The majority of patients in RA or CD clinical studies received one or more concomitant medications",
      "In RA, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents (NSAIDs), folic acid, corticosteroids and/or narcotics",
      "Concomitant CD medications were antibiotics, antivirals, corticosteroids, 6-MP/AZA and aminosalicylates",
      "In PsA clinical trials, concomitant medications included MTX in approximately half of the patients as well as NSAIDs, folic acid and corticosteroids"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS Most common adverse reactions (>10%) – infections (e.g",
      "upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact CELLTRION, Inc",
      "at 1-800-383-7504 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adverse Reactions in Adults The data described herein reflect exposure to infliximab in 4779 adult patients (1304 patients with RA, 1106 patients with CD, 202 with AS, 293 with PsA, 484 with UC, 1373 with Ps, and 17 patients with other conditions), including 2625 patients exposed beyond 30 weeks and",
      "[ For information on adverse reactions in pediatric patients see Adverse Reactions (6.1) ] ",
      "One of the most common reasons for discontinuation of treatment was infusion-related reactions (e.g., dyspnea, flushing, headache and rash)",
      "Infusion-Related Reactions Adverse Reactions During or Shortly After Infusion An infusion reaction was defined in clinical trials as any adverse event occurring during an infusion or within 1 hour after an infusion",
      "In all the clinical studies, approximately 20% of infliximab-treated patients experienced an infusion reaction compared with 10% of placebo-treated patients",
      "Of infliximab-treated patients who had an infusion reaction during the induction period, 27% experienced an infusion reaction during the maintenance period",
      "Of patients who did not have an infusion reaction during the induction period, 9% experienced an infusion reaction during the maintenance period",
      "Among all infliximab infusions, 3% were accompanied by nonspecific symptoms such as fever or chills, 1% were accompanied by cardiopulmonary reac"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ):",
      "reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy",
      "reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease",
      "Pediatric Crohn's Disease ( 1.2 ):",
      "reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy"
    ]
  },
  "influenza antigen vaccine": {
    "ingredient": "influenza antigen vaccine",
    "is_drug": true,
    "canonical_name": "influenza antigen vaccine",
    "fda_search_term": "influenza antigen vaccine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "tamsulosin hydrochloride"
    ],
    "generic_names": [
      "TAMSULOSIN HYDROCHLORIDE"
    ],
    "manufacturers": [
      "XLCare Pharmaceuticals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Kidney, Liver, and Heart Transplant Cyclosporine, when used in high doses, can cause hepatotoxicity and nephrotoxicity ( see BOXED WARNING )",
      "Nephrotoxicity It is not unusual for serum creatinine and BUN levels to be elevated during cyclosporine therapy",
      "These elevations in renal transplant patients do not necessarily indicate rejection, and each patient must be fully evaluated before dosage adjustment is initiated",
      "Nephrotoxicity has been noted in 25% of cases of renal transplantation, 38% of cases of cardiac transplantation, and 37% of cases of liver transplantation",
      "Mild nephrotoxicity was generally noted 2 to 3 months after transplant and consisted of an arrest in the fall of the preoperative elevations of BUN and creatinine at a range of 35 to 45 mg/dl and 2.0 to 2.5 mg/dl, respectively",
      "These elevations were often responsive to dosage reduction",
      "More overt nephrotoxicity was seen early after transplantation and was characterized by a rapidly rising BUN and creatinine",
      "Since these events are similar to rejection episodes, care must be taken to differentiate between them",
      "This form of nephrotoxicity is usually responsive to cyclosporine dosage reduction",
      "Although specific diagnostic criteria which reliably differentiate renal graft rejection from drug toxicity have not been found, a number of parameters have been significantly associated to one or the other"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "Tamsulosin hydrochloride capsules 0.4 mg should not be used with strong inhibitors of CYP3A4 (e.g., ketoconazole)",
      "Tamsulosin hydrochloride capsules should be used with caution in combination with moderate inhibitors of CYP3A4 (e.g., erythromycin), in combination with strong (e.g., paroxetine) or moderate (e.g., terbinafine) inhibitors of CYP2D6, or in patients known to be CYP2D6 poor metabolizers, particularly ",
      "( 5.2 , 7.1 , 12.3 )",
      "Concomitant use of PDE5 inhibitors with tamsulosin can potentially cause symptomatic hypotension ( 5.2 , 7.3 , 12.3 )",
      "7.1 Cytochrome P450 Inhibition Strong and Moderate Inhibitors of CYP3A4 or CYP2D6 Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6",
      "Concomitant treatment with ketoconazole (a strong inhibitor of CYP3A4) resulted in an increase in the C max and AUC of tamsulosin by a factor of 2.2 and 2.8, respectively [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]",
      "The effects of concomitant administration of a moderate CYP3A4 inhibitor (e.g., erythromycin) on the pharmacokinetics of tamsulosin hydrochloride have not been evaluated [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]",
      "Concomitant treatment with paroxetine (a strong inhibitor of CYP2D6) resulted in an increase in the C max and AUC of tamsulosin by a factor of 1.3 and 1.6, respectively [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]",
      "A similar increase in exposure is expected in CYP2D6 poor metabolizers (PM) as compared to extensive metabolizers (EM)"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common adverse events (≥2% of patients and at a higher incidence than placebo) with the 0.4 mg dose or 0.8 mg dose were headache, dizziness, rhinitis, infection, abnormal ejaculation, asthenia, back pain, diarrhea, pharyngitis, chest pain, cough increased, somnolence, na",
      "at 1-866-495-1995 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice",
      "The incidence of treatment-emergent adverse events has been ascertained from six short-term U.S",
      "and European placebo-controlled clinical trials in which daily doses of 0.1 to 0.8 mg tamsulosin hydrochloride capsules were used",
      "These studies evaluated safety in 1783 patients treated with tamsulosin hydrochloride capsules and 798 patients administered placebo",
      "Table 1 summarizes the treatment-emergent adverse events that occurred in ≥2% of patients receiving either tamsulosin hydrochloride capsules 0.4 mg or 0.8 mg and at an incidence numerically higher than that in the placebo group during two 13-week U.S",
      "trials (US92-03A and US93-01) conducted in 1487 men",
      "Table 1 Treatment-Emergent* Adverse Events Occurring in ≥2% of Tamsulosin Hydrochloride Capsules or Placebo Patients in Two U.S",
      "Short-Term Placebo-Controlled Clinical Studies BODY SYSTEM/ ADVERSE EVENT TAMSULOSIN HYDROCHLORIDE CAPSULES GROUPS PLACEBO 0.4 mg n=502 0.8 mg n=492 n=493 BODY AS WHOLE Headache 97 (19.3%) 104 (21.1%) 99 (20.1%) Infection† 45 (9%) 53 (10.8%) 37 (7.5%) Asthenia 39 (7.8%) 42 (8.5%) 27 (5.5%) Back pain"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see Clinical Studies (14)]",
      "Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension",
      "Tamsulosin hydrochloride capsules are an alpha 1 adrenoceptor antagonist indicated for treatment of the signs and symptoms of benign prostatic hyperplasia (1) Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension (1)"
    ]
  },
  "inositol": {
    "ingredient": "inositol",
    "is_drug": true,
    "canonical_name": "inositol",
    "fda_search_term": "inositol",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "B Complex Liquescence",
      "Neuro T Support Liquescence",
      "Serotonin Dopamine Liquescence 3019"
    ],
    "generic_names": [
      "ALFALFA, BANANA, VALERIANA OFFICINALIS, CHOLINUM, GABA (GAMMA AMINOBUTYRIC ACID), INOSITOL, OLEANDER, HYPOPHYSIS SUIS, HYPOTHALAMUS SUIS, PINEAL GLAND (SUIS), SCUTELLARIA LATERIFLORA, ACETYLCHOLINE CHLORIDE, NOREPINEPHRINE (BITARTRATE), CADMIUM METALLICUM, DOPAMINE (HYDROCHLORIDE), SEROTONIN (HYDROCHLORIDE), ADRENALINUM",
      "CHOLINUM (CHOLINE), INOSITOL (VITAMIN B8), FOLIC ACID (VITAMIN B9), PANTOTHENIC ACID (CALCIUM PANTOTHENATE, VITAMIN B5), THIAMINUM HYDROCHLORICUM (VITAMIN B1), HEART (BOVINE), HEPAR (BOVINE), METHYLCOBALAMIN (VITAMIN B12), NICOTINAMIDUM (VITAMIN B3), PABA (PARA AMINOBENZOIC ACID VITAMIN B10), PYRIDOXINUM HYDROCHLORICUM (VITAMIN B6), BIOTIN (VITAMIN B7), HORDEUM VULGARE, RIBOFLAVINUM (VITAMIN B2), TORULA CEREVISIAE",
      "SEROTONIN DOPAMINE LIQUESCENCE"
    ],
    "manufacturers": [
      "Nutritional Specialties, Inc.",
      "Professional Complementary Health Formulas"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: Professional Use Only If pregnant or breast-feeding, ask a health professional before use",
      "In case of overdose, get medical help or contact a Poison Control Center right away",
      "If condition worsens, seek medical attention",
      "KEEP OUT OF REACH OF CHILDREN Do not use if tamper evident seal is broken or missing",
      "Store in a cool place after opening"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS: Provides potentized homeo-nutritional support of neurotransmitters and balancing of emotional states.† †Claims based on traditional homeopathic practice, not accepted medical evidence",
      "Not FDA evaluated"
    ]
  },
  "insulin": {
    "ingredient": "insulin",
    "is_drug": true,
    "canonical_name": "insulin",
    "fda_search_term": "insulin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ADMELOG",
      "BASAGLAR KwikPen",
      "BASAGLAR Tempo Pen",
      "Pancreas Liquescence"
    ],
    "generic_names": [
      "CINNAMOMUM, GYMNEMA SYLVESTRE, PHOSPHORICUM ACIDUM, SYZYGIUM JAMBOLANUM, TRIGONELLA FOENUM-GRACEUM, ARGENTUM NITRICUM, CHIONANTHUS VIRGINICA, HEPAR SUIS, PANCREAS SUIS, RHUS AROMATICA, SULPHUR, LYCOPODIUM CLAVATUM, CHROMIUM PICOLINATE, CHROMIUM METALLICUM, PHOSPHORUS, VANADIUM METALLICUM, ZINCUM METALLICUM, MUREX PURPUREA, DNA, INSULINUM (HUMAN), URANIUM NITRICUM",
      "INSULIN GLARGINE",
      "INSULIN LISPRO"
    ],
    "manufacturers": [
      "Eli Lilly and Company",
      "Nutritional Specialties, Inc.",
      "Sanofi-Aventis U.S. LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: Professional Use Only If pregnant or breast-feeding, ask a health professional before use",
      "In case of overdose, get medical help or contact a Poison Control Center right away",
      "If condition worsens, seek medical attention",
      "KEEP OUT OF REACH OF CHILDREN Do not use if tamper evident seal is broken or missing",
      "Store in a cool place after opening"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with ADMELOG",
      "Table 2: Clinically Significant Drug Interactions with ADMELOG Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicyla",
      "Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when ADMELOG is concomitantly administered with these drugs",
      "Drugs That May Decrease the Blood Glucose Lowering Effect of ADMELOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), proteas",
      "Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when ADMELOG is concomitantly administered with these drugs",
      "Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of ADMELOG Drugs: Alcohol, beta-blockers, clonidine, and lithium salts",
      "Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia",
      "Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when ADMELOG is concomitantly administered with these drugs",
      "Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine and reserpine",
      "Intervention: Increased frequency of glucose monitoring may be required when ADMELOG is concomitantly administered with these drugs"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere: Hypoglycemia [see Warnings and Precautions (5.3) ] Hypoglycemia Due to Medication Errors [see Warnings and Precautions (5.4) ] Hypersensitivity Reactions [see Warnings and Precautions (5.5) ] Hypokalemia [see Warnings and P",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adverse Reactions with Subcutaneous Injections of ADMELOG Two clinical trials with ADMELOG were conducted: one in patients with type 1 diabetes and one in patients with type 2 diabetes [see Clinical Studies (14) ] ",
      "The data in Table 1 reflect the exposure of 252 patients with type 1 diabetes to ADMELOG with mean exposure duration of 49 weeks",
      "The type 1 diabetes population had the following characteristics: Mean age was 43 years and mean duration of diabetes was 20 years",
      "Fifty-nine percent were male, 80% were White, 6% were Black or African American and 7% were Hispanic",
      "At baseline, the mean eGFR was 90 mL/min/1.73 m 2 and 49% of patients had eGFR ≥90 mL/min/1.73 m 2 ",
      "The mean BMI was 26 kg/m 2 ",
      "The mean HbA1c at baseline was 8.07%",
      "Two hundred fifty-three patients with type 2 diabetes were exposed to ADMELOG with mean exposure duration of 25 weeks",
      "The type 2 diabetes population had the following characteristics: Mean age was 62 years and mean duration of diabetes was 17 years",
      "Fifty-four percent were male, 90% were White, 6% were Black or African American and 17% were Hispanic"
    ],
    "indications": [
      "INDICATIONS: Provides potentized homeo-nutritional support of the pancreas.† †Claims based on traditional homeopathic practice, not accepted medical evidence",
      "Not FDA evaluated"
    ]
  },
  "insulin aspart": {
    "ingredient": "insulin aspart",
    "is_drug": true,
    "canonical_name": "insulin aspart",
    "fda_search_term": "insulin aspart",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      ".Insulin Aspart Protamine and Insulin Aspart",
      "NOVOLOG",
      "NovoLog Mix 70/30"
    ],
    "generic_names": [
      "INSULIN ASPART"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Novo Nordisk"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS The table below presents clinically significant drug interactions with NOVOLOG",
      "Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide an",
      "Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when NOVOLOG is concomitantly administered with these drugs",
      "Drugs That May Decrease the Blood Glucose Lowering Effect of NOVOLOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), proteas",
      "Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when NOVOLOG is concomitantly administered with these drugs",
      "Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of NOVOLOG Drugs: Alcohol, beta-blockers, clonidine, and lithium salts",
      "Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia",
      "Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia",
      "Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when NOVOLOG is concomitantly administered with these drugs",
      "Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine and reserpine Intervention: Increased frequency of glucose monitoring may be required when NOVOLOG is concomitantly administered with these drugs"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are also discussed elsewhere:",
      "Hypoglycemia [see Warnings and Precautions ( 5.3 )]",
      "Hypoglycemia Due to Medication Errors [see Warnings and Precautions (5.4 )]",
      "Hypersensitivity reactions [see Warnings and Precautions ( 5.5 )]",
      "Hypokalemia [see Warnings and Precautions ( 5.6 )] Adverse reactions observed with NOVOLOG include: hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus ( 6 )",
      "To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc",
      "at 1-800-727-6500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying designs, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practi",
      "The safety of NOVOLOG was evaluated in two treat-to-target trials of 6 months duration, conducted in patients with type 1 diabetes or type 2 diabetes [see Clinical Studies (14) ]",
      "The data in Table 1 reflect the exposure of 596 patients with type 1 diabetes to NOVOLOG in one clinical trial with a mean exposure duration to NOVOLOG of 24 weeks",
      "The mean age was 39 years",
      "Fifty-one percent were male, 94% were Caucasian, 2% were Black and 4% were other races",
      "The mean body mass index (BMI) was 25.6 kg/m 2 ",
      "The mean duration of diabetes was 15.7 years and the mean HbA 1c at baseline was 7.9%",
      "The data in Table 2 reflect the exposure of 91 patients with type 2 diabetes to NOVOLOG in one clinical trial with a mean exposure duration to NOVOLOG of 24 weeks"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE NOVOLOG is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus",
      "NOVOLOG is rapid acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus ( 1 )"
    ]
  },
  "insulin aspart protamine": {
    "ingredient": "insulin aspart protamine",
    "is_drug": true,
    "canonical_name": "insulin aspart",
    "fda_search_term": "insulin aspart",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      ".Insulin Aspart Protamine and Insulin Aspart",
      "NOVOLOG",
      "NovoLog Mix 70/30"
    ],
    "generic_names": [
      "INSULIN ASPART"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Novo Nordisk"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS The table below presents clinically significant drug interactions with NOVOLOG",
      "Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide an",
      "Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when NOVOLOG is concomitantly administered with these drugs",
      "Drugs That May Decrease the Blood Glucose Lowering Effect of NOVOLOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), proteas",
      "Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when NOVOLOG is concomitantly administered with these drugs",
      "Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of NOVOLOG Drugs: Alcohol, beta-blockers, clonidine, and lithium salts",
      "Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia",
      "Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia",
      "Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when NOVOLOG is concomitantly administered with these drugs",
      "Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine and reserpine Intervention: Increased frequency of glucose monitoring may be required when NOVOLOG is concomitantly administered with these drugs"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are also discussed elsewhere:",
      "Hypoglycemia [see Warnings and Precautions ( 5.3 )]",
      "Hypoglycemia Due to Medication Errors [see Warnings and Precautions (5.4 )]",
      "Hypersensitivity reactions [see Warnings and Precautions ( 5.5 )]",
      "Hypokalemia [see Warnings and Precautions ( 5.6 )] Adverse reactions observed with NOVOLOG include: hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus ( 6 )",
      "To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc",
      "at 1-800-727-6500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying designs, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practi",
      "The safety of NOVOLOG was evaluated in two treat-to-target trials of 6 months duration, conducted in patients with type 1 diabetes or type 2 diabetes [see Clinical Studies (14) ]",
      "The data in Table 1 reflect the exposure of 596 patients with type 1 diabetes to NOVOLOG in one clinical trial with a mean exposure duration to NOVOLOG of 24 weeks",
      "The mean age was 39 years",
      "Fifty-one percent were male, 94% were Caucasian, 2% were Black and 4% were other races",
      "The mean body mass index (BMI) was 25.6 kg/m 2 ",
      "The mean duration of diabetes was 15.7 years and the mean HbA 1c at baseline was 7.9%",
      "The data in Table 2 reflect the exposure of 91 patients with type 2 diabetes to NOVOLOG in one clinical trial with a mean exposure duration to NOVOLOG of 24 weeks"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE NOVOLOG is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus",
      "NOVOLOG is rapid acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus ( 1 )"
    ]
  },
  "insulin degludec": {
    "ingredient": "insulin degludec",
    "is_drug": true,
    "canonical_name": "insulin degludec",
    "fda_search_term": "insulin degludec",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Insulin Degludec",
      "Tresiba",
      "Xultophy 100/3.6"
    ],
    "generic_names": [
      "INSULIN DEGLUDEC",
      "INSULIN DEGLUDEC AND LIRAGLUTIDE"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Novo Nordisk"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "Drugs that affect glucose metabolism : Adjustment of XULTOPHY 100/3.6 dosage may be needed; closely monitor blood glucose",
      "Anti-Adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine): Hypoglycemia signs and symptoms may be reduced or absent",
      "Effects of delayed gastric emptying on oral medications : May impact absorption of concomitantly administered oral medications",
      "( 7.2 ) 7.1 Medications that Can Affect Glucose Metabolism A number of medications affect glucose metabolism and may require dose adjustment of XULTOPHY 100/3.6 and particularly close monitoring [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.6 )]",
      "Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide a",
      "Drugs That May Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives)",
      "Intervention: Dosage increases and increased frequency of glucose monitoring may be required when XULTOPHY 100/3.6 is coadministered with these drugs",
      "Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of XULTOPHY 100/3.6 Drugs: Alcohol, beta-blockers, clonidine, and lithium salts",
      "Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described below or elsewhere in the prescribing information:",
      "Risk of Thyroid C-cell Tumors [see Warnings and Precautions ( 5.1 )]",
      "Acute Pancreatitis [see Warnings and Precautions ( 5.2 )]",
      "Hypoglycemia [see Warnings and Precautions ( 5.6 )]",
      "Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions ( 5.7 )]",
      "Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions ( 5.8 )]",
      "Hypersensitivity Reactions [see Warnings and Precautions ( 5.9 )]",
      "Acute Gallbladder Disease [see Warnings and Precautions ( 5.10 )]",
      "Hypokalemia [see Warnings and Precautions ( 5.11 )]",
      "Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions ( 5.13 )]",
      "Most common adverse reactions (incidence ≥5%) in clinical trials are nasopharyngitis, headache, nausea, diarrhea, increased lipase and upper respiratory tract infection",
      "Immunogenicity-related events, including urticaria, were more common among liraglutide-treated patients (0.8%) than among comparator-treated patients (0.4%) in clinical trials",
      "( 12.6 ) To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc",
      "at 1-800-727-6500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE XULTOPHY 100/3.6 is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus",
      "Limitations of Use:",
      "XULTOPHY 100/3.6 contains liraglutide",
      "Coadministration with any other product containing liraglutide or another glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended [see Warnings and Precautions ( 5.5 )]",
      "XULTOPHY 100/3.6 is not recommended for the treatment of diabetic ketoacidosis"
    ]
  },
  "insulin detemir": {
    "ingredient": "insulin detemir",
    "is_drug": true,
    "canonical_name": "insulin detemir",
    "fda_search_term": "insulin detemir",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "LEVEMIR",
      "Levemir"
    ],
    "generic_names": [
      "INSULIN DETEMIR"
    ],
    "manufacturers": [
      "A-S Medication Solutions"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Table 6 includes clinically significant drug interactions with LEVEMIR",
      "Table 6: Clinically Significant Drug Interactions with LEVEMIR Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicyla",
      "Intervention: Dosage reductions and increased frequency of glucose monitoring may be required when LEVEMIR is co-administered with these drugs",
      "Drugs That May Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), proteas",
      "Intervention: Dosage increases and increased frequency of glucose monitoring may be required when LEVEMIR is co-administered with these drugs",
      "Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of LEVEMIR Drugs: Alcohol, beta-blockers, clonidine, and lithium salts",
      "Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia",
      "Intervention: Dosage adjustment and increased frequency of glucose monitoring may be required when LEVEMIR is co-administered with these drugs",
      "Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine, and reserpine Intervention: Increased frequency of glucose monitoring may be required when LEVEMIR is co-administered with these drugs",
      "Drugs that Affect Glucose Metabolism: Adjustment of insulin dosage may be needed"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere:",
      "Hypoglycemia [see Warnings and Precautions ( 5.3 )]",
      "Hypoglycemia Due to Medication errors [see Warnings and Precautions ( 5.4 )]",
      "Hypersensitivity Reactions [see Warnings and Precautions ( 5.5 )]",
      "Hypokalemia [see Warnings and Precautions ( 5.6 )] Adverse reactions associated with LEVEMIR include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, rash and pruritus ( 6 )",
      "To report SUSPECTED ADVERSE REACTIONS, contact Novo Nordisk Inc",
      "at 1-800-727-6500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying designs, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial,",
      "The frequencies of adverse reactions (excluding hypoglycemia) reported during LEVEMIR clinical trials in patients with type 1 diabetes mellitus and type 2 diabetes mellitus are listed in Tables 1-4 below",
      "See Tables 5 and 6 for the hypoglycemia findings",
      "In two pooled trials, adults with type 1 diabetes were exposed to individualized doses of LEVEMIR (n=767) or NPH (n=388)",
      "The mean duration of exposure to LEVEMIR was 153 days, and the total exposure to LEVEMIR was 321 patient-years",
      "The most common adverse reactions are summarized in Table 1",
      "Table 1: Adverse Reactions Occurring in ≥ 5% of LEVEMIR-Treated Adult Patients with Type 1 Diabetes Mellitus in Two Trials of 16 Weeks and 24 Weeks Duration LEVEMIR, % (n = 767) Upper respiratory tract infection 26.1 Headache 22.6 Pharyngitis 9.5 Influenza-like illness 7.8 Abdominal Pain 6.0 Adults ",
      "The mean duration of exposure to LEVEMIR was 176 days, and the total exposure to LEVEMIR was 78 patient-years",
      "The most common adverse reactions are su"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE LEVEMIR is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus",
      "Limitations of Use LEVEMIR is not recommended for the treatment of diabetic ketoacidosis",
      "LEVEMIR is a long-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus ( 1 )",
      "Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis"
    ]
  },
  "insulin glargine": {
    "ingredient": "insulin glargine",
    "is_drug": true,
    "canonical_name": "insulin glargine",
    "fda_search_term": "insulin glargine",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "BASAGLAR KwikPen",
      "BASAGLAR Tempo Pen",
      "INSULIN GLARGINE",
      "TOUJEO"
    ],
    "generic_names": [
      "INSULIN GLARGINE",
      "INSULIN GLARGINE-YFGN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Civica, Inc.",
      "Eli Lilly and Company"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Table 6 includes clinically significant drug interactions with BASAGLAR Table 6: Clinically Significant Drug Interactions with BASAGLAR Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyrami",
      "Intervention: Dose reductions and increased frequency of glucose monitoring may be required when BASAGLAR is co-administered with these drugs",
      "Drugs That May Decrease the Blood Glucose Lowering Effect of BASAGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protea",
      "Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of BASAGLAR Drugs: Alcohol, beta-blockers, clonidine, and lithium salts",
      "Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia",
      "Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when BASAGLAR is co-administered with these drugs",
      "Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: beta-blockers, clonidine, guanethidine, and reserpine Intervention: Increased frequency of glucose monitoring may be required when BASAGLAR is co-administered with these drugs",
      "Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlinti"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere: Hypoglycemia [see Warnings and Precautions ( 5.3 )] ",
      "Hypoglycemia Due to Medication Errors [see Warnings and Precautions ( 5.4 )] ",
      "Hypersensitivity Reactions [see Warnings and Precautions ( 5.5 )] ",
      "Hypokalemia [see Warnings and Precautions ( 5.6 )] ",
      "Adverse reactions commonly (≥5%) associated with insulin glargine products are: Hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, rash, edema, and weight gain",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Two clinical trials with BASAGLAR were conducted: one in type 1 diabetes and one in type 2 diabetes",
      "The type 1 diabetes population had the following characteristics: Mean age was 41 years and mean duration of diabetes was 16 years",
      "75% were Caucasian, 2% Black or African American and 4% American Indian or Alaskan native",
      "4% were Hispanic",
      "At baseline, mean eGFR was 109 mL/min/1.73m 2 ",
      "73.5 percent of patients had eGFR>90 mL/min/1.73m 2 ",
      "The mean BMI was approximately 26 kg/m 2 ",
      "HbA 1c at baseline was 7.8%"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE BASAGLAR ® is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus",
      "BASAGLAR ® is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus",
      "( 1 ) Limitations of Use : Not recommended for treating diabetic ketoacidosis",
      "( 1 ) Limitations of Use BASAGLAR is not recommended for the treatment of diabetic ketoacidosis"
    ]
  },
  "insulin glulisine human": {
    "ingredient": "insulin glulisine human",
    "is_drug": true,
    "canonical_name": "insulin glulisine",
    "fda_search_term": "insulin glulisine",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Attention Deficit Mild Drops 2146",
      "DNA Insulin Drops 2019",
      "Pancreas DB Liquescence 3037"
    ],
    "generic_names": [
      "ATTENTION DEFICIT MILD DROPS",
      "DNA INSULIN DROPS",
      "PANCREAS DB LIQUESCENCE"
    ],
    "manufacturers": [
      "Professional Complementary Health Formulas"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Severe or persistent symptoms may be serious",
      "Consult a doctor promptly",
      "Keep out of the reach of children",
      "In case of overdose, get medical help or contact a poison control center right away",
      "If pregnant or breastfeeding, ask a healthcare professional before use",
      "Keep out of the reach of children",
      "If pregnant or breastfeeding, ask a healthcare professional before use"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS For the temporary relief of mild abdominal pain or tenderness, muscle pain, cramps, or weakness, loss of appetite, weight loss, diarrhea, nausea, or vomiting.*"
    ]
  },
  "insulin isophane protamine human": {
    "ingredient": "insulin isophane protamine human",
    "is_drug": true,
    "canonical_name": "insulin isophane protamine human",
    "fda_search_term": "insulin isophane protamine human",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Betadine",
      "SILICEA"
    ],
    "generic_names": [
      "POVIDONE-IODINE",
      "SILICEA"
    ],
    "manufacturers": [
      "Atlantis Consumer Healthcare, Inc.",
      "Rxhomeo Private Limited d.b.a. Rxhomeo, Inc"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS This product is to be used for self-limiting conditions If symptoms do not improve in 4 days, or worsen, discontinue use and seek assistance of health professional",
      "As with any drug, if you are pregnant, or nursing a baby, seek professional advice before taking this product",
      "Keep this and all medication out of reach of children Do not use if capseal is broken or missing",
      "Close the cap tightly after use"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "INDICATIONS Condition listed above or as directed by the physician"
    ]
  },
  "insulin lispro": {
    "ingredient": "insulin lispro",
    "is_drug": true,
    "canonical_name": "insulin lispro",
    "fda_search_term": "insulin lispro",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ADMELOG",
      "Insulin Lispro"
    ],
    "generic_names": [
      "INSULIN LISPRO"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "REMEDYREPACK INC.",
      "Sanofi-Aventis U.S. LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with ADMELOG",
      "Table 2: Clinically Significant Drug Interactions with ADMELOG Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicyla",
      "Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when ADMELOG is concomitantly administered with these drugs",
      "Drugs That May Decrease the Blood Glucose Lowering Effect of ADMELOG Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), proteas",
      "Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when ADMELOG is concomitantly administered with these drugs",
      "Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of ADMELOG Drugs: Alcohol, beta-blockers, clonidine, and lithium salts",
      "Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia",
      "Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when ADMELOG is concomitantly administered with these drugs",
      "Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine and reserpine",
      "Intervention: Increased frequency of glucose monitoring may be required when ADMELOG is concomitantly administered with these drugs"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed elsewhere: Hypoglycemia [see Warnings and Precautions (5.3) ] Hypoglycemia Due to Medication Errors [see Warnings and Precautions (5.4) ] Hypersensitivity Reactions [see Warnings and Precautions (5.5) ] Hypokalemia [see Warnings and P",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adverse Reactions with Subcutaneous Injections of ADMELOG Two clinical trials with ADMELOG were conducted: one in patients with type 1 diabetes and one in patients with type 2 diabetes [see Clinical Studies (14) ] ",
      "The data in Table 1 reflect the exposure of 252 patients with type 1 diabetes to ADMELOG with mean exposure duration of 49 weeks",
      "The type 1 diabetes population had the following characteristics: Mean age was 43 years and mean duration of diabetes was 20 years",
      "Fifty-nine percent were male, 80% were White, 6% were Black or African American and 7% were Hispanic",
      "At baseline, the mean eGFR was 90 mL/min/1.73 m 2 and 49% of patients had eGFR ≥90 mL/min/1.73 m 2 ",
      "The mean BMI was 26 kg/m 2 ",
      "The mean HbA1c at baseline was 8.07%",
      "Two hundred fifty-three patients with type 2 diabetes were exposed to ADMELOG with mean exposure duration of 25 weeks",
      "The type 2 diabetes population had the following characteristics: Mean age was 62 years and mean duration of diabetes was 17 years",
      "Fifty-four percent were male, 90% were White, 6% were Black or African American and 17% were Hispanic"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE ADMELOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus",
      "ADMELOG is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus"
    ]
  },
  "insulin lispro protamine": {
    "ingredient": "insulin lispro protamine",
    "is_drug": true,
    "canonical_name": "insulin lispro protamine",
    "fda_search_term": "insulin lispro protamine",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Enoxaparin Sodium",
      "Heparin Sodium"
    ],
    "generic_names": [
      "ENOXAPARIN SODIUM",
      "HEPARIN SODIUM"
    ],
    "manufacturers": [
      "Meitheal Pharmaceuticals Inc.",
      "NorthStar RxLLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Heparin is not intended for intramuscular use",
      "Hypersensitivity Patients with documented hypersensitivity to heparin should be given the drug only in clearly life-threatening situations",
      "(See ADVERSE REACTIONS, Hypersensitivity .) Hemorrhage Hemorrhage can occur at virtually any site in patients receiving heparin",
      "An unexplained fall in hematocrit, fall in blood pressure or any other unexplained symptom should lead to serious consideration of a hemorrhagic event",
      "Heparin sodium should be used with extreme caution in infants and in patients with disease states in which there is increased danger of hemorrhage",
      "Some of the conditions in which increased danger of hemorrhage exists are: Cardiovascular Subacute bacterial endocarditis, severe hypertension",
      "Surgical During and immediately following (a) spinal tap or spinal anesthesia or (b) major surgery, especially involving the brain, spinal cord or eye",
      "Hematologic Conditions associated with increased bleeding tendencies, such as hemophilia, thrombocytopenia and some vascular purpuras",
      "Gastrointestinal Ulcerative lesions and continuous tube drainage of the stomach or small intestine",
      "Other Menstruation, liver disease with impaired hemostasis"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Whenever possible, agents which may enhance the risk of hemorrhage should be discontinued prior to initiation of enoxaparin sodium therapy",
      "These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone",
      "If coadministration is essential, conduct close clinical and laboratory monitoring [see Warnings and Precautions (5.1) ] ",
      "Discontinue agents which may enhance hemorrhage risk prior to initiation of enoxaparin sodium or conduct close clinical and laboratory monitoring ( 2.6 , 7 )"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are also discussed in other sections of the labeling:",
      "Spinal/epidural hematomas [see Boxed Warning and Warnings and Precautions ( 5.1 )]",
      "Increased Risk of Hemorrhage [see Warnings and Precautions ( 5.1 )]",
      "Thrombocytopenia [see Warnings and Precautions ( 5.5 )] Most common adverse reactions (>1%) were bleeding, anemia, thrombocytopenia, elevation of serum aminotransferase, diarrhea, nausea, ecchymosis, fever, edema, peripheral edema, dyspnea, confusion, and injection site pain ( 6.1 ) To report SUSPEC",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practi",
      "During clinical development for the approved indications, 15,918 patients were exposed to enoxaparin sodium",
      "These included 1,228 for prophylaxis of deep vein thrombosis following abdominal surgery in patients at risk for thromboembolic complications, 1,368 for prophylaxis of deep vein thrombosis following hip or knee replacement surgery, 711 for prophylaxis of deep vein thrombosis in medical patients with",
      "Enoxaparin sodium doses in the clinical trials for prophylaxis of deep vein thrombosis following abdominal or hip or knee replacement surgery or in medical patients with severely restricted mobility during acute illness ranged from 40 mg subcutaneously once daily to 30 mg subcutaneously twice daily"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Enoxaparin sodium injection is a low molecular weight heparin (LMWH) indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( ",
      "1.4 Treatment of Acute ST-Segment Elevation Myocardial Infarction Eno"
    ]
  },
  "insulin neutral human": {
    "ingredient": "insulin neutral human",
    "is_drug": true,
    "canonical_name": "insulin human",
    "fda_search_term": "insulin human",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "AFREZZA",
      "Chemstat",
      "Pancreas Liquescence"
    ],
    "generic_names": [
      "CINNAMOMUM, GYMNEMA SYLVESTRE, PHOSPHORICUM ACIDUM, SYZYGIUM JAMBOLANUM, TRIGONELLA FOENUM-GRACEUM, ARGENTUM NITRICUM, CHIONANTHUS VIRGINICA, HEPAR SUIS, PANCREAS SUIS, RHUS AROMATICA, SULPHUR, LYCOPODIUM CLAVATUM, CHROMIUM PICOLINATE, CHROMIUM METALLICUM, PHOSPHORUS, VANADIUM METALLICUM, ZINCUM METALLICUM, MUREX PURPUREA, DNA, INSULINUM (HUMAN), URANIUM NITRICUM",
      "GLYCERINUM, TARAXACUM OFFICINALE, PHYTOLACCA DECANDRA, ARSENICUM ALBUM, NITRICUM ACIDUM, NUX VOMICA, PETROLEUM, PHOSPHORICUM ACIDUM, PHOSPHORUS, ACETYLSALICYLICUM ACIDUM, GLONOINUM, INSULINUM (HUMAN), LITHIUM CARBONICUM, THYROIDINUM (SUIS), ACETICUM ACIDUM, BENZOICUM ACIDUM, BENZYL ALCOHOL, BORICUM ACIDUM, CHLORINUM, CORTISONE ACETICUM, EUGENOL, FOLLICULINUM, ISOPROPYL PALMITATE, LACTICUM ACIDUM, PETROLEUM JELLY, PHENYL BUTAZONE, PLUMBUM METALLICUM, POTASSIUM SORBATE, RESORCINUM, SALICYLICUM ACIDUM,",
      "INSULIN HUMAN"
    ],
    "manufacturers": [
      "Energique, Inc.",
      "Mannkind Corporation",
      "Nutritional Specialties, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: Professional Use Only If pregnant or breast-feeding, ask a health professional before use",
      "In case of overdose, get medical help or contact a Poison Control Center right away",
      "If condition worsens, seek medical attention",
      "KEEP OUT OF REACH OF CHILDREN Do not use if tamper evident seal is broken or missing",
      "Store in a cool place after opening"
    ],
    "drug_interactions": [
      "2.5 Dosage Modifications for Drug Interactions Dosage modification may be needed when: AFREZZA is used concomitantly with certain drugs that increase and/or decrease the glucose lowering effect [see Drug Interactions ( 7.1 , 7.2 , 7.3 )]",
      "Switching from another insulin to AFREZZA [see Dosage and Administration ( 2.3 ) and Warnings and Precautions ( 5.2 )]"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in the labeling: Acute bronchospasm in patients with chronic lung disease [see Warnings and Precautions ( 5.1 )] Hypoglycemia [see Warnings and Precautions ( 5.3 )] Decline in pulmonary function [see Warnin",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The data described below reflect exposure of 3,017 patients to AFREZZA and include 1,026 patients with type 1 diabetes and 1,991 patients with type 2 diabetes",
      "The mean exposure duration was 8.2 months for patients with type 1 diabetes and those with type 2 diabetes",
      "In the overall population: 1,874 patients were exposed to AFREZZA for 6 months and 724 patients for greater than one year",
      "620 and 1,254 patients with type 1 and type 2 diabetes, respectively, were exposed to AFREZZA for up to 6 months",
      "238 and 486 patients with type 1 and type 2 diabetes, respectively, were exposed to AFREZZA for greater than one year (median exposure was 1.8 years)",
      "AFREZZA was studied in placebo and active-controlled trials (n = 3 and n = 10, respectively)",
      "The mean age of the population was 50 years and 20 patients were older than 75 years of age; 51% of the population were males; 83% were White, 5% were Black or African American, an"
    ],
    "indications": [
      "INDICATIONS: Provides potentized homeo-nutritional support of the pancreas.† †Claims based on traditional homeopathic practice, not accepted medical evidence",
      "Not FDA evaluated"
    ]
  },
  "insulin pen": {
    "ingredient": "insulin pen",
    "is_drug": true,
    "canonical_name": "insulin pen",
    "fda_search_term": "insulin pen",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Mekinist"
    ],
    "generic_names": [
      "TRAMETINIB"
    ],
    "manufacturers": [
      "Novartis Pharmaceuticals Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings: For external use only",
      "Do not use if you have sensitive skin and/or are sensitive to [active ingredient] When using this product skin irritation and dryness is more likely to occur if you use another topical acne medication at the same time",
      "If irritation occurs, only use one topical acne medication at a time avoid unnecessary sun exposure and use sun screen, Acne Clearing Moisture with SPF 45 skin irritation may occur, characterized by redness, burning, itching, peeling, and possibly swelling",
      "Irritation may be reduced by using the product less frequently or in a lower concentration Stop use and ask a doctor if irritation becomes severe"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS MEKINIST is indicated for use in combination with dabrafenib",
      "Refer to the dabrafenib prescribing information for additional risk information that applies to combination use treatment"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: New Primary Malignancies [see Warnings and Precautions ( 5.1)] Hemorrhage [see Warnings and Precautions (5.2)] Colitis and Gastrointestinal Perforation [see Warnings and Precautions (5",
      "4 )] Cardiomyopathy [see Warnings and Precautions (5",
      "5 )] Ocular Toxicities [see Warnings and Precautions (5",
      "6 )] Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5",
      "7 )] Serious Febrile Reactions [see Warnings and Precautions (5",
      "8 )] Serious Skin Toxicities [see Warnings and Precautions (5",
      "9 )] Hyperglycemia [see Warnings and Precautions (5",
      "10 )] Hemophagocytic Lymphohistiocytosis [see Warnings and Precautions (5",
      "12 )] There are additional adverse reactions associated with dabrafenib",
      "Refer to the dabrafenib prescribing information for additional information",
      "Most common adverse reactions (≥ 20%) for MEKINIST as a single agent include rash, diarrhea, and lymphedema",
      "( 6.1 ) Most common adverse reactions (≥ 20%) for MEKINIST in combination with dabrafenib include: Unresectable or metastatic melanoma: pyrexia, nausea, rash, chills, diarrhea, vomiting, hypertension, and peripheral edema",
      "( 6.1 ) Adjuvant treatment of melanoma: pyrexia, fatigue, nausea, headache, rash, chills, diarrhea, vomiting, arthralgia, and myalgia",
      "( 6.1 ) NSCLC: pyrexia, fatigue, nausea, vomiting, diarrhea, dry skin, decreased appetite, edema, rash, chills, hemorrhage, cough, and dyspnea",
      "( 6.1 ) Adult patients with solid tumors: pyrexia, fatigue, nausea, rash, chills, headache, hemorrhage, cough, vomiting, constipation, diarrhea, myalgia, arthralgia, and edema"
    ],
    "indications": [
      "Directions: Acne Clearing Cleanser Acne Clearing Tonic Acne Clearing Treatment 101"
    ]
  },
  "interferon": {
    "ingredient": "interferon",
    "is_drug": true,
    "canonical_name": "interferon",
    "fda_search_term": "interferon",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "CITOMIX",
      "Enviro I",
      "GUNA-VIRUS"
    ],
    "generic_names": [
      "ALDESLEUKIN - BINETRAKIN - CANAKINUMAB - CENTELLA ASIATICA - CRANBERRY - HUMAN INTERLEUKIN-6 (NONGLYCOSYLATED) - INTERFERON GAMMA-1B - LENOGRASTIM - PINEAPPLE - SUS SCROFA BONE MARROW - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA THYMUS -",
      "ALDESLEUKIN - EVERLASTING EXTRACT - FOMITOPSIS PINICOLA FRUITING BODY - INTERFERON GAMMA-1B - MELATONIN - METENKEFALIN - REISHI - RICE - SEROTONIN - SOYBEAN - SUS SCROFA BLOOD - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA SPLEEN -",
      "POTASSIUM GLUCONATE, GLANDULA SUPRARENALIS SUIS, HEPAR SUIS, COFFEA TOSTA, THEA SINENSIS, CARBO VEGETABILIS, FERRUM IODATUM, FERRUM METALLICUM, GELSEMIUM SEMPERVIRENS, IODIUM, IRIDIUM METALLICUM, LYCOPODIUM CLAVATUM, PULSATILLA (PRATENSIS), SELENIUM METALLICUM, ZINCUM METALLICUM, PEANUT, BLACK WALNUT, ENGLISH WALNUT, AMYGDALA AMARA, CASHEW, COCONUT, PECAN, BRAZIL NUT, TOMATO, SOLANUM TUBEROSUM, PIPER NIGRUM, EGGPLANT, RAPE SEED OIL, LINUM USITATISSIMUM, SESAME, SEED, CHEESE (STILTON), LAC VACCINUM, BEEF,"
    ],
    "manufacturers": [
      "Deseret Biologicals, Inc.",
      "Guna spa"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: If pregnant or breast-feeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, contact a physician or Poison Control Center right away",
      "Tamper Evident: Sealed for your protection",
      "Do not use if seal is broken or missing"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "For the temporary relief of symptoms including:",
      "sensitivity to food",
      "swelling of lips",
      "occasional diarrhea",
      "skin rash These statements are based upon homeopathic principles"
    ]
  },
  "interferon alfa": {
    "ingredient": "interferon alfa",
    "is_drug": true,
    "canonical_name": "interferon alfa",
    "fda_search_term": "interferon alfa",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "EMF Protect and Balance",
      "LAMIVUDINE and ZIDOVUDINE"
    ],
    "generic_names": [
      "ALFALFA, CADMIUM SULPHURATUM, CALCAREA CARBONICA, CUPRUM METALLICUM, FERRUM METALLICUM, FUCUS VESICULOSUS, HYPERICUM PERFORATUM, KALI PHOSPHORICUM, MAGNESIA PHOSPHORICA, MANGANUM METALLICUM, MERCURIUS VIVUS, PLUMBUM METALLICUM, SILICEA, SYMPHYTUM OFFICINALE, TARENTULA HISPANA, X-RAY, YTTERBIUM OXIDE",
      "LAMIVUDINE AND ZIDOVUDINE"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "Deseret Biologicals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only",
      "Keep away from heat or flame",
      "Do not use: in children less than 2 months of age and open skin wounds When using this product keep out of eyes, ears, and mouth",
      "In case of contact with eyes, rinse thoroughly with water",
      "Stop use and ask doctor if irritation or rash occurs",
      "Keep out of reach of children",
      "If swallowed, get medical help or contact Poison Control Center right away"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "Agents antagonistic with zidovudine: Concomitant use should be avoided",
      "Hematologic/bone marrow suppressive/cytotoxic agents: May increase the hematologic toxicity of zidovudine",
      "Sorbitol: Coadministration of lamivudine and sorbitol may decrease lamivudine concentrations; when possible, avoid chronic coadministration",
      "Agents antagonistic with zidovudine: Concomitant use should be avoided",
      "Hematologic/bone marrow suppressive/cytotoxic agents: May increase the hematologic toxicity of zidovudine",
      "Sorbitol: Coadministration of lamivudine and sorbitol may decrease lamivudine concentrations; when possible, avoid chronic coadministration",
      "(7.2) 7.1 Zidovudine Agents Antagonistic with Zidovudine Concomitant use of zidovudine with the following drugs should be avoided since an antagonistic relationship has been demonstrated in vitro :",
      "Nucleoside analogues, e.g., ribavirin Hematologic/Bone Marrow Suppressive/Cytotoxic Agents Coadministration with the following drugs may increase the hematologic toxicity of zidovudine:",
      "Other bone marrow suppressive or cytotoxic agents 7.2 Lamivudine Sorbitol Coadministration of single doses of lamivudine and sorbitol resulted in a sorbitol dose-dependent reduction in lamivudine exposures"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in other sections of the labeling:",
      "Hematologic toxicity, including neutropenia and anemia [see Boxed Warning, Warnings and Precautions (5.1)]",
      "Symptomatic myopathy [see Boxed Warning, Warnings and Precautions (5.2)]",
      "Lactic acidosis and severe hepatomegaly with steatosis [see Boxed Warning, Warnings and Precautions (5.3)]",
      "Exacerbations of hepatitis B [see Boxed Warning, Warnings and Precautions (5.4)]",
      "Hepatic decompensation in patients co-infected with HIV-1 and hepatitis C [see Warnings and Precautions (5.5)]",
      "Exacerbation of anemia in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine [see Warnings and Precautions (5.5)]",
      "Pancreatitis [see Warnings and Precautions (5.6)]",
      "Immune reconstitution syndrome [see Warnings and Precautions (5.7)]",
      "Lipoatrophy [see Warnings and Precautions (5.8)]",
      "Most commonly reported adverse reactions (incidence greater than or equal to 15%) in clinical trials of combination lamivudine and zidovudine were headache, nausea, malaise and fatigue, nasal signs and symptoms, diarrhea, and cough",
      "(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Hetero Labs Limited at 1-866-495-1995 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical prac",
      "Lamivudine plus Zidovudine Administered as Separate Formulations In 4 randomized, controlled trials of EPIVIR 300 mg per day plus RETROVIR 600 mg per day, the following selected adverse reactions and laboratory abnormalities were observed (Tables 1 and 2)",
      "Selected Clinical Adverse Reactions (Greater than or Equal to 5% Frequency) in 4 Controlled Clinical Trials with EPIVIR 300 mg per day and RETROVIR"
    ],
    "indications": [
      "Uses [s] Hand wash to help reduce bacteria that potentially can cause disease"
    ]
  },
  "interferon beta": {
    "ingredient": "interferon beta",
    "is_drug": true,
    "canonical_name": "interferon beta",
    "fda_search_term": "interferon beta",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "AVONEX",
      "Avonex",
      "Avonex Pen",
      "REBIF",
      "REBIF REBIDOSE",
      "Rebif"
    ],
    "generic_names": [
      "INTERFERON BETA-1A"
    ],
    "manufacturers": [
      "Biogen Inc.",
      "EMD Serono, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in the Warnings and Precautions section of the label: Depression and Suicide [see Warnings and Precautions (5.1) ] Hepatic Injury [see Warnings and Precautions (5.2) ] Anaphylaxis and Other Allergic Reactions [see Warni",
      "5563 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of REBIF cannot be directly compared to rates in the clinical trials of other drugs and ma",
      "A total of 712 patients with relapsing-remitting multiple sclerosis (RRMS) in two controlled clinical trials took REBIF (22 mcg or 44 mcg given three times per week) [ see Clinical Studies (14) ]",
      "Ages ranged from 18 to 55 years",
      "Nearly three-fourths of the patients were female, and more than 90% were Caucasian, largely reflecting the general demographics of the population of patients with multiple sclerosis",
      "The most commonly reported adverse reactions were injection site disorders, influenza-like symptoms (headache, fatigue, fever, rigors, chest pain, back pain, myalgia), abdominal pain, depression, elevation of liver enzymes and"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE REBIF is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults",
      "Rebif is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults"
    ]
  },
  "interferons": {
    "ingredient": "interferons",
    "is_drug": true,
    "canonical_name": "interferon",
    "fda_search_term": "interferon",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "CITOMIX",
      "Enviro I",
      "GUNA-VIRUS"
    ],
    "generic_names": [
      "ALDESLEUKIN - BINETRAKIN - CANAKINUMAB - CENTELLA ASIATICA - CRANBERRY - HUMAN INTERLEUKIN-6 (NONGLYCOSYLATED) - INTERFERON GAMMA-1B - LENOGRASTIM - PINEAPPLE - SUS SCROFA BONE MARROW - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA THYMUS -",
      "ALDESLEUKIN - EVERLASTING EXTRACT - FOMITOPSIS PINICOLA FRUITING BODY - INTERFERON GAMMA-1B - MELATONIN - METENKEFALIN - REISHI - RICE - SEROTONIN - SOYBEAN - SUS SCROFA BLOOD - SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - SUS SCROFA SPLEEN -",
      "POTASSIUM GLUCONATE, GLANDULA SUPRARENALIS SUIS, HEPAR SUIS, COFFEA TOSTA, THEA SINENSIS, CARBO VEGETABILIS, FERRUM IODATUM, FERRUM METALLICUM, GELSEMIUM SEMPERVIRENS, IODIUM, IRIDIUM METALLICUM, LYCOPODIUM CLAVATUM, PULSATILLA (PRATENSIS), SELENIUM METALLICUM, ZINCUM METALLICUM, PEANUT, BLACK WALNUT, ENGLISH WALNUT, AMYGDALA AMARA, CASHEW, COCONUT, PECAN, BRAZIL NUT, TOMATO, SOLANUM TUBEROSUM, PIPER NIGRUM, EGGPLANT, RAPE SEED OIL, LINUM USITATISSIMUM, SESAME, SEED, CHEESE (STILTON), LAC VACCINUM, BEEF,"
    ],
    "manufacturers": [
      "Deseret Biologicals, Inc.",
      "Guna spa"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: If pregnant or breast-feeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, contact a physician or Poison Control Center right away",
      "Tamper Evident: Sealed for your protection",
      "Do not use if seal is broken or missing"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "For the temporary relief of symptoms including:",
      "sensitivity to food",
      "swelling of lips",
      "occasional diarrhea",
      "skin rash These statements are based upon homeopathic principles"
    ]
  },
  "inulin": {
    "ingredient": "inulin",
    "is_drug": true,
    "canonical_name": "inulin",
    "fda_search_term": "inulin",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "JBA Verestor Mega Fiber Caffe Latte",
      "Livita Children",
      "METAVEX"
    ],
    "generic_names": [
      "FOLATE, MULTIVITAMIN",
      "INULIN, BANANA STEM EXTRACT, NATTOKINASE, PANAX GINSENG ROOT EXTRACT, TURMERIC ROOT EXTRACT",
      "METAVEX"
    ],
    "manufacturers": [
      "Advanced Pharmaceutical Services, Inc. Dba Affordable Quality Pharmaceuticals",
      "Oncora Pharma, LLC",
      "PureTek Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING: In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately",
      "Precaution Section Folate doses above 0.1 mg daily may obscure pernicious anemia, in that hematologic remission can occur while neurological manifestations remain progressive",
      "There is a potential danger in administering folate to patients with undiagnosed anemia since folate may obscure the diagnosis of pernicious anemia by alleviating the hematologic manifestations of the disease while allowing the neurologic complications to progress",
      "This may result in severe nervous system damage before the correct diagnosis is made",
      "Adequate doses of vitamin B12 may prevent, halt, or improve the neurologic changes caused by pernicious anemia",
      "The patient’s medical conditions and consumption of other drugs, herbs, and/or supplements should be considered",
      "For use on the order of a licensed healthcare practitioner",
      "Call your doctor about side effects",
      "To report side effects, call PureTek Corporation at 1-877-921-7873 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "Adverse Reactions: Folate: Allergic sensitizations have been reported following both oral and parenteral administration of folate"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "Adverse Reactions: Folate: Allergic sensitizations have been reported following both oral and parenteral administration of folate",
      "Adverse reactions have been reported with specific vitamins and minerals but generally at levels substantially higher than those contained herein",
      "However, allergic, and idiosyncratic reactions are possible at lower levels"
    ],
    "indications": [
      "INDICATIONS AND USAGE: Livita™ liquid is indicated to provide significant amounts of essential vitamins and minerals, including Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, folate, calcium, magnesium, and zinc, to supplement the diet",
      "This comprehensive nutrient profile helps prevent nutritional deficiencies of these vitamins and minerals, ensuring that the specific dietary needs of adults and children are met to support overall health, energy, and vitality",
      "The product is specially formulated to target common vitamin and mineral gaps in adults, thus promoting optimal health, immune function, bone strength, and metabolic balance",
      "It is intended to be used under the guidance of a licensed healthcare practitioner to ensure that any potential for nutritional deficiency is addressed in a manner that supports the individual's overall health and wellbeing"
    ]
  },
  "inulin zinc": {
    "ingredient": "inulin zinc",
    "is_drug": true,
    "canonical_name": "inulin zinc",
    "fda_search_term": "inulin zinc",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Attitude Diaper Cream Zinc Unscented",
      "Eminence Radiant Protection SPF Fluid"
    ],
    "generic_names": [
      "ZINC OXIDE"
    ],
    "manufacturers": [
      "9055-7588 Quebec Inc. (Attitude)",
      "Eminence Organic Skin Care"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses Multi-purpose mineral powder provides broad-spectrum SPF 46 PA+++ protection",
      "Leaves the skin flawless and protected"
    ]
  },
  "iodi": {
    "ingredient": "iodi",
    "is_drug": true,
    "canonical_name": "iodide",
    "fda_search_term": "iodide",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Allergies",
      "Hevert Detox Lymph"
    ],
    "generic_names": [
      "APIS MELLIFICA, ECHINACEA, HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACONITUM NAPELLUS, AETHUSA CYNAPIUM, AGARICUS MUSCARIUS, ALETRIS FARINOSA, ALFALFA, ALLIUM CEPA, ALLIUM SATIVUM, AMBROSIA ARTEMISIAEFOLIA, ARSENICUM ALBUM, ARTEMISIA VULGARIS, ARUNDO MAURITANICA, AVENA SATIVA, BELLADONNA, BELLIS PERRENIS, BOVISTA, BROMIUM, BRYONIA, CAFFEINUM, CALCAREA CARBONICA, CALLUNA VULGARIS, FLOS, CAPSICUM ANNUUM, CAT HAIR, CHAMOMILLA, CHELIDONIUM MAJUS, CHENOPODIUM ANTHELMINTICUM, CINNAMOMUM",
      "ARSENIC TRIOXIDE, CLEMATIS RECTA FLOWERING TOP, CONIUM MACULATUM FLOWERING TOP, LACHESIS MUTA VENOM, MERCURIC IODIDE, PHYTOLACCA AMERICANA ROOT, TOXICODENDRON PUBESCENS SHOOT, SCROPHULARIA NODOSA LEAF WITH STEM, AND SULFUR"
    ],
    "manufacturers": [
      "Hevert Arzneimittel GmbH & Co KG",
      "Newton Laboratories, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS SECTION WARNINGS: Keep out of reach of children",
      "Do not use if tamper-evident seal is broken or missing",
      "If symptoms worsen or persist for more than a few days, consult a doctor",
      "If pregnant or breast-feeding , ask a doctor before use"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS & USAGE SECTION Formulated for symptoms associated with food and environmental allergens such as congestion, swollen glands, runny nose, cough, rashes and stomach upset"
    ]
  },
  "iodide": {
    "ingredient": "iodide",
    "is_drug": true,
    "canonical_name": "iodide",
    "fda_search_term": "iodide",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Allergies",
      "Hevert Detox Lymph"
    ],
    "generic_names": [
      "APIS MELLIFICA, ECHINACEA, HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACONITUM NAPELLUS, AETHUSA CYNAPIUM, AGARICUS MUSCARIUS, ALETRIS FARINOSA, ALFALFA, ALLIUM CEPA, ALLIUM SATIVUM, AMBROSIA ARTEMISIAEFOLIA, ARSENICUM ALBUM, ARTEMISIA VULGARIS, ARUNDO MAURITANICA, AVENA SATIVA, BELLADONNA, BELLIS PERRENIS, BOVISTA, BROMIUM, BRYONIA, CAFFEINUM, CALCAREA CARBONICA, CALLUNA VULGARIS, FLOS, CAPSICUM ANNUUM, CAT HAIR, CHAMOMILLA, CHELIDONIUM MAJUS, CHENOPODIUM ANTHELMINTICUM, CINNAMOMUM",
      "ARSENIC TRIOXIDE, CLEMATIS RECTA FLOWERING TOP, CONIUM MACULATUM FLOWERING TOP, LACHESIS MUTA VENOM, MERCURIC IODIDE, PHYTOLACCA AMERICANA ROOT, TOXICODENDRON PUBESCENS SHOOT, SCROPHULARIA NODOSA LEAF WITH STEM, AND SULFUR"
    ],
    "manufacturers": [
      "Hevert Arzneimittel GmbH & Co KG",
      "Newton Laboratories, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS SECTION WARNINGS: Keep out of reach of children",
      "Do not use if tamper-evident seal is broken or missing",
      "If symptoms worsen or persist for more than a few days, consult a doctor",
      "If pregnant or breast-feeding , ask a doctor before use"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS & USAGE SECTION Formulated for symptoms associated with food and environmental allergens such as congestion, swollen glands, runny nose, cough, rashes and stomach upset"
    ]
  },
  "iodin": {
    "ingredient": "iodin",
    "is_drug": true,
    "canonical_name": "potassium iodide",
    "fda_search_term": "potassium iodide",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Allergies",
      "Pericardium Triple Warmer Meridian Opener"
    ],
    "generic_names": [
      "APIS MELLIFICA, ECHINACEA, HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACONITUM NAPELLUS, AETHUSA CYNAPIUM, AGARICUS MUSCARIUS, ALETRIS FARINOSA, ALFALFA, ALLIUM CEPA, ALLIUM SATIVUM, AMBROSIA ARTEMISIAEFOLIA, ARSENICUM ALBUM, ARTEMISIA VULGARIS, ARUNDO MAURITANICA, AVENA SATIVA, BELLADONNA, BELLIS PERRENIS, BOVISTA, BROMIUM, BRYONIA, CAFFEINUM, CALCAREA CARBONICA, CALLUNA VULGARIS, FLOS, CAPSICUM ANNUUM, CAT HAIR, CHAMOMILLA, CHELIDONIUM MAJUS, CHENOPODIUM ANTHELMINTICUM, CINNAMOMUM",
      "ARSENICUM ALBUM, AURUM METALLICUM, BARYTA CARBONICA, CALCAREA CARBONICA, GLONOINUM, IODIUM, KALI IODATUM, LACHESIS MUTUS, LITHIUM CARBONICUM, MERCURIUS SOLUBILIS, NAJA TRIPUDIANS, PHOSPHORICUM ACIDUM, PHOSPHORUS, SEPIA, SPONGIA TOSTA, TABACUM, THYROIDINUM (SUIS)"
    ],
    "manufacturers": [
      "Deseret Biologicals, Inc.",
      "Newton Laboratories, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS SECTION WARNINGS: Keep out of reach of children",
      "Do not use if tamper-evident seal is broken or missing",
      "If symptoms worsen or persist for more than a few days, consult a doctor",
      "If pregnant or breast-feeding , ask a doctor before use"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS & USAGE SECTION Formulated for symptoms associated with food and environmental allergens such as congestion, swollen glands, runny nose, cough, rashes and stomach upset"
    ]
  },
  "iodine": {
    "ingredient": "iodine",
    "is_drug": true,
    "canonical_name": "iodine",
    "fda_search_term": "iodine",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Betadine",
      "Lights Povindone Iodine Scrub",
      "MediChoice Povidone-Iodine Prep Pad"
    ],
    "generic_names": [
      "POVIDONE-IODINE"
    ],
    "manufacturers": [
      "Atlantis Consumer Healthcare, Inc.",
      "Lights Medical Manufacture Co., Ltd.",
      "O&M HALYARD, INC."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses First aid to help prevent infection in minor cuts scrapes burns"
    ]
  },
  "iodine 5": {
    "ingredient": "iodine 5",
    "is_drug": true,
    "canonical_name": "iodine 5",
    "fda_search_term": "iodine 5",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Aurodone Povidone Iodine 5 % Opthalmic Solution",
      "First Aid Antiseptic"
    ],
    "generic_names": [
      "POVIDONE IODINE 5 % TOPICAL SOLUTION",
      "POVIDONE-IODINE 5%"
    ],
    "manufacturers": [
      "Aurolab",
      "Walgreen Company"
    ],
    "dosage_forms": [],
    "warnings": [
      "For external use only",
      "Do not use in the eyes over large areas of the body longer than 1 week unless directed by a doctor Ask a doctor before use if you have deep or puncture wounds serious burns animal bites Stop use and ask a doctor if condition persists or gets worse Keep out of reach of children",
      "If swallowed, get medical help or contact a Poison Control Center right away"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses A first aid spray to hel prevent infection in minor cuts, scrapes and burns"
    ]
  },
  "iodixanol": {
    "ingredient": "iodixanol",
    "is_drug": true,
    "canonical_name": "iodixanol",
    "fda_search_term": "iodixanol",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Iodixanol",
      "Visipaque"
    ],
    "generic_names": [
      "IODIXANOL"
    ],
    "manufacturers": [
      "FRESENIUS KABI USA, LLC",
      "GE Healthcare Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis",
      "Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function",
      "Stop metformin at the time of, or prior to, iodixanol administration in patients with an eGFR between 30 mL/min/1.73 m 2 and 60 mL/min/1.73 m 2 ; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast",
      "Re-evaluate eGFR 48 hours after the imaging procedure, and reinstitute metformin only after renal function is stable",
      "Radioactive Iodine Administration of iodinated contrast agents may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy in patients with carcinoma of the thyroid",
      "The decrease in efficacy lasts for 6 to 8 weeks",
      "Beta-adrenergic Blocking Agents The use of beta-adrenergic blocking agents lowers the threshold for and increases the severity of contrast reactions, and reduces the responsiveness of treatment of hypersensitivity reactions with epinephrine",
      "Because of the risk of hypersensitivity reactions, use caution when administering iodixanol to patients taking beta-blockers",
      "Oral Cholecystographic Contrast Agents Renal toxicity has been reported in patients with liver dysfunction who were given an oral cholecystographic agent followed by intravascular iodinated contrast agents",
      "Postpone the administration of iodixanol in patients who have recently received an oral cholecystographic contrast agent"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Risks Associated with Inadvertent Intrathecal Administration [see Warnings and Precautions (5.1) ] Hypersensitivity Reactions [see Warnings and Precautions (5.2) ] Contrast-Induced Kid",
      "Gastrointestinal: diarrhea, nausea, vomiting",
      "Nervous System: agitation, anxiety, insomnia, nervousness, dizziness, headache, migraine, unusual skin sensations, sensory disturbance, fainting, sensation of spinning",
      "Skin: itchy rash, severe itching, hives",
      "Special Senses: Smell, taste, and vision alteration",
      "( 6.1 ) Pediatric patients experienced similar adverse reactions",
      "( 6.3 ) To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Iodixanol is often associated with sensations of discomfort, warmth or pain",
      "In a subgroup of 1,259 patients; 30% who received iodixanol or a comparator had application site discomfort, pain, warmth or cold",
      "Iodixanol had a trend toward fewer patient reports of moderate or severe pain or warmth",
      "Pain was reported in 2% of patients receiving iodixanol and 10% of patients"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Iodixanol injection is indicated in for: Iodixanol injection is a radiographic contrast agent indicated for the following: Intra-arterial Procedures ( 1.1 ) Adults and pediatric patients 12 years of age and over Intra-arterial digital subtraction angiography (270 mg Iodine/mL",
      "Angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography (320 mg Iodine/mL)",
      "Pediatric patients less than 12 years of age Angiocardiography, cerebral arteriography, and visceral arteriography (320 mg Iodine/mL)",
      "Intravenous Procedures ( 1.2 ) Adults and pediatric patients 12 years of age and over Computed tomography (CT) imaging head and body (270 mg Iodine/mL and 320 mg Iodine/mL)",
      "Excretory urography (270 mg Iodine/mL and 320 mg Iodine/mL)"
    ]
  },
  "iodohydroxy quinoline": {
    "ingredient": "iodohydroxy quinoline",
    "is_drug": true,
    "canonical_name": "iodohydroxy quinoline",
    "fda_search_term": "iodohydroxy quinoline",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Oseltamivir Phosphate"
    ],
    "generic_names": [
      "OSELTAMIVIR PHOSPHATE"
    ],
    "manufacturers": [
      "Lannett Company, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Live attenuated influenza vaccine (LAIV), intranasal: Avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate capsules use, unless medically indicated",
      "( 7 ) 7.1 Influenza Vaccines Live Attenuated Influenza Vaccine The concurrent use of oseltamivir phosphate capsules with live attenuated influenza vaccine (LAIV) intranasal has not been evaluated",
      "However, because of the potential for oseltamivir phosphate to inhibit replication of live vaccine virus and possibly reduce the efficacy of LAIV, avoid administration of LAIV within 2 weeks before or 48 hours after oseltamivir phosphate capsules administration, unless medically indicated",
      "Inactivated Influenza Vaccine Inactivated influenza vaccine can be administered at any time relative to use of oseltamivir phosphate capsules",
      "7.2 Drugs Without Clinically Significant Drug Interaction with Oseltamivir Phosphate No dose adjustments are needed for either oseltamivir or the concomitant drug when coadministering oseltamivir with amoxicillin, acetaminophen, aspirin, cimetidine, antacids (magnesium and aluminum hydroxides and ca"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are discussed below and elsewhere in the labeling: Serious skin and hypersensitivity reactions [see Warnings and Precautions (5.1) ] Neuropsychiatric events [see Warnings and Precautions (5.2) ] Most common adverse reactions (> 1% and more ",
      "( 6.1 ) Prophylaxis studies – Nausea, vomiting, headache, pain",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Lannett Company, Inc",
      "at 1-844-834-0530 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of ano",
      "Adverse Reactions from Treatment and Prophylaxis Trials in Adult and Adolescent Subjects (13 years of age and older) The overall safety profile of oseltamivir phosphate capsules is based on data from 2,646 adult and adolescent subjects that received the recommended dosage of 75 mg orally twice daily",
      "The most common adverse reactions in the pooled treatment and pooled prophylaxis trials in adults and adolescents are displayed in Table 5 ",
      "The majority of these adverse reactions were reported on a single occasion, occurred on either the first or second treatment day and resolved spontaneously within 1-2 days",
      "This summary includes otherwise healthy adults/adolescents and subjects \"at risk\" (subjects at higher risk of developing complications associated with influenza, e.g., elderly patients and patients with chronic cardiac or respiratory disease)",
      "In general, the safety profile in the subjects \"at ris"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Oseltamivir phosphate capsules are influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours",
      "( 1.1 ) Prophylaxis of influenza A and B in patients 1 year and older",
      "( 1.2 ) Limitations of Use : Not a substitute for annual influenza vaccination",
      "( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use",
      "( 1.3 ) Not recommended for patients with end-stage renal disease not undergoing dialysis"
    ]
  },
  "iodoquinol": {
    "ingredient": "iodoquinol",
    "is_drug": true,
    "canonical_name": "iodoquinol",
    "fda_search_term": "iodoquinol",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "HYDROCORTISONE, IODOQUINOL",
      "Hydrocortisone Acetate, Iodoquinol",
      "IODOQUINOL, HYDROCORTISONE ACETATE, ALOE POLYSACCHARIDES"
    ],
    "generic_names": [
      "HYDROCORTISONE ACETATE, IODOQUINOL",
      "HYDROCORTISONE, IODOQUINOL",
      "IODOQUINOL, HYDROCORTISONE ACETATE, ALOE POLYSACCHARIDES"
    ],
    "manufacturers": [
      "KMM Pharmaceuticals, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING: FOR EXTERNAL USE ONLY"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS: The following local adverse reactions are reported infrequently with topical corticosteroids",
      "These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infections, skin atrophy, stria"
    ],
    "indications": [
      "INDICATIONS: Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: “Possibly” Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stas",
      "Final classification of the less-than-effective indications requires further investigation"
    ]
  },
  "iohexol": {
    "ingredient": "iohexol",
    "is_drug": true,
    "canonical_name": "iohexol",
    "fda_search_term": "iohexol",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Iohexol",
      "OMNIPAQUE",
      "Omnipaque"
    ],
    "generic_names": [
      "IOHEXOL"
    ],
    "manufacturers": [
      "Amneal Pharmaceuticals Private Limited",
      "GE Healthcare",
      "GE Healthcare Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis",
      "Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function",
      "Stop metformin at the time of, or prior to, OMNIPAQUE administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast",
      "Re-evaluate eGFR 48 hours after the imaging procedure, and reinstitute metformin only after renal function is stable",
      "Radioactive Iodine OMNIPAQUE may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy",
      "Avoid thyroid therapy or testing for up to 6 weeks post OMNIPAQUE",
      "7.2 Drug-Laboratory Test Interactions Protein-Bound Iodine Test Iodinated contrast agents, including OMNIPAQUE, will temporarily increase protein-bound iodine in blood",
      "Do not perform protein-bound iodine test for at least 16 days following administration of OMNIPAQUE",
      "However, thyroid function tests that do not depend on iodine estimation, e.g., T 3 resin uptake or direct thyroxine assays, are not affected"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Risks Associated with Intrathecal Administration of OMNIPAQUE Injection 140 mg Iodine/mL and 350 mg Iodine/mL [see Warnings and Precautions (5.1) ] Risks Associated with Parenteral Adm",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Intrathecal Administration Adults Adverse reactions (≥1%) in 1,531 adult patients following intrathecal administration of OMNIPAQUE in clinical trials are presented in Table 16",
      "Adverse Reactions (≥1%)"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE OMNIPAQUE is a radiographic contrast agent indicated for intrathecal, intra-arterial, intravenous, oral, rectal, intraarticular, and body cavity imaging procedures in adults and pediatric patients",
      "( 1 ) 1.1 Intrathecal Procedures ‡ OMNIPAQUE is indicated for: Myelography and computerized tomography (CT) myelography (lumbar, thoracic, cervical, total columnar) in adults and pediatric patients aged 2 weeks and older CT cisternography in adults and pediatric patients aged 2 weeks and older 1.2 I"
    ]
  },
  "iopamidol": {
    "ingredient": "iopamidol",
    "is_drug": true,
    "canonical_name": "iopamidol",
    "fda_search_term": "iopamidol",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ISOVUE-M",
      "iopamidol"
    ],
    "generic_names": [
      "IOPAMIDOL"
    ],
    "manufacturers": [
      "Bracco Diagnostics Inc",
      "Slate Run Pharmaceuticals",
      "Slate Run Pharmaceuticals, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS The need for myelographic examination should be carefully evaluated",
      "Iopamidol should be administered with caution in patients with increased intracranial pressure or suspicion of intracranial tumor, abscess or hematoma, those with a history of convulsive disorder, severe cardiovascular disease, chronic alcoholism, or multiple sclerosis, and elderly patients",
      "Particular attention must be given to state of hydration, concentration of medium, dose, and technique used in these patients",
      "Contrast media may promote sickling in individuals who are homozygous for sickle cell disease when injected intravenously or intra-arterially",
      "Although Iopamidol Injection is not injected intravascularly, measurable plasma levels are attained after intrathecal administration of iopamidol",
      "If frankly bloody cerebrospinal fluid is observed, the possible benefits of a myelographic examination should be considered in terms of risk to the patient",
      "Patients on anticonvulsant medication should be maintained on this therapy",
      "Direct intracisternal or ventricular administration for standard radiography (without computerized tomographic enhancement) is not recommended",
      "Inadvertent intracranial entry of a large or concentrated bolus of the contrast medium, which increases the risk of neurotoxicity, can be prevented by careful patient management",
      "Also, effort should be directed to avoid rapid dispersion of the medium causing inadvertent rise to intracranial levels (e.g., by active patient movement)"
    ],
    "drug_interactions": [
      "Drug Interactions Other drugs should not be admixed with iopamidol (see CONTRAINDICATIONS , and DOSAGE AND ADMINISTRATION : Drug Incompatibilities )"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The most frequently reported adverse reactions following intrathecal administration of iopamidol are headache, nausea, vomiting, and musculoskeletal pain",
      "These reactions usually occur 1 to 10 hours after injection, almost all occurring within 24 hours",
      "They are usually mild to moderate in degree, lasting for a few hours and usually disappearing within 24 hours",
      "Rarely, headaches may be severe or persist for days",
      "Headache is often accompanied by nausea and vomiting, and tends to be more frequent and persistent in patients not optimally hydrated",
      "Backache, neck stiffness, numbness and paresthesias, leg or sciatic-type pain occurred less frequently, often in the form of a transient exacerbation of pre-existing symptomatology",
      "Transient alterations in vital signs may occur and their significance must be assessed on an individual basis",
      "The following table of incidence of reactions is based on clinical studies with Iopamidol Injection in about 686 patients",
      "Adverse Reactions Estimated Overall Incidence System > 1% ≤ 1% Body as a Whole headache (16.4%) pyrexia muscle weakness hot flashes malaise fatigue weakness Digestive nausea (7.3%) diarrhea vomiting (3.6%) heartburn Musculoskeletal back pain (2.2%) leg cramps leg pain (1.4%) sciatica neck pain (1.1%",
      "Major motor seizures have been reported in the clinical literature and since market introduction in t"
    ],
    "indications": [
      "INDICATIONS AND USAGE Iopamidol Injection is indicated for intrathecal administration in adult neuroradiology including myelography (lumbar, thoracic, cervical, total columnar), and for contrast enhancement of computed tomographic (CECT) cisternography and ventriculography",
      "Iopamidol Injection, 41% is indicated for thoraco-lumbar myelography in children over the age of two years"
    ]
  },
  "iopromide": {
    "ingredient": "iopromide",
    "is_drug": true,
    "canonical_name": "iopromide",
    "fda_search_term": "iopromide",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Ultravist"
    ],
    "generic_names": [
      "IOPROMIDE"
    ],
    "manufacturers": [
      "Bayer HealthCare Pharmaceuticals Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, biguanides can cause lactic acidosis",
      "Iodinated contrast agents appear to increase the risk of metformin-induced lactic acidosis, possibly as a result of worsening renal function",
      "Stop metformin at the time of, or prior to, ULTRAVIST administration in patients with an eGFR between 30 and 60 mL/min/1.73 m2; in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents",
      "Re-evaluate eGFR 48 hours after the imaging procedure and reinstitute only after renal function is stable",
      "Radioactive Iodine ULTRAVIST may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy",
      "Avoid thyroid therapy or testing for up to 6 weeks post ULTRAVIST",
      "7.2 Drug-Laboratory Test Interactions Protein-Bound Iodine Test Iodinated contrast agents, including ULTRAVIST, will temporarily increase protein-bound iodine in blood",
      "Do not perform protein-bound iodine test for at least 16 days following administration of ULTRAVIST",
      "However, thyroid function tests which do not depend on iodine estimations, for example, T 3 resin uptake and total or free thyroxine (T 4 ) assays are not affected"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are described elsewhere in the labeling:",
      "Risks Associated with Intrathecal Use [see Warnings and Precautions ( 5.1 )]",
      "Hypersensitivity Reactions [see Warnings and Precautions ( 5.2 )]",
      "Acute Kidney Injury [see Warnings and Precautions ( 5.3 )]",
      "Cardiovascular Adverse Reactions [see Warnings and Precautions ( 5.4 )]",
      "Thromboembolic Events [see Warnings and Precautions ( 5.5 )]",
      "Extravasation and Injection Site Reactions [see Warnings and Precautions ( 5.6 )]",
      "Thyroid Dysfunction in Pediatric Patients 0 to 3 Years of Age [see Warnings and Precautions ( 5.8 )]",
      "Severe Cutaneous Adverse Reactions [see Warnings and Precautions ( 5.11 )] Common adverse reactions (>1%) are headache, nausea, injection site and infusion site reactions, vasodilatation, vomiting, back pain, urinary urgency, chest pain, pain, dysgeusia, and abnormal vision",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc",
      "at 1-888-842-2937 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect or predict the rates observed in prac",
      "The common adverse reactions reported in >1% of patients in clinical studies with ULTRAVIST are shown in Table 4",
      "Table 4: Adverse Reactions Reported in >1% of Patients Receiving ULTRAVIST in Clinical Trials System Organ Class Adverse Reaction ULTRAVIST N=1,142 (%) Nervous system disorders Headache 46 (4) Dysgeusia 15 (1.3) Eye disorders Abnormal Vision 12 (1.1) Cardiac disorders Chest pain 18 (1.6) Vascular di"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE ULTRAVIST ® Injection is an iodinated contrast agent indicated for: ULTRAVIST is a radiographic contrast agent indicated for: Intra-Arterial Procedures †",
      "Cerebral arteriography and peripheral arteriography in adults ( 1.1 )",
      "Coronary arteriography and left ventriculography, visceral angiography, and aortography in adults ( 1.1 )",
      "Radiographic evaluation of cardiac chambers and related arteries in pediatric patients aged 2 years and older ( 1.1 ) Intravenous Procedures †",
      "Excretory urography in adults and pediatric patients aged 2 years and older ( 1.2 )"
    ]
  },
  "ioversol": {
    "ingredient": "ioversol",
    "is_drug": true,
    "canonical_name": "ioversol",
    "fda_search_term": "ioversol",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Optiray 300",
      "Optiray 320",
      "Optiray 350"
    ],
    "generic_names": [
      "IOVERSOL"
    ],
    "manufacturers": [
      "Liebel-Flarsheim Company LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS 7.1 Drug-Drug Interactions Metformin In patients with renal impairment, metformin can cause lactic acidosis",
      "Iodinated contrast agents appear to increase the risk of metformin induced lactic acidosis, possibly as a result of worsening renal function",
      "Stop metformin at the time of, or prior to, OPTIRAY administration in patients with an eGFR between 30 and 60 mL/min/1.73 m 2 ; in patients with a history of hepatic impairment, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast agents",
      "Re-evaluate eGFR 48 hours after the imaging procedure, and reinstitute only after renal function is stable",
      "Radioactive Iodine Administration of iodinated contrast agents may interfere with thyroid uptake of radioactive iodine (I 131) and decrease therapeutic efficacy in patients with carcinoma of the thyroid",
      "The decrease in efficacy lasts for 6-8 weeks",
      "Oral Cholecystographic Contrast Agents Renal toxicity has been reported in patients with liver impairment who were given oral cholecystographic agents followed by intravascular contrast agents",
      "Administration of OPTIRAY should be postponed in patients who have recently received a cholecystographic contrast agent",
      "7.2 Drug/Laboratory Test Interactions Protein-Bound Iodine, Radioactive Iodine Determinations The results of protein bound iodine and radioactive iodine uptake studies, which depend on iodine estimation, will not accurately reflect thyroid function for up to 16 days following administration of iodin",
      "However, thyroid function tests that do not depend on iodine estimations, e.g., T3 resin uptake and total or free thyroxine (T4) assays are not affected"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Risks Associated with Inadvertent Intrathecal Administration [see Warnings and Precautions ( 5.1 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.2 )] Contrast Induced A",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact LIEBEL-FLARSHEIM COMPANY LLC at 855-266-5037 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Adult Patients Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in ",
      "The following listing shows adverse reactions based upon clinical trials with OPTIRAY (ioversol) in 4,187 patients",
      "Adverse reactions are listed by organ system according to clinical importance",
      "More severe reactions are listed before others in a system regardless of incidence",
      "The most common reaction is nausea, occurring at a rate of 1 percent",
      "Cardiac disorders Cardiac arrest, myocardial infarction, arrhythmia, atrioventricular block complete, atrioventricular block, nodal rhythm, bradycardia, angina pectoris, palpitations Ear and labyrinth disorders Vertigo, tinnitus Eye disorders Vision blurred, periorbital edema, conjunctivitis Gastroi"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE OPTIRAY is indicated for: OPTIRAY is a radiographic contrast agent indicated for the following: Intra-arterial Procedures ( 1.1 ) Adults: Cerebral Arteriography (300, 320 mg iodine/mL) Peripheral Arteriography (300, 320, 350 mg iodine/mL ) Visceral and Renal Arteriography, Ao",
      "OPTIRAY 320: cerebral arteriography, peripheral arteriography, visceral and renal arteriography, aortography, coronary arteriography, and left ventriculography",
      "OPTIRAY 350: peripheral arteriography coronary arteriography, and left ventriculography",
      "In pediatric patients OPTIRAY 320 and OPTIRAY 350: angiocardiography",
      "1.2 Intra-venous In adults OPTIRAY 300: CT imaging of the head and body, venography, and intravenous excretory urography"
    ]
  },
  "ipeca tincture": {
    "ingredient": "ipeca tincture",
    "is_drug": true,
    "canonical_name": "ipeca tincture",
    "fda_search_term": "ipeca tincture",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [],
    "generic_names": [],
    "manufacturers": [],
    "dosage_forms": [],
    "warnings": [
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away",
      "If pregnant or breast-feeding, ask a health professional before use",
      "Do not use if tamper evident seal is broken or missing"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "INDICATIONS: Provides specific sarcode support for the stomach",
      "Gives temporary relief of aching in the stomach, nausea, flatulence, and fullness in the abdomen"
    ]
  },
  "ipilimumab": {
    "ingredient": "ipilimumab",
    "is_drug": true,
    "canonical_name": "ipilimumab",
    "fda_search_term": "ipilimumab",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "YERVOY"
    ],
    "generic_names": [
      "IPILIMUMAB"
    ],
    "manufacturers": [
      "E.R. Squibb & Sons, L.L.C."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling:",
      "Severe and fatal immune-mediated adverse reactions [see Warnings and Precautions (5.1) ] ",
      "Infusion-related reactions [see Warnings and Precautions (5.2) ] ",
      "Most common adverse reactions (≥20%) with YERVOY as a single agent are fatigue, diarrhea, pruritus, rash, nausea, and headache",
      "(6.1) Most common adverse reactions (≥20%) with YERVOY in combination with nivolumab are fatigue, diarrhea, rash, pruritus, nausea, musculoskeletal pain, pyrexia, cough, decreased appetite, vomiting, abdominal pain, dyspnea, upper respiratory tract infection, arthralgia, headache, hypothyroidism, co",
      "(6.1) Most common adverse reactions (≥20%) with YERVOY in combination with nivolumab and platinum-doublet chemotherapy are fatigue, musculoskeletal pain, nausea, diarrhea, rash, decreased appetite, constipation, and pruritus",
      "(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical prac",
      "The data described in the Warnings and Precautions section reflect exposure to YERVOY 3 mg/kg as a single agent (or in combination with an investigational gp100 peptide vaccine) in 511 patients in Study MDX010-20; YERVOY 1 mg/kg administered with nivolumab 3 mg/kg in 1,362 patients in CHECKMATE-214,"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma",
      "Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab",
      "Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy",
      "(1.2) Renal Cell Carcinoma (RCC)",
      "Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab"
    ]
  },
  "iplant rosemary": {
    "ingredient": "iplant rosemary",
    "is_drug": true,
    "canonical_name": "iplant rosemary",
    "fda_search_term": "iplant rosemary",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [],
    "generic_names": [],
    "manufacturers": [],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Warnings: For external use only 1",
      "When you feel irregular response on the applied area such as red spots, swollen skin, itching or rash caused by exposure to direct sunlight, please consult a dermatologist 2",
      "Do not apply to the areas of skin with wounds or other skin problems 3",
      "Cautions on storage 1) Keep out of the reach of children 2) Do not store in direct sunlight"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses Uses: Firming & Nourishing"
    ]
  },
  "ipratropium bromide": {
    "ingredient": "ipratropium bromide",
    "is_drug": true,
    "canonical_name": "ipratropium bromide",
    "fda_search_term": "ipratropium bromide",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "IPRATROPIUM BROMIDE",
      "Ipratropium Bromide",
      "Ipratropium Bromide and Albuterol Sulfate"
    ],
    "generic_names": [
      "IPRATROPIUM BROMIDE",
      "IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE"
    ],
    "manufacturers": [
      "Hikma Pharmaceuticals USA Inc.",
      "Lupin Pharmaceuticals, Inc.",
      "Proficient Rx LP"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Paradoxical Bronchospasm : In the clinical study of ipratropium bromide and albuterol sulfate, paradoxical bronchospasm was not observed",
      "However, paradoxical bronchospasm has been observed with both inhaled ipratropium bromide and albuterol products and can be life-threatening",
      "If this occurs, ipratropium bromide and albuterol sulfate should be discontinued immediately and alternative therapy instituted",
      "Do Not Exceed Recommended Dose : Fatalities have been reported in association with excessive use of inhaled products containing sympathomimetic amines and with the home use of nebulizers",
      "Cardiovascular Effect : Ipratropium bromide and albuterol sulfate, like other beta adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms",
      "Although such effects are uncommon for ipratropium bromide and albuterol sulfate at recommended doses, if they occur, the drug may need to be discontinued",
      "In addition, beta agonists have been reported to produce ECG changes, such as flattening of the T-wave, prolongation of the QTc interval, and ST segment depression",
      "The clinical significance of these findings is unknown",
      "Therefore, ipratropium bromide and albuterol sulfate, like other sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension",
      "Immediate Hypersensitivity Reactions : Immediate hypersensitivity reactions to albuterol and/or ipratropium bromide may occur after the administration of ipratropium bromide and albuterol sulfate as demonstrated by rare cases of urticaria, angioedema, rash, pruritus, oropharyngeal edema, bronchospas"
    ],
    "drug_interactions": [
      "Drug Interactions Anticholinergic agents : Although ipratropium bromide is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used anticholinergic medications",
      "Caution is, therefore, advised in the coadministration of ipratropium bromide and albuterol sulfate with other drugs having anticholinergic properties",
      "ß-adrenergic agents : Caution is advised in the coadministration of ipratropium bromide and albuterol sulfate and other sympathomimetic agents due to the increased risk of adverse cardiovascular effects",
      "ß-receptor blocking agents : These agents and albuterol sulfate inhibit the effect of each other",
      "β-receptor blocking agents should be used with caution in patients with hyperreactive airways, and if used, relatively selective β1 selective agents are recommended",
      "Diuretics : The electrocardiogram (ECG) changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β-agonists, especially when the recommended dose of the β-agonist is exceeded",
      "Although the clinical significance of these effects is not known, caution is advised in the coadministration of β-agonist-containing drugs, such as ipratropium bromide and albuterol sulfate, with non-potassium sparing diuretics",
      "Monoamine oxidase inhibitors or tricyclic antidepressants : Ipratropium bromide and albuterol sulfate should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents because the "
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Adverse reaction information concerning ipratropium bromide and albuterol sulfate was derived from the 12-week controlled clinical trial",
      "ADVERSE EVENTS OCCURRING IN ≥ 1% OF ≥ 1 TREATMENT GROUP(S) AND WHERE THE COMBINATION TREATMENT SHOWED THE HIGHEST PERCENTAGE Body System COSTART Term Albuterol n (%) Ipratropium n (%) Ipratropium Bromide and Albuterol Sulfate n (%) NUMBER OF PATIENTS 761 754 765 N (%) Patients with AE 327 (43) 329 (",
      "In the clinical trial, there was a 0.3% incidence of possible allergic-type reactions, including skin rash, pruritus, and urticaria",
      "Additional information derived from the published literature on the use of albuterol sulfate and ipratropium bromide singly or in combination includes precipitation or worsening of narrow-angle glaucoma, acute eye pain, blurred vision, mydriasis, paradoxical bronchospasm, wheezing, exacerbation of C",
      "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ipratropium bromide and albuterol sulfate inhalation solution is indicated for the treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator"
    ]
  },
  "irbesartan": {
    "ingredient": "irbesartan",
    "is_drug": true,
    "canonical_name": "irbesartan",
    "fda_search_term": "irbesartan",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "IRBESARTAN",
      "Irbesartan"
    ],
    "generic_names": [
      "IRBESARTAN"
    ],
    "manufacturers": [
      "Alembic Pharmaceuticals Limited",
      "Jubilant Cadista Pharmacuticals Inc.",
      "REMEDYREPACK INC."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Lithium: Risk of lithium toxicity",
      "( 7 ) Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and COX-2 inhibitors: Increased risk of renal impairment",
      "Reduced antihypertensive effects",
      "( 7 ) Dual blockade of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia",
      "( 7 ) 7.1 Agents Increasing Serum Potassium Coadministration of irbesartan tablets with other drugs that raise serum potassium levels may result in hyperkalemia, sometimes severe",
      "Monitor serum potassium in such patients",
      "7.2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of irbesartan and lithium",
      "Monitor lithium levels in patients receiving irbesartan and lithium",
      "7.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitor",
      "These effects are usually reversible"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following important adverse reactions are described elsewhere in the labeling: Hypotension in Volume or Salt-Depleted Patients [see Warnings and Precautions (5.2) ] Impaired Renal Function [see Warnings and Precautions (5.3) ] Nephropathy in type 2 diabetic patients: The most",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Solco Healthecare US LLC",
      "at 1-866-257-2597 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates",
      "Hypertension Irbesartan tablets have been evaluated for safety in more than 4300 patients with hypertension and about 5000 subjects overall",
      "This experience includes 1303 patients treated for over 6 months and 407 patients for 1 year or more",
      "In placebo-controlled clinical trials, the following adverse reactions were reported in at least 1% of patients treated with irbesartan tablets (n=1965) and at a higher incidence versus placebo (n=641), excluding those too general to be informative and those not reasonably associated with the use of",
      "Irbesartan use was not associated with an increased incidence of dry cough, as is typically associated with ACE inhibitor use",
      "In placebo-controlled studies, the incidence of cough"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Irbesartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure",
      "Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions",
      "( 1.1 ) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria",
      "( 1.2 ) 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure",
      "Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction"
    ]
  },
  "irgasan": {
    "ingredient": "irgasan",
    "is_drug": true,
    "canonical_name": "triclosan",
    "fda_search_term": "triclosan",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "EcoCare 250",
      "Ecolab",
      "Keystone"
    ],
    "generic_names": [
      "TRICLOSAN"
    ],
    "manufacturers": [
      "Ecolab Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Do not use in eyes When using this product if in eyes, rinse promptly and thoroughly with water discontinue use if irritation and redness develop Stop use and ask a doctor if skin irritation or redness occurs for more than 72 hours Keep out of reach of children",
      "If swallowed, get medical help or contact a Poison Control Center right away"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses for handwashing to decrease bacteria on the skin"
    ]
  },
  "irinotecan": {
    "ingredient": "irinotecan",
    "is_drug": true,
    "canonical_name": "irinotecan",
    "fda_search_term": "irinotecan",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Irinotecan Hydrochloride",
      "Irinotecan Hydrochloride 100 mg/5 mL",
      "Irinotecan hydrochloride"
    ],
    "generic_names": [
      "IRINOTECAN HYDROCHLORIDE"
    ],
    "manufacturers": [
      "Armas Pharmaceuticals Inc.",
      "Hospira, Inc.",
      "Northstar Rx LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with Irinotecan hydrochloride",
      "( 7.2 ) Strong CYP3A4 Inhibitors: Do not administer strong CYP3A4 inhibitors with Irinotecan hydrochloride",
      "( 7.3 ) 7.2 Strong CYP3A4 Inducers Exposure to irinotecan or its active metabolite SN-38 is substantially reduced in adult and pediatric patients concomitantly receiving the CYP3A4 enzyme-inducing anticonvulsants phenytoin, phenobarbital, carbamazepine, or St",
      "The appropriate starting dose for patients taking these or other strong inducers such as rifampin and rifabutin has not been defined",
      "Consider substituting non-enzyme inducing therapies at least 2 weeks prior to initiation of irinotecan hydrochloride injection therapy",
      "Do not administer strong CYP3A4 inducers with irinotecan hydrochloride injection unless there are no therapeutic alternatives",
      "7.3 Strong CYP3A4 or UGT1A1 Inhibitors Irinotecan and its active metabolite, SN-38, are metabolized via the human cytochrome P450 3A4 isoenzyme (CYP3A4) and uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1), respectively, [ see Clinical Pharmacology (12.3) ]",
      "Patients receiving concomitant ketoconazole, a CYP3A4 and UGT1A1 inhibitor, have increased exposure to irinotecan and its active metabolite SN-38",
      "Coadministration of irinotecan hydrochloride with other inhibitors of CYP3A4 (e.g., clarithromycin, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telaprevir, voriconazole) or UGT1A1 (e.g., atazanavir, gemfibrozil, indinavir) may increase systemic exposure to irin",
      "Discontinue strong CYP3A4 inhibitors at least 1 week prior to starting irinotecan hydrochloride injection therapy"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS Common adverse reactions ( > 30%) observed in single agent therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, neutropenia, leukopenia (including lymphocytopenia), anemia, asthenia, fever, body weight decreasing, alopecia",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact 1-888-557-1212 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical pract",
      "Common adverse reactions ( > 30%) observed in single agent therapy clinical studies are: nausea, vomiting, abdominal pain, diarrhea, constipation, anorexia, neutropenia, leukopenia (including lymphocytopenia), anemia, asthenia, fever, body weight decreasing, and alopecia",
      "Serious opportunistic infections have not been observed, and no complications have specifically been attributed to lymphocytopenia",
      "Second-Line Single-Agent Therapy Weekly Dosage Schedule In three clinical studies evaluating the weekly dosage schedule, 304 patients with metastatic carcinoma of the colon or rectum that had recurred or progressed following 5-FU-based therapy were treated with Irinotecan hydrochloride",
      "Seventeen of the patients died within 30 days of the administration of Irinotecan hydrochloride; in five cases (1.6%, 5/304), the deaths were potentially drug-related",
      "One of the patients died of neutropenic sepsis without fever",
      "Neutropenic fever occurred in nine (3.0%) other patients; these patients recovered with supportive care",
      "One hundred nineteen (39.1%) of the 304 patients were hospitalized because of adverse events; 81 (26.6%) patients were hospitalized for events judged to be related to administration of Irinotecan hydrochloride",
      "The primary reasons for drug-related hospitaliz"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Irinotecan hydrochloride injection is a topoisomerase inhibitor indicated for:",
      "Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy",
      "Irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy"
    ]
  },
  "iron": {
    "ingredient": "iron",
    "is_drug": true,
    "canonical_name": "iron",
    "fda_search_term": "iron",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "EMF Protect and Balance",
      "MEB Gluco-Vitality Patch",
      "MEB PainGuard Patch",
      "Nausia"
    ],
    "generic_names": [
      "ALFALFA, CADMIUM SULPHURATUM, CALCAREA CARBONICA, CUPRUM METALLICUM, FERRUM METALLICUM, FUCUS VESICULOSUS, HYPERICUM PERFORATUM, KALI PHOSPHORICUM, MAGNESIA PHOSPHORICA, MANGANUM METALLICUM, MERCURIUS VIVUS, PLUMBUM METALLICUM, SILICEA, SYMPHYTUM OFFICINALE, TARENTULA HISPANA, X-RAY, YTTERBIUM OXIDE",
      "ARSENICUM ALBUM, BRYONIA (ALBA), CADMIUM SULPHURATUM, COCCULUS INDICUS, COLCHICUM AUTUMNALE, CONIUM MACULATUM, CYCLAMEN EUROPAEUM, EUPHORBIA COROLLATA, FERRUM METALLICUM, IPECACUANHA, IRIS VERSICOLOR, LAC DEFLORATUM, LACTICUM ACIDUM, NUX VOMICA, PETROLEUM, PULSATILLA (PRATENSIS), SEPIA, TABACUM, THERIDION, ZINGIBER OFFICINALE",
      "MEB GLUCO-VITALITY PATCH",
      "MEB PAINGUARD PATCH"
    ],
    "manufacturers": [
      "Deseret Biologicals, Inc.",
      "Kadesh Incoporation Co,Ltd"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: If pregnant or breastfeeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, contact a physician or Poison Control Center right away",
      "Tamper Evident: Sealed for your protection",
      "Do not use if seal is broken or missing"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "For the temporary relief of symptoms including:",
      "fatigue These statements are based upon homeopathic principles",
      "They have not been reviewed by the Food and Drug Administration"
    ]
  },
  "iron bisglycinate": {
    "ingredient": "iron bisglycinate",
    "is_drug": true,
    "canonical_name": "iron bisglycinate",
    "fda_search_term": "iron bisglycinate",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "EMF Protect and Balance",
      "MEB Gluco-Vitality Patch",
      "MEB PainGuard Patch"
    ],
    "generic_names": [
      "ALFALFA, CADMIUM SULPHURATUM, CALCAREA CARBONICA, CUPRUM METALLICUM, FERRUM METALLICUM, FUCUS VESICULOSUS, HYPERICUM PERFORATUM, KALI PHOSPHORICUM, MAGNESIA PHOSPHORICA, MANGANUM METALLICUM, MERCURIUS VIVUS, PLUMBUM METALLICUM, SILICEA, SYMPHYTUM OFFICINALE, TARENTULA HISPANA, X-RAY, YTTERBIUM OXIDE",
      "MEB GLUCO-VITALITY PATCH",
      "MEB PAINGUARD PATCH"
    ],
    "manufacturers": [
      "Deseret Biologicals, Inc.",
      "Kadesh Incoporation Co,Ltd"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: If pregnant or breastfeeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, contact a physician or Poison Control Center right away",
      "Tamper Evident: Sealed for your protection",
      "Do not use if seal is broken or missing"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS: Allergic sensitization has been reported following both oral and parenteral administration of folic acid"
    ],
    "indications": [
      "INDICATIONS: FeRivaFA ™ is a multivitamin/multimineral dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency"
    ]
  },
  "iron bisglycinated": {
    "ingredient": "iron bisglycinated",
    "is_drug": true,
    "canonical_name": "iron(II) hydroxide",
    "fda_search_term": "iron(II) hydroxide",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Betadine"
    ],
    "generic_names": [
      "POVIDONE-IODINE"
    ],
    "manufacturers": [
      "Atlantis Consumer Healthcare, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only"
    ],
    "drug_interactions": [
      "Drug Interactions: Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution",
      "However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in ser"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Ophthalmic use: The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort",
      "Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain",
      "Rare reports of dizziness and nausea have been received",
      "Refer to WARNINGS for additional adverse reactions"
    ],
    "indications": [
      "Uses Multi-purpose mineral powder provides broad-spectrum SPF 46 PA+++ protection",
      "Leaves the skin flawless and protected"
    ]
  },
  "iron chelated": {
    "ingredient": "iron chelated",
    "is_drug": true,
    "canonical_name": "iron chelated",
    "fda_search_term": "iron chelated",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "EMF Protect and Balance",
      "SilvaPlex Throat"
    ],
    "generic_names": [
      "ALFALFA, CADMIUM SULPHURATUM, CALCAREA CARBONICA, CUPRUM METALLICUM, FERRUM METALLICUM, FUCUS VESICULOSUS, HYPERICUM PERFORATUM, KALI PHOSPHORICUM, MAGNESIA PHOSPHORICA, MANGANUM METALLICUM, MERCURIUS VIVUS, PLUMBUM METALLICUM, SILICEA, SYMPHYTUM OFFICINALE, TARENTULA HISPANA, X-RAY, YTTERBIUM OXIDE",
      "ARGENTUM METALICUM"
    ],
    "manufacturers": [
      "AG Essence",
      "Deseret Biologicals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: If pregnant or breastfeeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, contact a physician or Poison Control Center right away",
      "Tamper Evident: Sealed for your protection",
      "Do not use if seal is broken or missing"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "For the temporary relief of symptoms including:",
      "fatigue These statements are based upon homeopathic principles",
      "They have not been reviewed by the Food and Drug Administration"
    ]
  },
  "iron ferrous bis glycinate": {
    "ingredient": "iron ferrous bis glycinate",
    "is_drug": true,
    "canonical_name": "iron ferrous bis glycinate",
    "fda_search_term": "iron ferrous bis glycinate",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [],
    "generic_names": [],
    "manufacturers": [],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS It is important to recognize that a positive Coombs test, hemolytic anemia, and liver disorders may occur with methyldopa therapy",
      "The rare occurrences of hemolytic anemia or liver disorders could lead to potentially fatal complications unless properly recognized and managed",
      "Read this section carefully to understand these reactions",
      "With prolonged methyldopa therapy, 10 to 20 percent of patients develop a positive direct Coombs test which usually occurs between 6 and 12 months of methyldopa therapy",
      "Lowest incidence is at daily dosage of 1 g or less",
      "This on rare occasions may be associated with hemolytic anemia, which could lead to potentially fatal complications",
      "One cannot predict which patients with a positive direct Coombs test may develop hemolytic anemia",
      "Prior existence or development of a positive direct Coombs test is not in itself a contraindication to use of methyldopa",
      "If a positive Coombs test develops during methyldopa therapy, the physician should determine whether hemolytic anemia exists and whether the positive Coombs test may be a problem",
      "For example, in addition to a positive direct Coombs test there is less often a positive indirect Coombs test which may interfere with cross matching of blood"
    ],
    "drug_interactions": [
      "Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur",
      "Patients should be followed carefully to detect side reactions or unusual manifestations of drug idiosyncrasy",
      "Patients may require reduced doses of anesthetics when on methyldopa",
      "If hypotension does occur during anesthesia, it usually can be controlled by vasopressors",
      "The adrenergic receptors remain sensitive during treatment with methyldopa",
      "When methyldopa and lithium are given concomitantly, the patient should be carefully monitored for symptoms of lithium toxicity",
      "Read the circular for lithium preparations",
      "Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate",
      "This may adversely affect blood pressure control in patients treated with methyldopa",
      "Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Sedation, usually transient, may occur during the initial period of therapy or whenever the dose is increased",
      "Headache, asthenia, or weakness may be noted as early and transient symptoms",
      "However, significant adverse effects due to methyldopa have been infrequent and this agent usually is well tolerated",
      "The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity",
      "Cardiovascular : Aggravation of angina pectoris, congestive heart failure, prolonged carotid sinus hypersensitivity, orthostatic hypotension (decrease daily dosage), edema or weight gain, bradycardia",
      "Digestive: Pancreatitis, colitis, vomiting, diarrhea, sialadenitis, sore or \"black\" tongue, nausea, constipation, distension, flatus, dryness of mouth",
      "Endocrine: Hyperprolactinemia",
      "Hematologic: Bone marrow depression, leukopenia, granulocytopenia, thrombocytopenia, hemolytic anemia; positive tests for antinuclear antibody, LE cells, and rheumatoid factor, positive Coombs test",
      "Hepatic: Liver disorders including hepatitis, jaundice, abnormal liver function tests (see WARNINGS )",
      "Hypersensitivity: Myocarditis, pericarditis, vasculitis, lupus-like syndrome, drug-related fever, eosinophilia",
      "Nervous System/Psychiatric: Parkinsonism, Bell’s palsy, decreased mental acuity, involuntary choreoathetotic movements, symptoms of cerebrovascular insufficiency, psychic disturbances including nightmares and reversible mild psychoses or depression, headache, sedation, asthenia or weakness, dizzines",
      "Metabolic: Rise in BUN",
      "Musculoskeletal: Arthralgia, with or without joint swelling; myalgia",
      "Respiratory: Nasal stuffiness",
      "Skin: Toxic epidermal necrolysis, rash"
    ],
    "indications": [
      "INDICATIONS AND USAGE Hypertension"
    ]
  },
  "iron glycinate": {
    "ingredient": "iron glycinate",
    "is_drug": true,
    "canonical_name": "iron glycinate",
    "fda_search_term": "iron glycinate",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "EMF Protect and Balance"
    ],
    "generic_names": [
      "ALFALFA, CADMIUM SULPHURATUM, CALCAREA CARBONICA, CUPRUM METALLICUM, FERRUM METALLICUM, FUCUS VESICULOSUS, HYPERICUM PERFORATUM, KALI PHOSPHORICUM, MAGNESIA PHOSPHORICA, MANGANUM METALLICUM, MERCURIUS VIVUS, PLUMBUM METALLICUM, SILICEA, SYMPHYTUM OFFICINALE, TARENTULA HISPANA, X-RAY, YTTERBIUM OXIDE"
    ],
    "manufacturers": [
      "Deseret Biologicals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS For External use only",
      "Use only as directed",
      "Keep out of reach of children",
      "If swallowed, get medical help or contact a Poison Control Center right away",
      "■ More than one patch on your body at a time ■ On cut, irritated or swollen skin ■ On puncture wounds ■ For more than one week without consulting a doctor ■ If you are allergic to any active or inactive ingredients ■ If pouch is damaged or opened",
      "If pregnant or breast feeding Contact a physician prior to use",
      "WHEN USING: ■ Use only as directed ■ Read and follow all directions and warnings on this carton ■ Do not allow contact with the eyes ■ Do not use at the same time as other topical analgesics ■ Do not bandage tightly or apply local heat (such as heating pads) to the area of use ■ Do not microwave ■ D",
      "Used patches still contain the drug product that can produce serious adverse effects if a child or pet chews or ingests this patch",
      "Stop use and consult a doctor if ■ Condition worsens ■ Redness is present ■ Irritation develops ■ Symptoms persist for more than 7 days or clear up and occur again within a few days ■ You experience signs of skin injury, such as pain, swelling or blistering where the product was applied"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS: Allergic sensitization has been reported following both oral and parenteral administration of folic acid"
    ],
    "indications": [
      "INDICATIONS: FeRivaFA ™ is a multivitamin/multimineral dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency"
    ]
  },
  "iron iii glycinate": {
    "ingredient": "iron iii glycinate",
    "is_drug": true,
    "canonical_name": "iron(III) glycinate",
    "fda_search_term": "iron(III) glycinate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Glimepiride",
      "Mekinist"
    ],
    "generic_names": [
      "GLIMEPIRIDE",
      "TRAMETINIB"
    ],
    "manufacturers": [
      "American Health Packaging",
      "Novartis Pharmaceuticals Corporation"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Use In Pregnancy CLARITHROMYCIN SHOULD NOT BE USED IN PREGNANT WOMEN EXCEPT IN CLINICAL CIRCUMSTANCES WHERE NO ALTERNATIVE THERAPY IS APPROPRIATE",
      "IF PREGNANCY OCCURS WHILE TAKING THIS DRUG, THE PATIENT SHOULD BE APPRISED OF THE POTENTIAL HAZARD TO THE FETUS",
      "CLARITHROMYCIN HAS DEMONSTRATED ADVERSE EFFECTS OF PREGNANCY OUTCOME AND/OR EMBRYO-FETAL DEVELOPMENT IN MONKEYS, RATS, MICE, AND RABBITS AT DOSES THAT PRODUCED PLASMA LEVELS 2 TO 17 TIMES THE SERUM LEVELS ACHIEVED IN HUMANS TREATED AT THE MAXIMUM RECOMMENDED HUMAN DOSES",
      "(See PRECAUTIONS: Pregnancy .) Hepatotoxicity Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported with clarithromycin",
      "This hepatic dysfunction may be severe and is usually reversible",
      "In some instances, hepatic failure with fatal outcome has been reported and generally has been associated with serious underlying diseases and/or concomitant medications",
      "Discontinue clarithromycin immediately if signs and symptoms of hepatitis occur",
      "QT Prolongation Clarithromycin has been associated with prolongation of the QT interval and infrequent cases of arrhythmia",
      "Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving clarithromycin",
      "Fatalities have been reported"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS MEKINIST is indicated for use in combination with dabrafenib",
      "Refer to the dabrafenib prescribing information for additional risk information that applies to combination use treatment"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: New Primary Malignancies [see Warnings and Precautions ( 5.1)] Hemorrhage [see Warnings and Precautions (5.2)] Colitis and Gastrointestinal Perforation [see Warnings and Precautions (5",
      "4 )] Cardiomyopathy [see Warnings and Precautions (5",
      "5 )] Ocular Toxicities [see Warnings and Precautions (5",
      "6 )] Interstitial Lung Disease/Pneumonitis [see Warnings and Precautions (5",
      "7 )] Serious Febrile Reactions [see Warnings and Precautions (5",
      "8 )] Serious Skin Toxicities [see Warnings and Precautions (5",
      "9 )] Hyperglycemia [see Warnings and Precautions (5",
      "10 )] Hemophagocytic Lymphohistiocytosis [see Warnings and Precautions (5",
      "12 )] There are additional adverse reactions associated with dabrafenib",
      "Refer to the dabrafenib prescribing information for additional information",
      "Most common adverse reactions (≥ 20%) for MEKINIST as a single agent include rash, diarrhea, and lymphedema",
      "( 6.1 ) Most common adverse reactions (≥ 20%) for MEKINIST in combination with dabrafenib include: Unresectable or metastatic melanoma: pyrexia, nausea, rash, chills, diarrhea, vomiting, hypertension, and peripheral edema",
      "( 6.1 ) Adjuvant treatment of melanoma: pyrexia, fatigue, nausea, headache, rash, chills, diarrhea, vomiting, arthralgia, and myalgia",
      "( 6.1 ) NSCLC: pyrexia, fatigue, nausea, vomiting, diarrhea, dry skin, decreased appetite, edema, rash, chills, hemorrhage, cough, and dyspnea",
      "( 6.1 ) Adult patients with solid tumors: pyrexia, fatigue, nausea, rash, chills, headache, hemorrhage, cough, vomiting, constipation, diarrhea, myalgia, arthralgia, and edema"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test",
      "( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test",
      "( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection",
      "( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test",
      "( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options"
    ]
  },
  "iron proteinsuccinylate": {
    "ingredient": "iron proteinsuccinylate",
    "is_drug": true,
    "canonical_name": "iron proteinsuccinylate",
    "fda_search_term": "iron proteinsuccinylate",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "EMF Protect and Balance",
      "MEB Gluco-Vitality Patch",
      "MEB PainGuard Patch",
      "Nausia"
    ],
    "generic_names": [
      "ALFALFA, CADMIUM SULPHURATUM, CALCAREA CARBONICA, CUPRUM METALLICUM, FERRUM METALLICUM, FUCUS VESICULOSUS, HYPERICUM PERFORATUM, KALI PHOSPHORICUM, MAGNESIA PHOSPHORICA, MANGANUM METALLICUM, MERCURIUS VIVUS, PLUMBUM METALLICUM, SILICEA, SYMPHYTUM OFFICINALE, TARENTULA HISPANA, X-RAY, YTTERBIUM OXIDE",
      "ARSENICUM ALBUM, BRYONIA (ALBA), CADMIUM SULPHURATUM, COCCULUS INDICUS, COLCHICUM AUTUMNALE, CONIUM MACULATUM, CYCLAMEN EUROPAEUM, EUPHORBIA COROLLATA, FERRUM METALLICUM, IPECACUANHA, IRIS VERSICOLOR, LAC DEFLORATUM, LACTICUM ACIDUM, NUX VOMICA, PETROLEUM, PULSATILLA (PRATENSIS), SEPIA, TABACUM, THERIDION, ZINGIBER OFFICINALE",
      "MEB GLUCO-VITALITY PATCH",
      "MEB PAINGUARD PATCH"
    ],
    "manufacturers": [
      "Deseret Biologicals, Inc.",
      "Kadesh Incoporation Co,Ltd"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: If pregnant or breastfeeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, contact a physician or Poison Control Center right away",
      "Tamper Evident: Sealed for your protection",
      "Do not use if seal is broken or missing"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "For the temporary relief of symptoms including:",
      "fatigue These statements are based upon homeopathic principles",
      "They have not been reviewed by the Food and Drug Administration"
    ]
  },
  "iron pyrophosphate": {
    "ingredient": "iron pyrophosphate",
    "is_drug": true,
    "canonical_name": "iron pyrophosphate",
    "fda_search_term": "iron pyrophosphate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Colgate Max Fresh Cool Mint",
      "Prime Tooth Care Hami Melon"
    ],
    "generic_names": [
      "SODIUM FLUORIDE"
    ],
    "manufacturers": [
      "Colgate-Palmolive Company",
      "Prime Tooth Care LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings When using this product Do not swallow Do not use in eye area Keep out of reach of children under 6 years of age",
      "If more than used for brushing is accidentally swallowed, get medical help or contact a Poison Control Center right away"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Use helps protect against cavities"
    ]
  },
  "iron sucrose": {
    "ingredient": "iron sucrose",
    "is_drug": true,
    "canonical_name": "iron sucrose",
    "fda_search_term": "iron sucrose",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Iron Sucrose",
      "Venofer"
    ],
    "generic_names": [
      "IRON SUCROSE"
    ],
    "manufacturers": [
      "American Regent, Inc.",
      "International Medication Systems, Limited",
      "Mylan Institutional LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Iron sucrose may reduce the absorption of concomitantly administered oral iron preparations"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling:",
      "Hypersensitivity Reactions [see Warnings and Precautions (5.1) ]",
      "Hypotension [see Warnings and Precautions (5.2) ]",
      "Iron Overload [see Warnings and Precautions (5.3) ]",
      "Adult patients: The most common adverse reactions (≥2%) are diarrhea, nausea, vomiting, headache, dizziness, hypotension, pruritus, pain in extremity, arthralgia, back pain, muscle cramp, injection site reactions, chest pain, and peripheral edema",
      "Pediatric patients: The most common adverse reactions (≥2%) are headache, respiratory tract viral infection, peritonitis, vomiting, pyrexia, dizziness, cough, nausea, arteriovenous fistula thrombosis, hypotension, and hypertension",
      "( 6.1) To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Adverse Reactions in Clinical Trials Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug may not reflect the rates observed in practice",
      "Adverse Reactions in Adult Patients with CKD The frequency of adverse reactions associated with the use of iron sucrose has been documented in six clinical trials involving 231 patients with HDD-CKD, 139 patients with NDD-CKD and 75 patients with PDD-CKD",
      "Adverse reactions reported by ≥ 2% of treated patients in the six clinical trials for which the rate for iron sucrose exceeds the rate for comparator are listed by indication in Table 1",
      "Patients with HDD-CKD received 100 mg doses at 10 consecutive dialysis sessions until a cumulative dose of 1000 mg was administered",
      "Patients with NDD-CKD received either 5 doses of 200 mg over 2 weeks or 2 doses of 500 mg separated by fourteen days, and patients with PDD-CKD received 2 doses of 300 mg followed by a dose of 400 mg over a period of 4 weeks",
      "Adverse Reactions Reported in ≥ 2% of"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Iron sucrose injection is indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD)",
      "Iron sucrose injection is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD)"
    ]
  },
  "iron witn": {
    "ingredient": "iron witn",
    "is_drug": true,
    "canonical_name": "iron witn",
    "fda_search_term": "iron witn",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "EMF Protect and Balance",
      "MEB Gluco-Vitality Patch",
      "MEB PainGuard Patch",
      "Nausia"
    ],
    "generic_names": [
      "ALFALFA, CADMIUM SULPHURATUM, CALCAREA CARBONICA, CUPRUM METALLICUM, FERRUM METALLICUM, FUCUS VESICULOSUS, HYPERICUM PERFORATUM, KALI PHOSPHORICUM, MAGNESIA PHOSPHORICA, MANGANUM METALLICUM, MERCURIUS VIVUS, PLUMBUM METALLICUM, SILICEA, SYMPHYTUM OFFICINALE, TARENTULA HISPANA, X-RAY, YTTERBIUM OXIDE",
      "ARSENICUM ALBUM, BRYONIA (ALBA), CADMIUM SULPHURATUM, COCCULUS INDICUS, COLCHICUM AUTUMNALE, CONIUM MACULATUM, CYCLAMEN EUROPAEUM, EUPHORBIA COROLLATA, FERRUM METALLICUM, IPECACUANHA, IRIS VERSICOLOR, LAC DEFLORATUM, LACTICUM ACIDUM, NUX VOMICA, PETROLEUM, PULSATILLA (PRATENSIS), SEPIA, TABACUM, THERIDION, ZINGIBER OFFICINALE",
      "MEB GLUCO-VITALITY PATCH",
      "MEB PAINGUARD PATCH"
    ],
    "manufacturers": [
      "Deseret Biologicals, Inc.",
      "Kadesh Incoporation Co,Ltd"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS: If pregnant or breastfeeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, contact a physician or Poison Control Center right away",
      "Tamper Evident: Sealed for your protection",
      "Do not use if seal is broken or missing"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "For the temporary relief of symptoms including:",
      "fatigue These statements are based upon homeopathic principles",
      "They have not been reviewed by the Food and Drug Administration"
    ]
  },
  "isoconazole nitrate": {
    "ingredient": "isoconazole nitrate",
    "is_drug": true,
    "canonical_name": "isoconazole nitrate",
    "fda_search_term": "isoconazole nitrate",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [],
    "generic_names": [],
    "manufacturers": [],
    "dosage_forms": [],
    "warnings": [
      "Cardiac Conduction: Diltiazem prolongs AV node refractory periods without significantly prolonging sinus node recovery time, except in patients with sick sinus syndrome",
      "This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second",
      "or third-degree AV block (six of 1243 patients for 0.48%)",
      "Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction",
      "A patient with Prinzmetal's angina developed periods of asystole (2 to 5 seconds) after a single dose of 60 mg of diltiazem (see ADVERSE REACTIONS )",
      "Congestive Heart Failure: Although diltiazem has a negative inotropic effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function have not shown a reduction in cardiac index nor consistent negative effects on contractility (dP/dt)",
      "Experience with the use of diltiazem alone or in combination with beta-blockers in patients with impaired ventricular function is very limited",
      "Caution should be exercised when using the drug in such patients",
      "Hypotension: Decreases in blood pressure associated with diltiazem therapy may occasionally result in symptomatic hypotension",
      "Acute Hepatic Injury: In rare instances, significant elevations in enzymes such as alkaline phosphatase, LDH, SGOT, SGPT, and other phenomena consistent with acute hepatic injury have been noted"
    ],
    "drug_interactions": [
      "Drug Interactions Due to the potential for additive effects, caution and careful titration are warranted in patients receiving diltiazem concomitantly with any agents known to affect cardiac contractility and/or conduction (see WARNINGS )",
      "Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with diltiazem (see WARNINGS )",
      "As with all drugs, care should be exercised when treating patients with multiple medications",
      "Diltiazem is both a substrate and an inhibitor of the cytochrome P450 3A4 enzyme system",
      "Other drugs that are specific substrates, inhibitors, or inducers of this enzyme system may have a significant impact on the efficacy and side effect profile of diltiazem",
      "Patients taking other drugs that are substrates of CYP450 3A4, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting or stopping concomitantly administered diltiazem in order to maintain optimum therapeutic blood levels",
      "Anesthetics: The depression of cardiac contractility, conductivity, and automaticity, as well as the vascular dilation associated with anesthetics, may be potentiated by calcium channel blockers",
      "When used concomitantly, anesthetics and calcium blockers should be titrated carefully",
      "Benzodiazepines: Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3",
      "to 4-fold and the C max by 2-fold, compared to placebo"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities usually have been excluded",
      "In domestic placebo-controlled angina trials, the incidence of adverse reactions reported during diltiazem therapy was not greater than that reported during placebo therapy",
      "The following represent occurrences observed in clinical studies of angina patients",
      "In many cases, the relationship to diltiazem has not been established",
      "The most common occurrences from these studies, as well as their frequency of presentation, are edema (2.4%), headache (2.1%), nausea (1.9%), dizziness (1.5%), rash (1.3%), and asthenia (1.2%)",
      "In addition, the following events were reported infrequently (less than 1%): Cardiovascular: Angina, arrhythmia, AV block (first-degree), AV block (second",
      "or third-degree – see WARNINGS , Cardiac Conduction ), bradycardia, bundle branch block, congestive heart failure, ECG abnormality, flushing, hypotension, palpitations, syncope, tachycardia, ventricular extrasystoles Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, hallucinati",
      "Dermatological: Petechiae, photosensitivity, pruritus, urticaria Other: Amblyopia, CPK elevation, dry mouth, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, nocturia, osteoarticular pain, polyuria, sexual difficulties, tinnitus The follow"
    ],
    "indications": [
      "INDICATIONS AND USAGE Diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm"
    ]
  },
  "isoflavone": {
    "ingredient": "isoflavone",
    "is_drug": true,
    "canonical_name": "isoflavones",
    "fda_search_term": "isoflavones",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Bealions Estrogen"
    ],
    "generic_names": [
      "SOY ISOFLAVONES"
    ],
    "manufacturers": [
      "Guangdong Yucheng Cosmetics Co., Ltd"
    ],
    "dosage_forms": [],
    "warnings": [
      "For ecternal use only"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses：Helps improve skin tone and texture associated with estrogen decline.Supports hydration, firmness, and elasticity in aging skin.Helps relieve menopausal discomforts"
    ]
  },
  "isoflavones": {
    "ingredient": "isoflavones",
    "is_drug": true,
    "canonical_name": "isoflavones",
    "fda_search_term": "isoflavones",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Bealions Estrogen"
    ],
    "generic_names": [
      "SOY ISOFLAVONES"
    ],
    "manufacturers": [
      "Guangdong Yucheng Cosmetics Co., Ltd"
    ],
    "dosage_forms": [],
    "warnings": [
      "For ecternal use only"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses：Helps improve skin tone and texture associated with estrogen decline.Supports hydration, firmness, and elasticity in aging skin.Helps relieve menopausal discomforts"
    ]
  },
  "isoflurane": {
    "ingredient": "isoflurane",
    "is_drug": true,
    "canonical_name": "isoflurane",
    "fda_search_term": "isoflurane",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "FORANE",
      "Isoflurane"
    ],
    "generic_names": [
      "ISOFLURANE"
    ],
    "manufacturers": [
      "Baxter Healthcare Corporation",
      "Piramal Critical Care, Inc.",
      "Shandong New Time Pharmaceutical Co., Ltd."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "Concomitant use of N 2 O and/or opioids reduces the MAC of Isoflurane USP",
      "Adjust dose accordingly",
      "Isoflurane USP decreases the doses of neuromuscular blocking agents required",
      "Adjust dose accordingly",
      "( 7.3 ) 7.1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane",
      "Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate",
      "7.2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane [see Dosage and Administration (2.1) ]",
      "7.3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents",
      "In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2 O/opioid anesthesia"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS Most common adverse reactions (incidence > 5%) are agitation, cough, breath holding, nausea, chills/shivering, vomiting, laryngospasm, delirium",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Piramal Critical Care, Inc",
      "at 1-888-822-8431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience The following adverse reactions were identified from controlled clinical trials of adult and pediatric subjects exposed to Isoflurane USP",
      "The trials were conducted using a variety of pre-medications, other anesthetics, and surgical procedures of varying lengths",
      "The most serious reported adverse reactions in alphabetical order are agitation, arrhythmia, breath holding, elevated liver enzyme, hypotension and laryngospasm",
      "The most frequent adverse reactions (incidence ³ 5%) described in Table 1 are agitation, breath holding, chills/shivering, cough, delirium, laryngospasm, nausea, and vomiting",
      "Adverse reactions with an incidence between 1% and 5% are provided in Table 2",
      "Adverse reactions with an incidence less than 1% are provided in Table 3",
      "Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Table 2: Adverse Reactions ≥ 5% System Organ Class (SOC) Adverse Reaction Frequency PSYCHIATRIC DISORDERS Delirium 6.2% (N=2830) NERVOUS SYSTEM DISORDERS Agitation (Excitement) Induction 51.8% (N=515) 1 RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS Breath holding Induction 23.9% (N=515) 1 Cough I"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Isoflurane USP may be used for induction and maintenance of general anesthesia",
      "Adequate data have not been developed to establish its application in obstetrical anesthesia",
      "Isoflurane USP, a general anesthetic, is an inhalation agent indicated for induction and maintenance of general anesthesia"
    ]
  },
  "isoleucine": {
    "ingredient": "isoleucine",
    "is_drug": true,
    "canonical_name": "isoleucine",
    "fda_search_term": "isoleucine",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Aminosyn-PF",
      "OSTEOBIOS",
      "Vital Skin Hair Nails"
    ],
    "generic_names": [
      "CALCITONIN HUMAN - CALCIUM CARBONATE - CALCIUM FLUORIDE - CALCIUM PHOSPHATE - ISOLEUCINE - LEUCINE - LYSINE - METHIONINE - PHENYLALANINE - SUS SCROFA BONE - SUS SCROFA PARATHYROID GLAND - THREONINE - TRYPTOPHAN - VALINE -",
      "ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, AND TYROSINE",
      "L-ALANINE, L-ARGININE, L-CARNITINE, CYSTEINUM, L-GLUTAMINE, L-HISTIDINE, L-ISOLEUCINE, L-LEUCINE, L-LYSINE, L-METHIONINE, L-ORNITHINE, L-PROLINE, L-SERINE, L-TRYPTOPHAN, L-TYROSINE, L-VALINE, APIS MELLIFICA, BIOTIN, EPIDERMIS SUIS, GALIUM APARINE, HAMAMELIS VIRGINIANA, HEPAR SUIS, HGH, HYPOPHYSIS SUIS, NATRUM MURIATICUM, PANTOTHENIC ACID, PHOSPHORICUM ACIDUM, RIBOFLAVINUM, THUJA OCCIDENTALIS"
    ],
    "manufacturers": [
      "Guna spa",
      "ICU Medical Inc.",
      "Liddell Laboratories, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Stop use and ask doctor if symptoms persist more than 5 days",
      "If pregnant or breast-feeding ask a health professional before use",
      "Keep out of reach of children ",
      "In case of overdose, get medical help or contact a Poison Control Center right away",
      "Contains ethyl alcohol 30%"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTIONS Local reactions consisting of erythema, phlebitis and thrombosis at the infusion site have occurred with peripheral intravenous infusion of amino acids particularly if other substances, such as antibiotics, are also administered through the same site",
      "In such cases the infusion site should be changed promptly to another vein",
      "Use of large peripheral veins, inline filters, and slowing the rate of infusion may reduce the incidence of local venous irritation",
      "Electrolyte additives should be spread throughout the day",
      "Irritating additive medications may need to be injected at another venous site",
      "Generalized flushing, fever and nausea also have been reported during peripheral infusions of amino acid solutions",
      "If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary"
    ],
    "indications": [
      "Take 15 minutes before meals"
    ]
  },
  "isoniazid": {
    "ingredient": "isoniazid",
    "is_drug": true,
    "canonical_name": "isoniazid",
    "fda_search_term": "isoniazid",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Isoniazid",
      "isoniazid"
    ],
    "generic_names": [
      "ISONIAZID"
    ],
    "manufacturers": [
      "Bryant Ranch Prepack",
      "Chartwell RX, LLC",
      "Marlex Pharmaceuticals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS See the boxed warning ",
      "Severe Cutaneous Adverse Reactions Severe cutaneous adverse reactions (SCARs) including toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) have been reported with the u",
      "Symptoms can be serious and potentially life threatening",
      "If symptoms or signs of SCARs develop, discontinue isoniazid tablets immediately and institute appropriate therapy",
      "Cerebellar Syndrome Cerebellar syndrome which may include abnormal motor coordination presenting as gait, trunk, and limb ataxia, dysmetria and dysdiadochokinesia, intention tremor, dysarthria, or nystagmus, has been reported in postmarketing case reports with the use of isoniazid (see ADVERSE REACT",
      "Most cases of cerebellar syndrome involved patients with chronic kidney disease (CKD), however, cerebellar syndrome was also reported in patients without CKD",
      "Discontinue isoniazid tablets if symptoms or signs of cerebellar syndrome occur"
    ],
    "drug_interactions": [
      "Drug Interactions Food Isoniazid should not be administered with food",
      "Studies have shown that the bioavailability of isoniazid is reduced significantly when administered with food",
      "and histamine-containing foods should be avoided in patients receiving isoniazid",
      "Because isoniazid has some monoamine oxidase inhibiting activity, an interaction with tyramine-containing foods (cheese, red wine) may occur",
      "Diamine oxidase may also be inhibited, causing exaggerated response (e.g., headache, sweating, palpitations, flushing, hypotension) to foods containing histamine (e.g., skipjack, tuna, other tropical fish)",
      "Acetaminophen A report of severe acetaminophen toxicity was reported in a patient receiving isoniazid",
      "It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed",
      "However, current evidence suggests that isoniazid does induce P-450IIE1, a mixed-function oxidase enzyme that appears to generate the toxic metabolites, in the liver",
      "Furthermore it has been proposed that isoniazid resulted in induction of P-450IIE1 in the patient's liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites",
      "Studies have demonstrated that pretreatment with isoniazid potentiates acetaminophen hepatotoxicity in rats 1,2 "
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The most frequent reactions are those affecting the nervous system and the liver",
      "Nervous System Reactions Peripheral neuropathy is the most common toxic effect",
      "It is dose-related, occurs most often in the malnourished and in those predisposed to neuritis (e.g., alcoholics and diabetics) and is usually preceded by paresthesias of the feet and hands",
      "The incidence is higher in \"slow inactivators\"",
      "Other neurotoxic effects, which are uncommon with conventional doses, are convulsions, toxic encephalopathy, optic neuritis and atrophy, memory impairment and toxic psychosis",
      "Cerebellar syndrome, which may include abnormal motor coordination manifesting as gait, trunk, and limb ataxia, dysmetria and dysdiadochokinesia, intention tremor, dysarthria, or nystagmus, have been reported in post marketing case reports (see WARNINGS )",
      "Hepatic Reactions See boxed warning ",
      "Elevated serum transaminase (SGOT; SGPT), bilirubinemia, bilirubinuria, jaundice and occasionally severe and sometimes fatal hepatitis",
      "The common prodromal symptoms of hepatitis are anorexia, nausea, vomiting, fatigue, malaise and weakness",
      "Mild hepatic dysfunction, evidenced by mild and transient elevation of serum transaminase levels occurs in 10 to 20 percent of patients taking isoniazid",
      "This abnormality usually appears in the first 1 to 3 months of treatment but can occur at any time during therapy",
      "In most instances, enzyme levels return to normal and generally, there is no necessity to discontinue medication during the period of mild serum transaminase elevation",
      "In occasional instances, progressive liver damage occurs, with accompanying symptoms",
      "If the SGOT value exceeds three to five times the upper limit of normal, discontinuation of the isoniazid should be strongly considered",
      "The frequency of progressive liver damage increases with age"
    ],
    "indications": [
      "INDICATIONS AND USAGE Isoniazid tablets, USP are recommended for all forms of tuberculosis in which organisms are susceptible",
      "However, active tuberculosis must be treated with multiple concomitant anti-tuberculosis medications to prevent the emergence of drug resistance",
      "Single-drug treatment of active tuberculosis with isoniazid or any other medication, is inadequate therapy",
      "Isoniazid tablets, USP are recommended as preventive therapy for the following groups, regardless of age",
      "(Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (greater than or equal to 5 mm) and persons with risk factors for HIV infection whose HIV infection status is "
    ]
  },
  "isoprenaline": {
    "ingredient": "isoprenaline",
    "is_drug": true,
    "canonical_name": "isoproterenol",
    "fda_search_term": "isoproterenol",
    "groq_confidence": 0.98,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Isoproterenol Hydrochloride",
      "Isoproterenol hydrochloride"
    ],
    "generic_names": [
      "ISOPROTERENOL HYDROCHLORIDE"
    ],
    "manufacturers": [
      "KVK-Tech, Inc.",
      "Micro Labs Limited",
      "Nordic Pharma, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Table 1",
      "Clinically Relevant Interactions with Isoproterenol Epinephrine Clinical Impact Both drugs are direct cardiac stimulants, and their combined effects may induce serious arrhythmias upon simultaneous administration",
      "Intervention Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously",
      "Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxinesodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine",
      "Intervention Monitor hemodynamic parameters in patients who concurrently are taking tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium and certain antihistamines",
      "Adjust doses appropriately",
      "Drugs that may reduce clinical response of Isoproterenol Clinical Impact The cardiostimulating and bronchodilating effects of isoproterenol are antagonized by beta-adrenergic blocking drugs, such as propranolol",
      "Intervention Monitor for hemodynamic response and relief of bronchospasm and adjust dose appropriately",
      "Do not administer isoproterenol hydrochloride injection and epinephrine simultaneously due to combined effects may induce serious arrhythmias ( 7 ) Concomitant use of tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium and certain antihistamines; hemodynamic parameters may "
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions have been associated with use of isoproterenol",
      "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure",
      "Nervous system disorders: Nervousness, headache, dizziness, visual blurring Cardiovascular: Tachycardia, tachyarrhythmias, palpitations, angina, ventricular arrhythmias, Adams-Stokes attacks, pulmonary edema Respiratory: Dyspnea Other: Flushing of the skin, sweating, mild tremors, pallor, nausea Com",
      "at 1-844-267-4641 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch "
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Isoproterenol hydrochloride injection is indicated: To improve hemodynamic status in patients in distributive shock and shock due to reduced cardiac output For bronchospasm occurring during anesthesia Isoproterenol hydrochloride injection is a beta-adrenergic agonist indicate"
    ]
  },
  "isoprenoline sulphate": {
    "ingredient": "isoprenoline sulphate",
    "is_drug": true,
    "canonical_name": "isoprenoline sulphate",
    "fda_search_term": "isoprenoline sulphate",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "tamsulosin hydrochloride"
    ],
    "generic_names": [
      "TAMSULOSIN HYDROCHLORIDE"
    ],
    "manufacturers": [
      "XLCare Pharmaceuticals, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNING If symptoms persist more than a few days, contact a licensed practitioner",
      "As with any other drug, if you are pregnant or nursing a baby, seek the advice of a health care professional before using this product",
      "Keep this and all medications out of the reach of children",
      "In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS",
      "Tamsulosin hydrochloride capsules 0.4 mg should not be used with strong inhibitors of CYP3A4 (e.g., ketoconazole)",
      "Tamsulosin hydrochloride capsules should be used with caution in combination with moderate inhibitors of CYP3A4 (e.g., erythromycin), in combination with strong (e.g., paroxetine) or moderate (e.g., terbinafine) inhibitors of CYP2D6, or in patients known to be CYP2D6 poor metabolizers, particularly ",
      "( 5.2 , 7.1 , 12.3 )",
      "Concomitant use of PDE5 inhibitors with tamsulosin can potentially cause symptomatic hypotension ( 5.2 , 7.3 , 12.3 )",
      "7.1 Cytochrome P450 Inhibition Strong and Moderate Inhibitors of CYP3A4 or CYP2D6 Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6",
      "Concomitant treatment with ketoconazole (a strong inhibitor of CYP3A4) resulted in an increase in the C max and AUC of tamsulosin by a factor of 2.2 and 2.8, respectively [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]",
      "The effects of concomitant administration of a moderate CYP3A4 inhibitor (e.g., erythromycin) on the pharmacokinetics of tamsulosin hydrochloride have not been evaluated [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]",
      "Concomitant treatment with paroxetine (a strong inhibitor of CYP2D6) resulted in an increase in the C max and AUC of tamsulosin by a factor of 1.3 and 1.6, respectively [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]",
      "A similar increase in exposure is expected in CYP2D6 poor metabolizers (PM) as compared to extensive metabolizers (EM)"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The most common adverse events (≥2% of patients and at a higher incidence than placebo) with the 0.4 mg dose or 0.8 mg dose were headache, dizziness, rhinitis, infection, abnormal ejaculation, asthenia, back pain, diarrhea, pharyngitis, chest pain, cough increased, somnolence, na",
      "at 1-866-495-1995 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice",
      "The incidence of treatment-emergent adverse events has been ascertained from six short-term U.S",
      "and European placebo-controlled clinical trials in which daily doses of 0.1 to 0.8 mg tamsulosin hydrochloride capsules were used",
      "These studies evaluated safety in 1783 patients treated with tamsulosin hydrochloride capsules and 798 patients administered placebo",
      "Table 1 summarizes the treatment-emergent adverse events that occurred in ≥2% of patients receiving either tamsulosin hydrochloride capsules 0.4 mg or 0.8 mg and at an incidence numerically higher than that in the placebo group during two 13-week U.S",
      "trials (US92-03A and US93-01) conducted in 1487 men",
      "Table 1 Treatment-Emergent* Adverse Events Occurring in ≥2% of Tamsulosin Hydrochloride Capsules or Placebo Patients in Two U.S",
      "Short-Term Placebo-Controlled Clinical Studies BODY SYSTEM/ ADVERSE EVENT TAMSULOSIN HYDROCHLORIDE CAPSULES GROUPS PLACEBO 0.4 mg n=502 0.8 mg n=492 n=493 BODY AS WHOLE Headache 97 (19.3%) 104 (21.1%) 99 (20.1%) Infection† 45 (9%) 53 (10.8%) 37 (7.5%) Asthenia 39 (7.8%) 42 (8.5%) 27 (5.5%) Back pain"
    ],
    "indications": [
      "Indications To optimize body minerals"
    ]
  },
  "isoprinosine": {
    "ingredient": "isoprinosine",
    "is_drug": true,
    "canonical_name": "imipenem",
    "fda_search_term": "imipenem",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Imipenem and Cilastatin"
    ],
    "generic_names": [
      "IMIPENEM AND CILASTATIN",
      "IMIPENEM AND CILASTATIN SODIUM"
    ],
    "manufacturers": [
      "Fresenius Kabi USA, LLC",
      "WG Critical Care, LLC"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Ganciclovir: Generalized seizures have been reported in patients who received ganciclovir",
      "Do not co-administer unless benefit outweighs risk ( 7.1 )",
      "Probenecid: Concomitant administration of Imipenem and Cilastatin for Injection (I.V.) and probenecid results in increases in the plasma level and half-life of imipenem",
      "Concomitant administration is not recommended ( 7.2 )",
      "Valproic acid/divalproex sodium: Concomitant use with Imipenem and Cilastatin for Injection (I.V.) is generally not recommended",
      "Consider other antibacterial drugs to treat infections in patients whose seizures are well-controlled on valproic acid or divalproex sodium ( 5.3 , 7.3 )",
      "7.1 Ganciclovir Generalized seizures have been reported in patients who received ganciclovir and Imipenem and Cilastatin for Injection (I.V.)",
      "These drugs should not be used concomitantly with Imipenem and Cilastatin for Injection (I.V.) unless the potential benefits outweigh the risks",
      "7.2 Probenecid Concomitant administration of Imipenem and Cilastatin for Injection (I.V.) and probenecid results in increases in the plasma level and half-life of imipenem",
      "Therefore, it is not recommended that probenecid be given concomitantly with Imipenem and Cilastatin for Injection (I.V.)"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described in greater detail in the Warnings and Precautions section",
      "Hypersensitivity Reactions [see Warnings and Precautions ( 5.1 )] Seizure Potential [see Warnings and Precautions ( 5.2 )] Increased Seizure Potential Due to Interaction with Valproic Acid [see Warnings and Precautions ( 5.3 )] Clostridioides difficile -Associated Diarrhea (CDAD) [see Warnings and P",
      "The most frequently occurring adverse reactions (> 1%) in pediatric patients greater than or equal to 3 months of age were diarrhea, rash, phlebitis, gastroenteritis, vomiting, IV site irritation, urine discoloration ( 6.1 )",
      "The most frequently occurring adverse reactions (> 1%) in neonates to 3 months of age were convulsions, diarrhea, oliguria/anuria, oral candidiasis, rash, tachycardia ( 6.1 )",
      "To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adult Patients During clinical investigations 1,723 patients were treated with Imipenem and Cilastatin for Injection (I.V.)",
      "Table 4 shows the incidence of adverse reactions reported during the clinical investigations of adult patients treated with Imipenem and Cilastatin for Injection (I.V.)",
      "Table 4: Incidence (%)* of Adverse Reactions Reported During Clinical Inv"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: L",
      "( 1.1 ) Urinary tract infections",
      "( 1.2 ) Intra-abdominal infections",
      "( 1.3 ) Gynecologic infections",
      "( 1.4 ) Bacterial septicemia"
    ]
  },
  "isopro": {
    "ingredient": "isopro",
    "is_drug": true,
    "canonical_name": "isopro",
    "fda_search_term": "isopro",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Dukal Sterile Alcohol Prep Pad",
      "Isopropyl Alcohol",
      "Isopropyl alcohol"
    ],
    "generic_names": [
      "ISOPROPYL ALCOHOL"
    ],
    "manufacturers": [
      "AmerisourceBergen (Good Neighbor Pharmacy) 46122",
      "Cariba International",
      "Dukal LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Flammable Keep away from fire or flame, heat, spark, electrical Do not use as a fuel source"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Use first aid to help prevent the risk of infection in: minor cuts scrapes burns"
    ]
  },
  "isopropanol": {
    "ingredient": "isopropanol",
    "is_drug": true,
    "canonical_name": "isopropanol",
    "fda_search_term": "isopropanol",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Instant Hand Sanitizeing Wipe"
    ],
    "generic_names": [
      "ISOPROPANOL AND COMPOUND DOUBLE-STRANDED QUATERNARY AMMONIUM SALTS"
    ],
    "manufacturers": [
      "Shandong Yayun Sanitary Products Co., Ltd."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only",
      "Keep away from heat or flame"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Use Instant Hand Sanitizeing Wipe to help reduce bacteria that potentially can cause disease",
      "For use when soap and water are not available"
    ]
  },
  "isopropyl alcohol": {
    "ingredient": "isopropyl alcohol",
    "is_drug": true,
    "canonical_name": "isopropyl alcohol",
    "fda_search_term": "isopropyl alcohol",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Dukal Sterile Alcohol Prep Pad",
      "Isopropyl Alcohol",
      "Isopropyl alcohol"
    ],
    "generic_names": [
      "ISOPROPYL ALCOHOL"
    ],
    "manufacturers": [
      "AmerisourceBergen (Good Neighbor Pharmacy) 46122",
      "Cariba International",
      "Dukal LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Flammable Keep away from fire or flame, heat, spark, electrical Do not use as a fuel source"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Use first aid to help prevent the risk of infection in: minor cuts scrapes burns"
    ]
  },
  "isopropyl myris": {
    "ingredient": "isopropyl myris",
    "is_drug": true,
    "canonical_name": "isopropyl myristate",
    "fda_search_term": "isopropyl myristate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Thera Plus Maximum Strength Feminine Anti-Itch",
      "anti itch"
    ],
    "generic_names": [
      "BENZOCAINE, RESORCINOL",
      "HYDROCORTISONE"
    ],
    "manufacturers": [
      "FOURSTAR GROUP USA, INC.",
      "Meijer, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Do not use",
      "in the genital area if you have a vaginal discharge",
      "Consult a doctor",
      "for the treatment of diaper rash",
      "Consult a doctor",
      "When using this product",
      "avoid contact with the eyes",
      "do not use more than directed unless told to do so by a doctor",
      "do not put directly into the rectum by using fingers or any mechanical device or applicator Stop use and ask a doctor if",
      "condition worsens symptoms persist for more than 7 days or clear up and occur again within a few days, and do not begin use of any other hydrocortisone product unless you have asked a doctor"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "REF HH62G02UMC www.medline.com Made in USA with US and Foreign components for Medline industries, Inc., Northfield, IL 60093 USA 1-800-MEDLINE RG17VJO"
    ],
    "indications": [
      "temporarily relieves itching associated with minor skin irritations, inflammation, and rashes due to:",
      "poison ivy, oak, sumac",
      "seborrheic dermatitis",
      "temporarily relieves external anal and genital itching",
      "other uses of this product should only be under the advice and supervision of a doctor"
    ]
  },
  "isopropyl myristate": {
    "ingredient": "isopropyl myristate",
    "is_drug": true,
    "canonical_name": "isopropyl myristate",
    "fda_search_term": "isopropyl myristate",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Thera Plus Maximum Strength Feminine Anti-Itch",
      "anti itch"
    ],
    "generic_names": [
      "BENZOCAINE, RESORCINOL",
      "HYDROCORTISONE"
    ],
    "manufacturers": [
      "FOURSTAR GROUP USA, INC.",
      "Meijer, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Do not use",
      "in the genital area if you have a vaginal discharge",
      "Consult a doctor",
      "for the treatment of diaper rash",
      "Consult a doctor",
      "When using this product",
      "avoid contact with the eyes",
      "do not use more than directed unless told to do so by a doctor",
      "do not put directly into the rectum by using fingers or any mechanical device or applicator Stop use and ask a doctor if",
      "condition worsens symptoms persist for more than 7 days or clear up and occur again within a few days, and do not begin use of any other hydrocortisone product unless you have asked a doctor"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "REF HH62G02UMC www.medline.com Made in USA with US and Foreign components for Medline industries, Inc., Northfield, IL 60093 USA 1-800-MEDLINE RG17VJO"
    ],
    "indications": [
      "temporarily relieves itching associated with minor skin irritations, inflammation, and rashes due to:",
      "poison ivy, oak, sumac",
      "seborrheic dermatitis",
      "temporarily relieves external anal and genital itching",
      "other uses of this product should only be under the advice and supervision of a doctor"
    ]
  },
  "isopropyl myristate monopropylene glycol": {
    "ingredient": "isopropyl myristate monopropylene glycol",
    "is_drug": true,
    "canonical_name": "isopropyl myristate",
    "fda_search_term": "isopropyl myristate",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Thera Plus Maximum Strength Feminine Anti-Itch",
      "anti itch"
    ],
    "generic_names": [
      "BENZOCAINE, RESORCINOL",
      "HYDROCORTISONE"
    ],
    "manufacturers": [
      "FOURSTAR GROUP USA, INC.",
      "Meijer, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Do not use",
      "in the genital area if you have a vaginal discharge",
      "Consult a doctor",
      "for the treatment of diaper rash",
      "Consult a doctor",
      "When using this product",
      "avoid contact with the eyes",
      "do not use more than directed unless told to do so by a doctor",
      "do not put directly into the rectum by using fingers or any mechanical device or applicator Stop use and ask a doctor if",
      "condition worsens symptoms persist for more than 7 days or clear up and occur again within a few days, and do not begin use of any other hydrocortisone product unless you have asked a doctor"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "REF HH62G02UMC www.medline.com Made in USA with US and Foreign components for Medline industries, Inc., Northfield, IL 60093 USA 1-800-MEDLINE RG17VJO"
    ],
    "indications": [
      "temporarily relieves itching associated with minor skin irritations, inflammation, and rashes due to:",
      "poison ivy, oak, sumac",
      "seborrheic dermatitis",
      "temporarily relieves external anal and genital itching",
      "other uses of this product should only be under the advice and supervision of a doctor"
    ]
  },
  "isoproterenol": {
    "ingredient": "isoproterenol",
    "is_drug": true,
    "canonical_name": "isoproterenol",
    "fda_search_term": "isoproterenol",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Isoproterenol Hydrochloride",
      "Isoproterenol hydrochloride"
    ],
    "generic_names": [
      "ISOPROTERENOL HYDROCHLORIDE"
    ],
    "manufacturers": [
      "KVK-Tech, Inc.",
      "Micro Labs Limited",
      "Nordic Pharma, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Table 1",
      "Clinically Relevant Interactions with Isoproterenol Epinephrine Clinical Impact Both drugs are direct cardiac stimulants, and their combined effects may induce serious arrhythmias upon simultaneous administration",
      "Intervention Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously",
      "Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxinesodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine",
      "Intervention Monitor hemodynamic parameters in patients who concurrently are taking tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium and certain antihistamines",
      "Adjust doses appropriately",
      "Drugs that may reduce clinical response of Isoproterenol Clinical Impact The cardiostimulating and bronchodilating effects of isoproterenol are antagonized by beta-adrenergic blocking drugs, such as propranolol",
      "Intervention Monitor for hemodynamic response and relief of bronchospasm and adjust dose appropriately",
      "Do not administer isoproterenol hydrochloride injection and epinephrine simultaneously due to combined effects may induce serious arrhythmias ( 7 ) Concomitant use of tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium and certain antihistamines; hemodynamic parameters may "
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions have been associated with use of isoproterenol",
      "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure",
      "Nervous system disorders: Nervousness, headache, dizziness, visual blurring Cardiovascular: Tachycardia, tachyarrhythmias, palpitations, angina, ventricular arrhythmias, Adams-Stokes attacks, pulmonary edema Respiratory: Dyspnea Other: Flushing of the skin, sweating, mild tremors, pallor, nausea Com",
      "at 1-844-267-4641 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch "
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Isoproterenol hydrochloride injection is indicated: To improve hemodynamic status in patients in distributive shock and shock due to reduced cardiac output For bronchospasm occurring during anesthesia Isoproterenol hydrochloride injection is a beta-adrenergic agonist indicate"
    ]
  },
  "isosorbide": {
    "ingredient": "isosorbide",
    "is_drug": true,
    "canonical_name": "isosorbide",
    "fda_search_term": "isosorbide",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ISOSORBIDE MONONITRATE",
      "Isosorbide Mononitrate"
    ],
    "generic_names": [
      "ISOSORBIDE MONONITRATE"
    ],
    "manufacturers": [
      "Aphena Pharma Solutions - Tennessee, LLC",
      "Edenbridge Pharmaceuticals LLC.",
      "Torrent Pharmaceuticals Limited"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Amplification of the vasodilatory effects of isosorbide mononitrate by sildenafil can result in severe hypotension",
      "The time course and dose dependence of this interaction have not been studied",
      "Appropriate supportive care has not been studied, but it seems reasonable to treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion",
      "The benefits of ISMN in patients with acute myocardial infarction or congestive heart failure have not been established; because the effects of isosorbide mononitrate are difficult to terminate rapidly, this drug is not recommended in these settings",
      "If isosorbide mononitrate is used in these conditions, careful clinical or hemodynamic monitoring must be used to avoid the hazards of hypotension and tachycardia"
    ],
    "drug_interactions": [
      "Drug Interactions The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators",
      "Alcohol, in particular, has been found to exhibit additive effects of this variety",
      "Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination",
      "Dose adjustments of either class of agents may be necessary"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The table below shows the frequencies of the adverse events that occurred in >5% of the subjects in three placebo-controlled North American studies, in which patients in the active treatment arm received 30 mg, 60 mg, 120 mg, or 240 mg of isosorbide mononitrate extended-release tab",
      "In parentheses, the same table shows the frequencies with which these adverse events were associated with the discontinuation of treatment",
      "Overall, 8% of the patients who received 30 mg, 60 mg, 120 mg, or 240 mg of isosorbide mononitrate in the three placebo-controlled North American studies discontinued treatment because of adverse events",
      "Most of these discontinued because of headache",
      "Dizziness was rarely associated with withdrawal from these studies",
      "Since headache appears to be a dose-related adverse effect and tends to disappear with continued treatment, it is recommended that ISMN treatment be initiated at low doses for several days before being increased to desired levels",
      "FREQUENCY AND ADVERSE EVENTS (DISCONTINUED) * * Some individuals discontinued for multiple reasons",
      "* * Patients were started on 60 mg and titrated to their final dose",
      "Three Controlled North American Studies Dose Placebo 30mg 60mg 120mg * * 240mg * * Patients 96 60 102 65 65 Headache 15%(0%) 38%(5%) 51%(8%) 42%(5%) 57%(8%) Dizziness 4%(0%) 8%(0%) 11%(1%) 9%(2%) 9%(2%) In addition, the three North American trials were pooled with 11 controlled trials conducted in E",
      "Among the 14 controlled trials, a total of 711 patients were randomized to isosorbide mononitrate extended-release tablets",
      "When the pooled data were reviewed, headache and dizziness were the only adverse events that were reported by >5% of patients",
      "Other adverse events, each reported by ≤5% of exposed patients, and in many cases of uncertain relation to drug treatment, were: Autonomic Nervous System Disorders: Dry mouth, hot flushes",
      "Body as a Whole: Asthenia, back pain, chest pain, edema, fatigue, fever, flu"
    ],
    "indications": [
      "INDICATIONS AND USAGE Isosorbide mononitrate extended-release tablets, USP are indicated for the prevention of angina pectoris due to coronary artery disease",
      "The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode"
    ]
  },
  "isosorbide dinitrate": {
    "ingredient": "isosorbide dinitrate",
    "is_drug": true,
    "canonical_name": "isosorbide dinitrate",
    "fda_search_term": "isosorbide dinitrate",
    "groq_confidence": 0.99,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ISOSORBIDE DINITRATE",
      "Isosorbide Dinitrate",
      "Isosorbide dinitrate"
    ],
    "generic_names": [
      "ISOSORBIDE DINITRATE"
    ],
    "manufacturers": [
      "AvPAK",
      "Proficient Rx LP",
      "Zydus Pharmaceuticals (USA) Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Amplification of the vasodilatory effects of isosorbide dinitrate by sildenafil can result in severe hypotension",
      "The time course and dose dependence of this interaction have not been studied",
      "Appropriate supportive care has not been studied, but it seems reasonable to treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion",
      "The benefits of immediate-release oral isosorbide dinitrate in patients with acute myocardial infarction or congestive heart failure have not been established",
      "If one elects to use isosorbide dinitrate in these conditions, careful clinical or hemodynamic monitoring must be used to avoid the hazards of hypotension and tachycardia",
      "Because the effects of oral isosorbide dinitrate are so difficult to terminate rapidly, this formulation is not recommended in these settings"
    ],
    "drug_interactions": [
      "Drug Interactions The vasodilating effects of isosorbide dinitrate may be additive with those of other vasodilators",
      "Alcohol, in particular, has been found to exhibit additive effects of this variety",
      "Concomitant use of isosorbide dinitrate with phosphodiesterase inhibitors in any form is contraindicated (see CONTRAINDICATIONS )",
      "Concomitant use of isosorbide dinitrate with riociguat, a soluble guanylate cyclase stimulator, is contraindicated (see CONTRAINDICATIONS )"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Adverse reactions to isosorbide dinitrate are generally dose-related, and almost all of these reactions are the result of isosorbide dinitrate's activity as a vasodilator",
      "Headache, which may be severe, is the most commonly reported side effect",
      "Headache may be recurrent with each daily dose, especially at higher doses",
      "Transient episodes of lightheadedness, occasionally related to blood pressure changes, may also occur",
      "Hypotension occurs infrequently, but in some patients it may be severe enough to warrant discontinuation of therapy",
      "Syncope, crescendo angina, and rebound hypertension have been reported but are uncommon",
      "Extremely rarely, ordinary doses of organic nitrates have caused methemoglobinemia in normal-seeming patients",
      "Methemoglobinemia is so infrequent at these doses that further discussion of its diagnosis and treatment is deferred (see OVERDOSAGE )",
      "Data are not available to allow estimation of the frequency of adverse reactions during treatment with isosorbide dinitrate tablets",
      "To report SUSPECTED ADVERSE REACTIONS contact AvKARE at 1-855-361-3993; email drugsafety@avkare.com ; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch "
    ],
    "indications": [
      "INDICATIONS AND USAGE Isosorbide dinitrate tablets are indicated for the prevention of angina pectoris due to coronary artery disease",
      "The onset of action of immediate-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode"
    ]
  },
  "isosorbide mononitrate": {
    "ingredient": "isosorbide mononitrate",
    "is_drug": true,
    "canonical_name": "isosorbide mononitrate",
    "fda_search_term": "isosorbide mononitrate",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ISOSORBIDE MONONITRATE",
      "Isosorbide Mononitrate"
    ],
    "generic_names": [
      "ISOSORBIDE MONONITRATE"
    ],
    "manufacturers": [
      "Aphena Pharma Solutions - Tennessee, LLC",
      "Edenbridge Pharmaceuticals LLC.",
      "Torrent Pharmaceuticals Limited"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Amplification of the vasodilatory effects of isosorbide mononitrate by sildenafil can result in severe hypotension",
      "The time course and dose dependence of this interaction have not been studied",
      "Appropriate supportive care has not been studied, but it seems reasonable to treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion",
      "The benefits of ISMN in patients with acute myocardial infarction or congestive heart failure have not been established; because the effects of isosorbide mononitrate are difficult to terminate rapidly, this drug is not recommended in these settings",
      "If isosorbide mononitrate is used in these conditions, careful clinical or hemodynamic monitoring must be used to avoid the hazards of hypotension and tachycardia"
    ],
    "drug_interactions": [
      "Drug Interactions The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators",
      "Alcohol, in particular, has been found to exhibit additive effects of this variety",
      "Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination",
      "Dose adjustments of either class of agents may be necessary"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS The table below shows the frequencies of the adverse events that occurred in >5% of the subjects in three placebo-controlled North American studies, in which patients in the active treatment arm received 30 mg, 60 mg, 120 mg, or 240 mg of isosorbide mononitrate extended-release tab",
      "In parentheses, the same table shows the frequencies with which these adverse events were associated with the discontinuation of treatment",
      "Overall, 8% of the patients who received 30 mg, 60 mg, 120 mg, or 240 mg of isosorbide mononitrate in the three placebo-controlled North American studies discontinued treatment because of adverse events",
      "Most of these discontinued because of headache",
      "Dizziness was rarely associated with withdrawal from these studies",
      "Since headache appears to be a dose-related adverse effect and tends to disappear with continued treatment, it is recommended that ISMN treatment be initiated at low doses for several days before being increased to desired levels",
      "FREQUENCY AND ADVERSE EVENTS (DISCONTINUED) * * Some individuals discontinued for multiple reasons",
      "* * Patients were started on 60 mg and titrated to their final dose",
      "Three Controlled North American Studies Dose Placebo 30mg 60mg 120mg * * 240mg * * Patients 96 60 102 65 65 Headache 15%(0%) 38%(5%) 51%(8%) 42%(5%) 57%(8%) Dizziness 4%(0%) 8%(0%) 11%(1%) 9%(2%) 9%(2%) In addition, the three North American trials were pooled with 11 controlled trials conducted in E",
      "Among the 14 controlled trials, a total of 711 patients were randomized to isosorbide mononitrate extended-release tablets",
      "When the pooled data were reviewed, headache and dizziness were the only adverse events that were reported by >5% of patients",
      "Other adverse events, each reported by ≤5% of exposed patients, and in many cases of uncertain relation to drug treatment, were: Autonomic Nervous System Disorders: Dry mouth, hot flushes",
      "Body as a Whole: Asthenia, back pain, chest pain, edema, fatigue, fever, flu"
    ],
    "indications": [
      "INDICATIONS AND USAGE Isosorbide mononitrate extended-release tablets, USP are indicated for the prevention of angina pectoris due to coronary artery disease",
      "The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode"
    ]
  },
  "isotonic seawater": {
    "ingredient": "isotonic seawater",
    "is_drug": true,
    "canonical_name": "isotonic seawater",
    "fda_search_term": "isotonic seawater",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [],
    "generic_names": [],
    "manufacturers": [],
    "dosage_forms": [],
    "warnings": [
      "Warnings Ask a doctor before use if you have heart disease high blood pressure thyroid disease diabetes difficulty in urination due to enlargement of the prostate gland unless directed by a doctor"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses For the temporary relief of nasal congestion due to: a cold hay fever upper respiratory allergies Relieves symptoms of nasal discomfort caused by dryness and sinus pressure"
    ]
  },
  "isotretinoin": {
    "ingredient": "isotretinoin",
    "is_drug": true,
    "canonical_name": "isotretinoin",
    "fda_search_term": "isotretinoin",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Isotretinoin"
    ],
    "generic_names": [
      "ISOTRETINOIN"
    ],
    "manufacturers": [
      "Actavis Pharma, Inc.",
      "Mayne Pharma",
      "Upsher-Smith Laboratories, LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Psychiatric Disorders Isotretinoin capsules may cause depression, psychosis and, rarely, suicidal ideation, suicide attempts, suicide, and aggressive and/or violent behaviors",
      "No mechanism of action has been established for these events (see ADVERSE REACTIONS: Psychiatric )",
      "Prescribers should read the brochure, Recognizing Psychiatric Disorders in Adolescents and Young Adults: A Guide for Prescribers of Isotretinoin",
      "Prescribers should be alert to the warning signs of psychiatric disorders to guide patients to receive the help they need",
      "Therefore, prior to initiation of isotretinoin capsules therapy, patients and family members should be asked about any history of psychiatric disorder, and at each visit during therapy patients should be assessed for symptoms of depression, mood disturbance, psychosis, or aggression to determine if ",
      "Signs and symptoms of depression, as described in the brochure (\"Recognizing Psychiatric Disorders in Adolescents and Young Adults\"), include sad mood, hopelessness, feelings of guilt, worthlessness or helplessness, loss of pleasure or interest in activities, fatigue, difficulty concentrating, chang",
      "Patients should stop isotretinoin capsules and the patient or a family member should promptly contact their prescriber if the patient develops depression, mood disturbance, psychosis, or aggression, without waiting until the next visit",
      "Discontinuation of isotretinoin capsules therapy may be insufficient; further evaluation may be necessary",
      "While such monitoring may be helpful, it may not detect all patients at risk",
      "Patients may report mental health problems or family history of psychiatric disorders"
    ],
    "drug_interactions": [
      "Drug Interactions Vitamin A: Because of the relationship of isotretinoin capsules to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects",
      "Tetracyclines: Concomitant treatment with isotretinoin capsules and tetracyclines should be avoided because isotretinoin capsules use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines",
      "Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (\"minipills\" that do not contain an estrogen) may be an inadequate method of contraception during isotretinoin capsules therapy",
      "Although other hormonal contraceptives are highly effective, there have been reports of pregnancy from patients who can become pregnant who have used combined oral contraceptives, as well as transdermal patch/injectable/implantable/vaginal ring hormonal birth control products",
      "These reports are more frequent for patients who can become pregnant who use only a single form of contraception",
      "It is not known if hormonal contraceptives differ in their effectiveness when used with isotretinoin capsules",
      "Therefore, it is critically important for patients who can become pregnant to select and commit to use two forms of effective contraception simultaneously, at least one of which must be a primary form (see PRECAUTIONS )",
      "Norethindrone/ethinyl estradiol: In a study of 31 premenopausal female patients with severe recalcitrant nodular acne receiving OrthoNovum ® 7/7/7 Tablets as an oral contraceptive agent, isotretinoin capsules at the recommended dose of 1 mg/kg/day, did not induce clinically relevant changes in the p",
      "Prescribers are advised to consult the package insert of medication administered concomitantly with horm"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Clinical Trials and Postmarketing Surveillance The adverse reactions listed below reflect the experience from investigational studies of isotretinoin , and the postmarketing experience",
      "The relationship of some of these events to isotretinoin therapy is unknown",
      "Many of the side effects and adverse reactions seen in patients receiving isotretinoin are similar to those described in patients taking very high doses of vitamin A (dryness of the skin and mucous membranes, e.g",
      "of the lips, nasal passage, and eyes)",
      "Dose Relationship Cheilitis and hypertriglyceridemia are usually dose related",
      "Most adverse reactions reported in clinical trials were reversible when therapy was discontinued; however, some persisted after cessation of therapy (see WARNINGS and ADVERSE REACTIONS )",
      "Body as a Whole allergic reactions, including vasculitis, systemic hypersensitivity (see PRECAUTIONS: Hypersensitivity ), edema, fatigue, lymphadenopathy, weight loss Cardiovascular palpitation, tachycardia, vascular thrombotic disease, stroke Endocrine/Metabolic hypertriglyceridemia (see WARNINGS: ",
      "Gastrointestinal inflammatory bowel disease (see WARNINGS: Inflammatory Bowel Disease ), hepatitis (see WARNINGS: Hepatotoxicity ), pancreatitis (see WARNINGS: Lipids ), bleeding and inflammation of the gums, colitis, esophagitis/esophageal ulceration, ileitis, nausea, other nonspecific gastrointest",
      "Hematologic allergic reactions (see PRECAUTIONS: Hypersensitivity ), anemia, thrombocytopenia, neutropenia, rare reports of agranulocytosis (see PRECAUTIONS: Information for Patients )",
      "See PRECAUTIONS: Laboratory Tests for other hematological parameters",
      "Musculoskeletal skeletal hyperostosis, calcification of tendons and ligaments, premature epiphyseal closure, decreases in bone mineral density (see WARNINGS: Skeletal ), musculoskeletal symptoms (sometimes severe) including back pain, myalgia, an"
    ],
    "indications": [
      "INDICATIONS AND USAGE Severe Recalcitrant Nodular Acne Isotretinoin capsules are indicated for the treatment of severe recalcitrant nodular acne",
      "Nodules are inflammatory lesions with a diameter of 5 mm or greater",
      "The nodules may become suppurative or hemorrhagic",
      "\"Severe,\" by definition, 2 means \"many\" as opposed to \"few or several\" nodules",
      "Because of significant adverse effects associated with its use, isotretinoin capsules should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics"
    ]
  },
  "ispaghula husk": {
    "ingredient": "ispaghula husk",
    "is_drug": true,
    "canonical_name": "ispaghula husk",
    "fda_search_term": "ispaghula husk",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "CVS Health",
      "Unflavored Organic Natural Fiber"
    ],
    "generic_names": [
      "NATURAL FIBER SUPPLEMENT",
      "PSYLLIUM HUSK"
    ],
    "manufacturers": [
      "CVS Pharmacy,Inc.",
      "Raritan Pharmaceuticals Inc"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings Allergy alert: As with any natural grain product, inhaled or ingested psyllium powder may cause an allergic reaction in people sensitive to psyllium",
      "Choking Taking this product without adequate fluid may cause it to swell and block your throat or esophagus and may cause choking",
      "Do not take this product if you have difficulty in swallowing",
      "If you experience chest pain, vomiting or difficulty in swallowing or breathing after taking this product, seek immediate medical attention"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Use For relief of occasional constipation and to induce regularity",
      "Generally produces bowel movements within 12-72 hours"
    ]
  },
  "isradipine": {
    "ingredient": "isradipine",
    "is_drug": true,
    "canonical_name": "isradipine",
    "fda_search_term": "isradipine",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Isradipine"
    ],
    "generic_names": [
      "ISRADIPINE"
    ],
    "manufacturers": [
      "AvKARE",
      "Elite Laboratories, Inc.",
      "Teva Pharmaceuticals USA, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "Drug Interactions Nitroglycerin: Isradipine has been safely coadministered with nitroglycerin",
      "Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of isradipine and hydrochlorothiazide does not result in altered pharmacokinetics of either drug",
      "In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect",
      "Propranolol: In a single dose study in normal volunteers, co-administration of propranolol had a small effect on the rate but no effect on the extent of isradipine bioavailability",
      "Significant increases in AUC (27%) and C max (58%) and decreases in t max (23%) of propranolol were noted in this study",
      "However, concomitant administration of 5 mg b.i.d",
      "isradipine and 40 mg b.i.d",
      "propranolol to healthy volunteers under steady-state conditions had no relevant effect on either drug's bioavailability",
      "AUC and C max differences were <20% between isradipine given singly and in combination with propranolol, and between propranolol given singly and in combination with isradipine",
      "Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS In multiple dose U.S",
      "studies in hypertension, 1228 patients received isradipine alone or in combination with other agents, principally a thiazide diuretic, 934 of them in controlled comparisons with placebo or active agents",
      "An additional 652 patients (which includes 374 normal volunteers) received isradipine in U.S",
      "studies of conditions other than hypertension, and 1321 patients received isradipine in non-U.S",
      "About 500 patients received isradipine in long-term hypertension studies, 410 of them for at least 6 months",
      "The adverse reaction rates given below are principally based on controlled hypertension studies, but rarer serious events are derived from all exposures to isradipine, including foreign marketing experience",
      "Most adverse reactions were mild and related to the vasodilatory effects of isradipine (dizziness, edema, palpitations, flushing, tachycardia), and many were transient",
      "About 5% of isradipine patients left studies prematurely because of adverse reactions (vs",
      "3% of placebo patients and 6% of active control patients), principally due to headache, edema, dizziness, palpitations, and gastrointestinal disturbances",
      "The following table shows the most common adverse reactions, volunteered or elicited, considered by the investigator to be at least possibly drug related",
      "The results for the isradipine treated patients are presented for all doses pooled together (reported by 1% or greater of patients receiving any dose of isradipine), and also for the two treatment regimens most applicable to the treatment of hypertension with isradipine: (1) initial and maintenance ",
      "followed by maintenance dose of 5 mg b.i.d",
      "Isradipine All Doses N=934 2.5 mg b.i.d",
      "† 150 10 mg b.i.d",
      "†† 59 Placebo 297 Active Controls * 414 Adverse Experience % % % % % % Headache 13.7 12.6 10.7 22 14.1 9.4 Dizziness 7.3 8 5.3 3.4 4.4 8.2 Edema 7.2 3.5 8.7 8.5 3 2.9 Palpitations 4 1 4.7"
    ],
    "indications": [
      "INDICATIONS AND USAGE Hypertension Isradipine capsules are indicated in the management of hypertension",
      "It may be used alone or concurrently with thiazide-type diuretics"
    ]
  },
  "itraconazole": {
    "ingredient": "itraconazole",
    "is_drug": true,
    "canonical_name": "itraconazole",
    "fda_search_term": "itraconazole",
    "groq_confidence": 0.95,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "ITRACONAZOLE",
      "Itraconazole",
      "Tolsura"
    ],
    "generic_names": [
      "ITRACONAZOLE"
    ],
    "manufacturers": [
      "Alembic Pharmaceuticals Inc.",
      "Amneal Pharmaceuticals LLC",
      "Mayne Pharma Commercial LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Hepatic Effects: Itraconazole have been associated with rare cases of serious hepatotoxicity, including liver failure and death",
      "Some of these cases had neither pre-existing liver disease nor a serious underlying medical condition, and some of these cases developed within the first week of treatment",
      "If clinical signs or symptoms develop that are consistent with liver disease, treatment should be discontinued and liver function testing performed",
      "Continued itraconazole use or reinstitution of treatment with itraconazole is strongly discouraged unless there is a serious or life-threatening situation where the expected benefit exceeds the risk",
      "(See PRECAUTIONS: Information for Patients and ADVERSE REACTIONS.) Cardiac Dysrhythmias: Life-threatening cardiac dysrhythmias and/or sudden death have occurred in patients using drugs such as cisapride, pimozide, methadone, or quinidine concomitantly with itraconazole and/or other CYP3A4 inhibitors",
      "Concomitant administration of these drugs with itraconazole is contraindicated",
      "(See BOXED WARNING, CONTRAINDICATIONS, and PRECAUTIONS: Drug Interactions.) Cardiac Disease: Itraconazole capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF",
      "Itraconazole capsules should not be used for other indications in patients with evidence of ventricular dysfunction unless the benefit clearly outweighs the risk",
      "For patients with risk factors for congestive heart failure, physicians should carefully review the risks and benefits of itraconazole therapy",
      "These risk factors include cardiac disease such as ischemic and valvular disease; significant pulmonary disease such as chronic obstructive pulmonary disease; and renal failure and other edematous disorders"
    ],
    "drug_interactions": [
      "Drug Interactions: Effect of Itraconazole on Other Drugs Itraconazole and its major metabolite, hydroxy-itraconazole, are potent CYP3A4 inhibitors",
      "Itraconazole is an inhibitor of the drug transporters P-glycoprotein and breast cancer resistance protein (BCRP)",
      "Consequently, itraconazole has the potential to interact with many concomitant drugs resulting in either increased or sometimes decreased concentrations of the concomitant drugs",
      "Increased concentrations may increase the risk of adverse reactions associated with the concomitant drug which can be severe or life-threatening in some cases (e.g., QT prolongation, torsade de pointes , respiratory depression, hepatic adverse reactions, hypersensitivity reactions, myelosuppression,",
      "Reduced concentrations of concomitant drugs may reduce their efficacy",
      "Table 1 lists examples of drugs that may have their concentrations affected by itraconazole, but it is not a comprehensive list",
      "Refer to the approved product labeling to become familiar with the interaction pathways, risk potential, and specific actions to be taken with regards to each concomitant drug prior to initiating therapy with itraconazole",
      "Although many of the clinical drug interactions in Table 1 are based on information with a similar azole antifungal, ketoconazole, these interactions are expected to occur with itraconazole",
      "Table 1:Drug Interactions with Itraconazole that Affect Concomitant Drug Concentrations Examples of Concomitant Drugs Within Class Prevention or Management Drug Interactions with Itraconazole that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the",
      "Analgesics Methadone Contraindicated during and 2 weeks after itraconazole treatment"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice",
      "Itraconazole has been associated with rare cases of serious hepatotoxicity, including liver failure and death",
      "Some of these cases had neither pre-existing liver disease nor a serious underlying medical condition",
      "If clinical signs or symptoms develop that are consistent with liver disease, treatment should be discontinued and liver function testing performed",
      "The risks and benefits of itraconazole use should be reassessed",
      "(See WARNINGS: Hepatic Effects and PRECAUTIONS: Hepatotoxicity and Information for Patients.) Adverse Events in the Treatment of Systemic Fungal Infections Adverse event data were derived from 602 patients treated for systemic fungal disease in U.S",
      "clinical trials who were immunocompromised or receiving multiple concomitant medications",
      "Treatment was discontinued in 10.5% of patients due to adverse events",
      "The median duration before discontinuation of therapy was 81 days (range: 2 to 776 days)",
      "The table lists adverse events reported by at least 1% of patients",
      "Table 3: Clinical Trials of Systemic Fungal Infections: Adverse Events Occurring with an Incidence of Greater than or Equal to 1% Body System/Adverse Event Incidence (%) (N=602) Gastrointestinal Nausea Vomiting Diarrhea Abdominal Pain Anorexia 11 5 3 2 1 Body as a Whole Edema Fatigue Fever Malaise 4"
    ],
    "indications": [
      "INDICATIONS AND USAGE Itraconazole capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: 1",
      "Blastomycosis, pulmonary and extrapulmonary 2",
      "Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non",
      "meningeal histoplasmosis, and 3",
      "Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy"
    ]
  },
  "ivabradine": {
    "ingredient": "ivabradine",
    "is_drug": true,
    "canonical_name": "ivabradine",
    "fda_search_term": "ivabradine",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "IVABRADINE",
      "ivabradine"
    ],
    "generic_names": [
      "IVABRADINE"
    ],
    "manufacturers": [
      "Golden State Medical Supply, Inc.",
      "Ingenus Pharmaceuticals, LLC",
      "Zydus Lifesciences Limited"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers",
      "( 7.1 ) Negative chronotropes increase risk of bradycardia; monitor heart rate",
      "( 7.2 ) 7.1 Cytochrome P450-Based Interactions Ivabradine is primarily metabolized by CYP3A4",
      "Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them",
      "Increased plasma concentrations may exacerbate bradycardia and conduction disturbances",
      "The concomitant use of strong CYP3A4 inhibitors is contraindicated [see Contraindications (4) and Clinical Pharmacology (12.3) ]",
      "Examples of strong CYP3A4 inhibitors include azole antifungals (e.g.,itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g.nelfinavir), and nefazodone",
      "Avoid concomitant use of moderate CYP3A4 inhibitors when using ivabradine tablets",
      "Examples of moderate CYP3A4 inhibitors include diltiazem, verapamil, and grapefruit juice [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3) ]",
      "Avoid concomitant use of CYP3A4 inducers when using ivabradine tablets"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS Clinically significant adverse reactions that appear in other sections of the labeling include: Atrial Fibrillation [see Warnings and Precautions (5.2) ] Bradycardia and Conduction Disturbances [see Warnings and Precautions (5.3) ] Most common adverse reactions occurring in ≥ 1% ",
      "( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Ingenus Pharmaceuticals, LLC at 1-877-748-1970 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adult Patients with Heart Failure In SHIFT, safety was evaluated in 3,260 patients treated with ivabradine tablets and 3,278 patients given placebo",
      "The median duration of ivabradine tablets exposure was 21.5 months",
      "The most common adverse drug reactions in the SHIFT trial are shown in Table 2 [see Warnings and Precautions (5.2) , ( 5.3 )]",
      "Adverse Drug Reactions with Rates ≥ 1.0% Higher on Ivabradine than Placebo occurring in > 1% on Ivabradine in SHIFT Ivabradine N = 3,260 Placebo N = 3,278 Bradycardia 10 % 2.2 % Hypertension, Blood Pressure Increased 8.9 % 7.8 % Atrial fibrillation 8.3 % 6.6 % Phosphenes, visual brightness 2.8 % 0.5",
      "Phosphenes are usually triggered by sudden variations in light intensity",
      "Ivabradine tablets can cause phosphenes, thought to be mediated through ivabradine tablets effects on retinal photoreceptors [see Clinical Pharmacol"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction",
      "( 1.1 ) 1.1 Heart Failure in Adult Patients Ivabradine tablets are indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart ra"
    ]
  },
  "ivermectin": {
    "ingredient": "ivermectin",
    "is_drug": true,
    "canonical_name": "ivermectin",
    "fda_search_term": "ivermectin",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Ivermectin"
    ],
    "generic_names": [
      "IVERMECTIN"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Asclemed USA, Inc.",
      "Belmora LLC"
    ],
    "dosage_forms": [],
    "warnings": [
      "WARNINGS Historical data have shown that microfilaricidal drugs, such as diethylcarbamazine citrate (DEC-C), might cause cutaneous and/or systemic reactions of varying severity (the Mazzotti reaction) and ophthalmological reactions in patients with onchocerciasis",
      "These reactions are probably due to allergic and inflammatory responses to the death of microfilariae",
      "Patients treated with ivermectin for onchocerciasis may experience these reactions in addition to clinical adverse reactions possibly, probably, or definitely related to the drug itself (See ADVERSE REACTIONS, Onchocerciasis )",
      "The treatment of severe Mazzotti reactions has not been subjected to controlled clinical trials",
      "Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension",
      "Antihistamines and/or aspirin have been used for most mild to moderate cases",
      "Neurotoxicity with the use of ivermectin, including alteration of consciousness of variable severity (e.g., somnolence/drowsiness, stupor, and coma), confusion, disorientation and death, has been reported in patients without onchocerciasis or in patients with onchocerciasis in the absence of Loa loa",
      "These reactions have generally resolved with supportive care and the discontinuation of ivermectin"
    ],
    "drug_interactions": [
      "Drug Interactions Post-marketing reports of increased INR (International Normalized Ratio) have been rarely reported when ivermectin was co-administered with warfarin"
    ],
    "adverse_reactions": [
      "ADVERSE REACTIONS Strongyloidiasis In four clinical studies involving a total of 109 patients given either one or two doses of 170 to 200 mcg/kg of ivermectin, the following adverse reactions were reported as possibly, probably, or definitely related to ivermectin: Body as a Whole: asthenia/fatigue ",
      "In comparative trials, patients treated with ivermectin experienced more abdominal distention and chest discomfort than patients treated with albendazole",
      "However, ivermectin was better tolerated than thiabendazole in comparative studies involving 37 patients treated with thiabendazole",
      "The Mazzotti-type and ophthalmologic reactions associated with the treatment of onchocerciasis or the disease itself would not be expected to occur in strongyloidiasis patients treated with ivermectin (See ADVERSE REACTIONS, Onchocerciasis )",
      "Laboratory Test Findings In clinical trials involving 109 patients given either one or two doses of 170 to 200 mcg/kg ivermectin, the following laboratory abnormalities were seen regardless of drug relationship: elevation in ALT and/or AST (2%), decrease in leukocyte count (3%)",
      "Leukopenia and anemia were seen in one patient",
      "Onchocerciasis In clinical trials involving 963 adult patients treated with 100 to 200 mcg/kg ivermectin, worsening of the following Mazzotti reactions during the first 4 days post-treatment were reported: arthralgia/synovitis (9.3%), axillary lymph node enlargement and tenderness (11.0% and 4.4%, r"
    ],
    "indications": [
      "INDICATIONS AND USAGE Ivermectin is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract Ivermectin is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis ",
      "This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin (See CLINICAL PHARMACOLOGY, Clinical Studies )",
      "Onchocerciasis Ivermectin is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus ",
      "This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa",
      "The comparative studies used diethylcarbamazine citrate (DEC-C)"
    ]
  },
  "ivy leaves": {
    "ingredient": "ivy leaves",
    "is_drug": true,
    "canonical_name": "ivy leaves",
    "fda_search_term": "ivy leaves",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Attitude Diaper Cream Zinc Unscented"
    ],
    "generic_names": [
      "ZINC OXIDE"
    ],
    "manufacturers": [
      "9055-7588 Quebec Inc. (Attitude)"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Table 2 includes drugs with clinically important drug interactions when administered concomitantly with ACIPHEX delayed-release tablets and instructions for preventing or managing them",
      "Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs",
      "Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with ACIPHEX Delayed-Release Tablets Antiretrovirals Clinical Impact: The effect of PPI on antiretroviral drugs is variable",
      "The clinical importance and the mechanisms behind these interactions are not always known",
      "Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the development of drug resistance",
      "Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with rabeprazole may increase toxicity ",
      "There are other antiretroviral drugs which do not result in clinically relevant interactions with rabeprazole",
      "Intervention: Rilpivirine -containing products : Concomitant use with ACIPHEX delayed-release tablets is contraindicated [see Contraindications (4) ] ",
      "See prescribing information",
      "Atazanavir : See prescribing information for atazanavir for dosing information"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious adverse reactions are described below and elsewhere in labeling: Acute Interstitial Nephritis [ see Warnings and Precautions (5.3) ] Cyanocobalamin (vitamin B-12) Deficiency [ see Warnings and Precautions (5.4) ] Clostridium difficile Associated Diarrhea [ s",
      "Most common adverse reactions in adolescents (≥2%) are headache, diarrhea, nausea, vomiting, and abdominal pain ( 6.1 )",
      "To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc",
      "at 1-888-274-2378 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Studies Experience Because clinical trials are conducted under varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another d",
      "Adults The data described below reflect exposure to ACIPHEX delayed-release tablets in 1064 adult patients exposed for up to 8 weeks",
      "The studies were primarily placebo",
      "and active-controlled trials in adult patients with Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD), Duodenal Ulcers and Gastric Ulcers",
      "The population had a mean age of 53 years (range 18-89 years) and had a ratio of approximately 60% male: 40% female",
      "The racial distribution was 86% Caucasian, 8% African American, 2% Asian, and 5% other",
      "Most patients received either 10 mg, 20 mg or 40 mg per day of ACIPHEX delayed-release tablets",
      "An analysis of adverse reactions appearing in ≥2% of patients treated with ACIPHEX delayed-release tablets (n=1064) and with a greater frequency than placebo (n=89) in controlled North American and European acute treatment trials, revealed the following adverse reactions: pain (3% v"
    ],
    "indications": [
      "Uses Multi-purpose mineral powder provides broad-spectrum SPF 46 PA+++ protection",
      "Leaves the skin flawless and protected"
    ]
  },
  "ixazomib": {
    "ingredient": "ixazomib",
    "is_drug": true,
    "canonical_name": "ixazomib",
    "fda_search_term": "ixazomib",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "NINLARO"
    ],
    "generic_names": [
      "IXAZOMIB"
    ],
    "manufacturers": [
      "Takeda Pharmaceuticals America, Inc."
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [
      "7 DRUG INTERACTIONS Strong CYP3A inducers : Avoid concomitant use with NINLARO",
      "( 7.1 , 12.3 ) 7.1 Strong CYP3A Inducers Avoid concomitant administration of NINLARO with strong CYP3A inducers (such as rifampin, phenytoin, carbamazepine, and St",
      "John's Wort) [see Clinical Pharmacology (12.3) ] "
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are described in detail in other sections of the prescribing information: Thrombocytopenia [see Warnings and Precautions (5.1) ] Gastrointestinal Toxicities [see Warnings and Precautions (5.2) ] Peripheral Neuropathy [see Warnings and Precautions (",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-844-617-6468 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "The safety population from the randomized, double-blind, placebo-controlled clinical study included 720 patients with relapsed and/or refractory multiple myeloma, who received NINLARO in combination with lenalidomide and dexamethasone (NINLARO regimen; N=361) or placebo in combination with lenalidom",
      "The most frequently reported adverse reactions (≥20% with a difference of ≥5% compared to placebo) in the NINLARO regimen were thrombocytopenia, neutropenia, diarrhea, constipation, peripheral neuropathy, nausea, peripheral edema, rash, vomiting, and bronchitis",
      "Serious adverse reactions reported in ≥2% of patients in the NINLARO regimen included diarrhea (3%), thrombocytopenia (2%) and bronchitis (2%)",
      "One or more of the three drugs was permanently discontinued in 4% of patients report"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy",
      "NINLARO is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy",
      "( 1 ) Limitations of Use : NINLARO is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials",
      "( 1 ) Limitations of Use : NINLARO is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials [see Warnings and Precautions (5.9) and Clinical Studies (14.2 , 14.3) ] "
    ]
  },
  "ixekizumab": {
    "ingredient": "ixekizumab",
    "is_drug": true,
    "canonical_name": "ixekizumab",
    "fda_search_term": "ixekizumab",
    "groq_confidence": 1.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "TALTZ"
    ],
    "generic_names": [
      "IXEKIZUMAB"
    ],
    "manufacturers": [
      "Eli Lilly and Company"
    ],
    "dosage_forms": [],
    "warnings": [],
    "drug_interactions": [],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse drug reactions are discussed in greater detail in other sections of the label: Infections [see Warnings and Precautions ( 5.1 )] Hypersensitivity Reactions [see Contraindications ( 4 ) and Warnings and Precautions ( 5.3 )] Eczematous Eruptions [see Warnings ",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-545-5979 (1-800-LillyRx) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying and controlled conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in ",
      "Adult Plaque Psoriasis Weeks 0 to 12 : Three placebo-controlled trials in subjects with plaque psoriasis were integrated to evaluate the safety of TALTZ compared to placebo for up to 12 weeks",
      "A total of 1167 subjects (mean age 45 years; 66% men; 94% White) with plaque psoriasis received TALTZ (160 mg at Week 0, 80 mg every 2 weeks [Q2W] for 12 weeks) subcutaneously",
      "In two of the trials, the safety of TALTZ (use up to 12 weeks) was also compared with an active comparator, U.S",
      "approved etanercept [see Clinical Studies ( 14 )] ",
      "In the 12-week, placebo-controlled period, adverse events occurred in 58% of the TALTZ Q2W group (2.5 per subject-year of follow-up) compared with 47% of the placebo group (2.1 per subject-year of follow-up)",
      "Serious adverse events occurred in 2% of the TALTZ group (0.07 per subject-year of follow-up), and in 2% of the placebo group (0.07 per subject-year of follow-up)",
      "Table 2 summarizes the adverse reactions that occurred at a rate o"
    ],
    "indications": [
      "1 INDICATIONS AND USAGE TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy",
      "( 1.1 ) adults with active psoriatic arthritis",
      "( 1.2 ) adults with active ankylosing spondylitis",
      "( 1.3 ) adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation",
      "( 1.4 ) 1.1 Plaque Psoriasis TALTZ ® is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy"
    ]
  },
  "jaborandi": {
    "ingredient": "jaborandi",
    "is_drug": true,
    "canonical_name": "jaborandi",
    "fda_search_term": "jaborandi",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "PILOCARPUS",
      "Pilocarpus",
      "UNDA 15",
      "UNDA 20",
      "UNDA 21",
      "UNDA 40",
      "UNDA 41"
    ],
    "generic_names": [
      "ALLIUM CEPA, AURUM METALLICUM, EUCALYPTUS GLOBULUS, INULA HELENIUM, TRIGONELLA FOENUM-GRAECUM",
      "ALUMINIUM METALLICUM, ARGENTUM METALLICUM, ARSENICUM ALBUM, AURUM METALLICUM, CALENDULA OFFICINALIS, CONDURANGO, JACARANDA CAROBA, ROBINIA PSEUDOACACIA, SABINA",
      "CAPSICUM ANNUUM, PILOCARPUS, THYMUS VULGARIS, URTICA URENS, AURUM METALLICUM, CUPRUM METALLICUM",
      "CONDURANGO, CALENDULA OFFICINALIS, CAMPHORA, HYDRASTIS CANADENSIS, THUJA OCCIDENTALIS, ALUMINIUM METALLICUM, AURUM METALLICUM",
      "PILOCARPUS JABORANDI LEAF"
    ],
    "manufacturers": [
      "Boiron",
      "Seroyal USA"
    ],
    "dosage_forms": [],
    "warnings": [
      "Warning: Stop use and ask a doctor if symptoms persist or worsen",
      "If pregnant or breastfeeding, ask a health professional before use",
      "Keep out of reach of children",
      "In case of overdose, get medical help or contact a Poison Control Center right away"
    ],
    "drug_interactions": [],
    "adverse_reactions": [],
    "indications": [
      "Uses For the temporary relief of mild fever",
      "Directions Adults and adolescents (12 years and older) Take 5 drops three times daily or as recommended by your healthcare practitioner",
      "Children (under 12 years) Take under the direction of your healthcare practitioner"
    ]
  },
  "jasmine fragrance": {
    "ingredient": "jasmine fragrance",
    "is_drug": true,
    "canonical_name": "jasmine fragrance",
    "fda_search_term": "jasmine fragrance",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Moisturizing Antibacterial",
      "Quick Action"
    ],
    "generic_names": [
      "BENZALKONIUM CHLORIDE",
      "SALICYLIC ACID"
    ],
    "manufacturers": [
      "Walmart Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only Allergy alert This product may cause a severe allergic realction",
      "Symptoms may include: wheezing/difficulty breathing hives shock rash facial swelling If an allergic reaction occurs, stop use and seek medical help right away",
      "Do not use if you are allergic to chlorhexidine gluconate or any other ingredients in this product",
      "When using this product keep out of eyes, ears and mouth",
      "May cause serious and permanent eye injury if permitted to enter or allowed to remain",
      "if contact occurs, rinse with cold water right away do not use routinely if you have wounds which involve more than the superficial layers of the skin Stop use and ask a doctor if irritation, sensitization, or allergic reaction occurs",
      "These may be signs of a serious condition",
      "Keep out of reach of children",
      "If swallowed, get medical help or contact a Poison Control Center right away"
    ],
    "drug_interactions": [],
    "adverse_reactions": [
      "ADVERSE REACTION Information: 1-888-287-1915 or Walmart.com/help DISTRIBUTED BY: Walmart Inc., Bentonville, AR 72716 PLASTIC TUBE Do Not Recycle how2recycle.info Made in the USA with domestic and imported ingredients",
      "Factory Certified"
    ],
    "indications": [
      "Use surgical hand scrub: significantly reduces the number of microorganisms on the hands and forearms prior to surgery or patient care"
    ]
  },
  "jojoba ext": {
    "ingredient": "jojoba ext",
    "is_drug": true,
    "canonical_name": "jojoba ext",
    "fda_search_term": "jojoba ext",
    "groq_confidence": 0.0,
    "rejection_reason": null,
    "fda_found": true,
    "brand_names": [
      "Betadine",
      "Naproxen"
    ],
    "generic_names": [
      "NAPROXEN",
      "POVIDONE-IODINE"
    ],
    "manufacturers": [
      "A-S Medication Solutions",
      "Atlantis Consumer Healthcare, Inc."
    ],
    "dosage_forms": [],
    "warnings": [
      "Warnings For external use only"
    ],
    "drug_interactions": [
      "7 DRUG INTERACTIONS See Table 1 for clinically significant drug interactions with naproxen",
      "Table 1: Clinically Significant Drug Interactions with naproxen Drugs That Interfere with Hemostasis Clinical Impact:",
      "Naproxen and anticoagulants such as warfarin have a synergistic effect on bleeding",
      "The concomitant use of naproxen and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone",
      "Serotonin release by platelets plays an important role in hemostasis",
      "Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone",
      "Intervention: Monitor patients with concomitant use of naproxen tablets or naproxen sodium tablets with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleedin",
      "Aspirin Clinical Impact: A pharmacodynamic (PD) study has demonstrated an interaction in which lower dose naproxen (220mg/day or 220mg twice daily) interfered with the antiplatelet effect of low-dose immediate-release aspirin, with the interaction most marked during the washout period of naproxen ( ",
      "There is reason to expect that the interaction would be present with prescription doses of naproxen or with enteric-coated low-dose aspirin; however, the peak interference with aspirin function may be later than observed in the PD study due to the longer washout period",
      "Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone"
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling:",
      "Cardiovascular Thrombotic Events [ see Warnings and Precautions ( 5.1 ) ]",
      "GI Bleeding, Ulceration, and Perforation [ see Warnings and Precautions ( 5.2 ) ]",
      "Hepatotoxicity [ see Warnings and Precautions ( 5.3 ) ]",
      "Hypertension [ see Warnings and Precautions ( 5.4 ) ]",
      "Heart Failure and Edema [ see Warnings and Precautions ( 5.5 ) ]",
      "Renal Toxicity and Hyperkalemia [ see Warnings and Precautions ( 5.6 ) ]",
      "Anaphylactic Reactions [ see Warnings and Precautions ( 5.7 ) ]",
      "Serious Skin Reactions [ see Warnings and Precautions ( 5.9 ) ]",
      "Hematologic Toxicity [ see Warnings and Precautions ( 5.12 ) ] Most common adverse reactions to naproxen were dyspepsia, abdominal pain, nausea, headache, rash, ecchymosis, and edema",
      "( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch",
      "6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice",
      "Adverse reactions reported in controlled clinical trials in 960 patients treated for rheumatoid arthritis or osteoarthritis are listed below",
      "In general, reactions in patients treated chronically were reported 2 to 10 times more frequently than they were in short-term studies in the 962 patients treated for mild to moderate pain or for dysmenorrhea",
      "The most frequent complaints reported related to the gastrointestinal tract"
    ],
    "indications": [
      "Uses Multi-purpose mineral powder provides broad-spectrum SPF 46 PA+++ protection",
      "Leaves the skin flawless and protected"
    ]
  }
}